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Abstract
Nitric oxide is a recognised dilator o f vascular smooth muscle and therefore is central in 
the control of blood flow. A lack of blood flow in humans can have very important 
implications in a number of disorders of both cutaneous tissue and internal circulation.
In this thesis we look at the synthesis of new nitric oxide donors, their stabilities and their 
possible medicinal usage. These donors have been based on the 5-nitrosothiol group, 
connected to sugar moieties, simple amino acids or linked glycoaminoacids.
The donors prepared have been used to investigate the skin blood flow and localised 
responses to nitric oxide, proving that NO has an important role in the maintenance of 
healthy skin. These will be further investigated as possible treatments for disorders 
involving a lack o f cutaneous blood flow, such as connective tissue disorders and the 
repeated ulceration often seen in diabetic patients.
A set of clinical tiials have been carried out comparing the responses of healthy patients 
and sufferers o f Raynaud’s Phenomenon to exogenous nitric oxide. In this we have 
highlighted a number of differences and have helped to determine a possible cause of the 
disorder.
W e have prepared a number of slow release NO donors which have been shown to 
produce a sustained vasodilatory response in blood vessels with removed or damaged 
endothelial cells. These show promise for use in the treatment of patients with circulatory 
disorders, especially for subjects following ti'eatment for atherosclerosis.
Basic studies investigating the stabilities of these compounds have been carried out, in 
order to aid our understanding of their mode of breakdown.
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F orew ord
Nitric oxide can be regarded as a bit of an underachiever. The career of NO may be 
compared with that o f dioxygen, somewhat unfavourably. Both were discovered by 
Joseph Priestley in the late eighteenth century, nitric oxide in 1772 and oxygen in 1774. 
Oxygen supports vitually all known life forms, supplies us with energy through the 
combustion o f fossil fuels and provides innumerable useful organic and inorganic 
compounds, notably that most vital of compounds, water. Nitiic oxide, on the other 
hand, is a radical which does not even react with itself. It will react with oxygen to form 
NO 2 , admittedly one of the few coloured gases but hardly an achievement worthy of 
great acclaim. It is a major contributant to the photochemical smogs which afflict many 
large cities and is also one of the chemicals responsible for ozone depletion. Oxygen has 
continued its career steadily acquiring a reputation as a molecule you can trust in times of 
need and has managed to retain the respect and admiration of the scientific community. 
Nitric oxide made a dramatic bid for stardom during the late 1980s. Suddenly every 
chemist, biologist and physiologist wanted a seat on the bandwagon. Nitric oxide leapt 
into every facet of human life and received multidisciplinary plaudits, claiming an 
involvement in everything from muscle relaxation and the immune system to long term 
memory. Nitric oxide was even given the prestigious Molecule o f the Year award in 
1992^ and even more significantly gained a mention in Cosmopolitan magazine. 
Unfortunately, success built overnight can disappear just as rapidly. Tales o f its 
prowess became muddled, contradictory and in some places downright inaccurate. 
Disputes broke out amongst the fans, some even began to query whether nitric oxide had 
a significant role to play in the ever changing modern lifestyle. Those who had once 
unquestioningly thrown money at nitric oxide began to demand a return for their 
investment or they would have to look elsewhere for a molecule capable of satisfying 
their needs.
It is at this pivotal point that we join the continuing saga of nitric oxide to find out 
whether this historic underachiever can fulfil the promise it has recently shown or will 
sink back into the oblivion from which it came.
Many papers and reviews have been written on both the chemistry of nitric oxide and its 
physiological role. This is an indication of the interest in nitric oxide and its potential 
importance. However, that so much has been said on the matter is also an indication of 
how little understanding we have of its action and how little agreement there is between 
the various scientists.
There are several major problems which afflict the nitric oxide community. The first is 
the difficulty in detecting nitric oxide. Various probes have been developed but these are 
difficult to use due to their extreme sensitivity and are highly inaccurate: results were 
often more affected by atmospheric conditions than NO concentrations. The probes can 
be used successfully to show the presence of NO but not the amounts produced. A 
second problem is to mimic accurately physiological conditions in the laboratory. 
Experiments may be canned out to explain all of the problems but few of these reflect 
what may happen in the body where any number of additional factors may be involved.
An additional problem  im peding progress in the field of nitric oxide is its 
interdisciplinary nature. NO is studied by chemists, biologists, biochemists and 
physiologists. Each of these gi'oups is undoubtedly very competent in a chosen field and 
yet is capable of causing chaos and confusion when they step outside the area of 
expertise. Statements which are often little short of ridiculous to even a minimally 
experienced member o f one discipline are routinely published and taken as gospel by 
members of another discipline. It is perhaps for these reasons that few major tangible 
benefits have been gained, considering the vast amounts of research performed.
Chapter 1:
A general overview of the chem istry and biology of nitric oxide^»^’^ ’^
Many excellent reviews have been written concerning nitric oxide and there is little value 
in repeating what has been said in any great detail. Some of what has been said is open 
to debate and may prove to be inaccurate upon further study. The nitric oxide field 
moves at such a rapid rate that much of what is currently thought concerning NO may 
change within a very brief period and may change our understanding of the entire area. 
This report will make no assumptions about nitric oxide except that it is a vasodilator. 
We will discuss the favoured explanation of this along with a short review of the other 
areas of possible NO involvement.
1.1. Chemical Reactions o f nitric oxide
1.1.1. The preparation and occurrence of nitric oxide
NO was first prepared by Priestley in 1772 by the action of HNO 3  on various metals. 
The most common reaction is that with copper (1) a common school experiment.
(1) 8 HNO 3  + 3C u 3 Cu(N 0 3 ) 2  + 4 H 2 O + 2NO
NO is an intermediate in the production of nitric acid in both the inefficient and obsolete 
Birkland - Eyde process (2) from 1903 and the Nobel prize winning Ostwald process (3) 
from 1908.
spark(2 ) N 2  + 0 2 - ^ 2 N 0
(3) 4 NH 3  + 502’’- ^ ^ ^ ‘4 N 0  + 6 H 2 O
It is perhaps unusual that intentional NO production requires large amounts of energy 
and yet it is a pollutant which forms all too readily when not wanted. The above 
Birkland - Eyde reaction occurs in automobile internal combustion engines and is a major 
contributant to the photochemical smogs which afflict many large cities, particularly Los 
Angeles. It is hoped that catalytic converters, fitted to all new cars, will help alleviate 
some of this problem. However these converters are easily poisoned and are notoriously
fragile. The reactions (4) and (5) are catalysed by noble metals contained within the 
converter.
(4 )  2 N 0 -------+  O g
( 5 )  C O  +  N O  ►  C O ;  +  V 2N 2
1.1 .2 . O zone D epletion
The widening holes in the ozone layer have become a serious concern in recent years, 
especially in the southern hemisphere where skin cancers are taking an increasing toll of 
human life. Much has been said about the influence of chlorofluorocarbons (CFCs) on 
ozone depletion. Production and usage of these has now been limited. NO, being a 
radical, also presents a danger to ozone levels. There are particular fears about the NO 
produced at high altitudes by supersonic aircraft in their exhaust fumes and its reaction 
with ozone (6 ). NO is also produced naturally in sunlight from NO 2  (7).
(6 ) O3  + NO ^  NO 2  + O2  
NO 2  + O ► NO + O2
(7) NO 2  * -N 0  + 0
It can be seen from (6 ) that NO not only reacts with O3  but also produces NO2  which 
reacts with oxygen radicals. These in reaction with O2 , would nomially produce ozone
In) 393nin
(8 ) O + O2  + M ^  O3  + M
1.2. N itric oxide donors
There are now a large number of NO donors available. These fall into two main 
categories: those which require metabolism in order to produce NO and those which will 
spontaneously release NO by thermal, chemical or photolytic decomposition. They may 
also transfer NO to another thiol to create a less stable nitrosothiol, e.g. cysteine. There
is also a third class of donor: those where the cause of decomposition is either unknown 
or in debate.
1.2.1. O rganic nitrates
Organic nitrates have been known for many years and have proved to be of great 
therapeutic use. The best known of these is probably glyceryl trinitrate (9), better known 
as the explosive nitroglycerine. Its incorporation into porous silica to create dynamite 
was first done by Alfred Nobel. The hypotensive action of NO was made famous by 
the discovery of abnormally low blood pressure amongst the girls who packed 
explosives during the First W orld War.^ Recently this has been the subject of a 
documentary on BBC television.^ In this it was noted that the workers involved in 
explosives often had heart attacks whilst taking holidays. The explanation for this 
involved their continual exposure to nitroglycerine during the working week, reducing 
their blood pressure. Eventually they developed tolerance to this and it had less of an 
effect on their blood pressure, allowing it to return to, or close to, normal values. 
However, at weekends they did not have this exposure and the blood pressure would 
rise to well above the normal levels. During a normal weekend there w asn’t ususally 
time for any great problems to occur, once back at work on the Monday their blood 
pressure would be reduced again. When there was a long weekend or a holiday the 
danger was much greater as the blood pressure would rise steadily throughout and a 
number of workers were unknowingly at risk of heart attacks whenever they took time 
off work. The study had not run for long enough to determine whether these workers 
would develope tolerance to such a degi'ee that they would run the risk of a heart attack 
every weekend.
(9)
ONO 2
ONO 2
ONO 2
O2 NO
(10)
^  ONO 2
H 3 Q
(11) C H -C H 2 -CH 2 ONO
H 3 C '
Both glyceryl trinitrate and isosorbide dinitrate (10) are common ingredients in the 
puffers used by angina sufferers and aie used in medicines to tieat other heart conditions. 
Amyl nitrite (11) has been used as a vasodilator since 1867, when it was used as an 
inhalant to treat asthma.^ Nowadays it is most commonly used in the so called Gay Bars 
in pill form known as poppers. There its muscle dilating capacity and aphrodisiac effects 
are said to prove useful amongst homosexuals. In a fascinating and controversial article 
from the Sunday Times^ (1994) it was suggested that amyl nitrite might be a major 
contributant to AIDS. This was based on the connection between homosexuals and 
many of the early cases of AIDS. The study showed amyl nitrite to do more damage to 
the immune system than HIV. This article provoked a very strong backlash from other 
members of the scientific community who felt it hindered their efforts to control the 
disease. Nothing more has been said on this line of investigation and it may be 
considered to be discredited. The actual mechanism of metabolism of the organic nitrates 
has not been satisfactorily resolved. 19 It has been proposed that thiols are necessary for 
the enzymatic transformation into NO, pai'ticularly cysteine. However it may be that 
nitrosothiols are not formed.
1.2 .2 . Spontaneous NO donors
1 .2 .2 .1 . Inorganic C om pounds
The best known inorganic donors are sodium nitroprusside (SNP) (12) and Roussin's 
Black Salt (RBS) (13)
( 1 2 ) Na2 [Fe(CN)5 NO]
(13) Na[Fe4 S3 (NO)7 ]
Both are highly effective vasodilators, SNP is used in heart surgery to reduce blood 
pressure. RBS is particularly potent as it not only has 7 NO ligands in each anion but it 
is more soluble in organic solvents than water. RBS is taken into the endothelial cells 
because of its lipid solubility and can remain there slowly releasing NO for several
h o u rs .ll RBS decomposes to produce NO by chemical and photolytic means. The 
means of NO release from SNP are much studied and little u n d e rs to o d .S p o n tan eo u s  
decom position is unlikely due to the very high form ation constants for the 
hexacyanoferrates and similar compounds. Photolytic decomposition (14) is fairly well 
documented but fails to explain the vasodilatoiy activity shown in the absence of light.
(14) [Fe(CN)5NO]2-— [Fe(CN);]^- + NO'
/ O
(15) [Fe(CN)5 NO]2 - + R S '— ^ [F e (C N );N . f  - - - ^ R S N O  + Fe species
SR
A reaction between SNP and thiol has been studied (15). In this nitrosothiols are 
produced and these decompose to produce disulphide and NO (16). Laboratory tests 
have supported this theory but suggest it may be too slow to account for the immediate 
vasodilatory action of SN P .13 The currently favoured explanation am ongst 
physiologists is that of enzymic involvement, l"^
RSN O  *-RS' + NO
(16) u
RSSR
1 .2 .2 .2 . N itro so th io ls
Potentially the most useful NO donors are S-nitrosothiols. The nitroso derivative of 
cysteine is thought to play an important role in the body, however it is too unstable to 
isolate. Two nitrosothiols with a high degree o f stability are S -n itro so -A - 
acetylpenicillamine (SNAP) (17) and S-nitrosoglutathione (GSNO) (18). These are 
highly coloured due to the SNO group, making them easy to study.
SNO G ^ S N O
I H
/  \  /  ' H "HOpC N NHg O
H
These are potent vasodilators in whole animals as well as in ex vivo  experiments, 
decomposing readily to produce NO (16). The route and speed of decomposition is very 
much dependent on the nature o f the thiol. SNAP is very stable as a solid at room 
temperature but rapidly decomposes in solution in the presence of copper ions. GSNO 
may require transnitrosation or enzymatic cleavage. 1^  Other nitrosothiols are often 
thermally decomposed and most are photolytically unstable.
1.3. In-v ivo  production of NO
Nitric oxide is thought to be produced in the body by the conversion of L-arginine to 
citrulline by enzymes known as NO synthases (19). There are two main NO synthases: 
constitutive and inducible. Both are NADPH dependent dioxygenases. Constitutive NO 
synthase (cNOS) is produced by smooth muscle where NO is always being produced to 
some degree. There is a basal NO production from the endothelial cells which acts 
against vascular smooth muscle contraction. Activation gives a rapid but short lived 
response. As NO is toxic only small amounts are produced. Inducible NO synthase 
(iNOS), involved in the immune system, is only present when the macrophages have 
been activated. In order to rid the body of infection it is longer lasting than cNOS. A 
final, less well understood, NOS type is brain or neural (nNOS).
d-.H 2 N ^ N H 2  H 2 N ^ N H 0 H H 2 N ^ 0
NH NH
(19)
NADPH NÀDP+ \  I/2NADPH I/2NADP
+ NO
H jN  CO;- H jN  C O ; H 3 N C O ;
NOS is a haem protein and it is thought that the process is regulated by NO itself. This 
is presumably by an interaction between NO and the haem iron centre. This could 
constitute a feedback mechanism preventing overproduction of NO. The accepted 
mechanism for the conversion of L-arginine to N-hydroxyarginine is thought to involve 
initial one electron oxidation of the guanidine nitrogen and hydroxylation of the amidine 
nitrogen utilising 1 eq. NADPH and O2 , as shown in the first stage of (19). The second 
stage is somewhat more complex and involves the iron-protoporphyrin IX component of 
NOS (20).
PPIX-Fe“
+PPIX-Fe'"00-
+ir
HaNv^NOH HjNv^NOH
NH
PPIX-Fe"'OOH  ^ \c?C?
HsNvLn-O- ^5?^
NH " 3^ NH
-H,0
PPIX-Fe“'OH
HaN^O
NH
+PPIX-Fc”^00- -IT -fT
-PPIX-Fc"00‘
H s N '^ 'C O j  I-I3N' 'C O 2 Hj]^^ 'C O 2  I-I3N" CO2
+ NO*
+PPIX-Fc‘"00
This process can be inhibited by arginine analogues acting as competitive inhibitors, such 
as L-N-monomethylarginine (LNMMA) (21) and the methyl ester of A-nitro-L-arginine 
(L-NAME) (22).
H 3 CHN;. NH 2
(21)
H 3 N
LNMMA
CO-
HoN.v. .  N H N O 2
(22)
L-NAME
H 3 N " COzMe
Processes caused by NO can be halted or reduced by the use of NO scavengers such as 
haemoglobin. In this way it can be shown whether an in vitro reaction is being caused 
by NO or not.
1.4. Physiological role of nitric oxide
1.4.1. NO and the immune system
The first indication of a role for nitric oxide in the immune response came when high 
levels o f nitrate were found in patients suffering from gastroenteritis. Cultured 
macrophages, one of the main cell groups involved in the non-specific immune response, 
were found to produce nitrite and nitrate. This was dependent on the presence of L- 
arginine. In the body NO is produced by the enzymatic action o f NO synthase on 
arginine (section 1.3). The ability of macrophages to kill abnormal cells such as 
tumours, was shown to be dependent on L -a r g in in e .l^  This demonstrated that NO must 
be part o f the natural defence of the body against invaders and abnormal cells within the 
body. It was initially suggested that NO itself might be sufficiently potent to be the 
cytotoxic a g e n t. 18 Tests have shown that in general it is not capable of killing cells on its 
own. 19 There are two main routes by which mammalian DNA can be damaged by 
NO.29 One involves the reaction of NO with molecular oxygen and the other the reaction 
of NO with superoxide. The reaction with O2  produces N 2 O 3 , a nitrosating agent. 
N 2 O 3  can react with secondary amines to form A-nitrosamines (1.5.1) which can be 
carcinogenic or mutagenic. N 2 O 3  can also nitrosate primary amines on DNA bases 
causing deamination and base mutation. The reaction with superoxide produces 
peroxynitrite (ONOO ). This may either rearrange to give nitrate or decompose to 
produce reactive oxygen inteimediates (ROIs) (23).^!
NO + O2  ► ONOO
(23) ONO O ' + ONOOH
ONOOH NO 2  + HO
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The production of the highly reactive hydroxyl radicals is an appealing solution. 
H owever peroxynitrite was not found to be particularly toxic against Leishm ania  
m a j o r It is possible that the toxicity of peroxynitrite involves interaction with cellular 
targets rather than the formation of hydroxyl radicals.^^ This would make it very much 
tissue specific rather than universally toxic. A final suggestion is that NO, having a high 
affinity for iron, can react with iron centres to give iron nitrosyls. If this occurs it can 
destroy the action of the iron sulphur clusters which are part of the bacterial respiratory 
system.^*^ Some of these clusters are involved in DNA synthesis and this will stop the 
bacterium growing. Yet again, examples where this is found not to occur are available in 
the literature. NO does not inhibit the enzyme aconitase which contains an important 
iron-sulphur cluster.^5 The most probable role for NO in the immune system is a 
combination o f the above suggestions, with NO being toxic enough to weaken the cell 
for other defence mechanisms to be efficient.
1.4 .2 . P latelet aggregation
W hen a blood vessel is damaged, tiny fragments contained in the blood adhere to the 
surface and form a plug. These are called platelets. Further aggregation of these 
platelets causes a clot to fonn. This prevents excessive blood loss. Platelets adhere to 
damaged, altered or abnormal surfaces. Spontaneous platelet aggregation in the blood 
vessel may cause a thrombus, which can have serious consequences. This can occur in 
the heart where platelets adhere to non-con tractile scar tissue or vessels coated in 
atherosclerotic plaque. If aggregation takes place then myocardial infarction may occur. 
When the platelets are activated NO is produced in a feedback mechanism to counteract 
the substances promoting adhesion and aggregation. NO is produced both by the 
endothelial cells which the platelets come into contact with and the platelets themselves. 
It is thought that NO and prostacyclin act synergistically to inhibit platelet aggregation 
and to break up the aggregates already f o r m e d . B o t h  SNAP and GSNO are effective 
in the prevention of platelet aggi*egation. This may well provide an important role for 
such compounds as there aie few effective drugs currently available.
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1.4 .3 . B ra in
Signals move along nerve cells as electrical impulses but chemical messengers are used 
to convey the signal across the gaps between the nerve cells (synapses). Two of the 
major neurotransmitters are the amino acids aspartate and glutamate. These pass from 
the pre-synaptic cells to the post-synaptic cells. The presence o f enhanced levels of 
cGMP, paralleling that which occurs in smooth muscle relaxation, suggested a role for 
NO in the nervous system. It is currently thought that NO is acting as a retrograde 
messenger between the synapses. NO produced by the post-synaptic cell diffuses to the 
surrounding pre-synaptic cells, strengthening the link between them. In this way the 
system becomes sensitised to a particular stimulus and will be able to respond more 
efficiently when next exposed to that stimulus. This may be responsible for functions 
such as long term memory and complex automated actions - such as the playing of 
musical instruments. It is also thought that NO in the central nervous system may be 
responsible for the modulation of pain perception and the mediation of short term 
electrocortical activation. The best studied role of NO in the nervous system is that 
which concerns the NANC (non-adrenergic non cholinergic) nerves where NO is 
released in response to an electrical signal.^^ This then acts upon smooth muscle as 
covered in 1.4.4.
1.4.4. Sm ooth m uscle relaxation
In human physiology there are three types of muscle: skeletal, responsible for the 
movement of joints; cardiac, responsible for keeping the heart beating and smooth 
muscle, which surrounds hollow organs and tubes. Smooth muscle controls such 
actions as peristalsis, by intestinal muscle relaxation, urine continence by the muscle at 
the bladder neck and for our purposes most importantly, vasodilation and the reduction 
of blood pressure. It was noted by Furchgott and Z a w a d sk i^ S  that a precontracted blood 
vessel with a damaged endothelium was not responsive to the vasodilator acetylcholine. 
This dem onstrated that acetylcholine acted upon the endothelial cells which then
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produced a vasodilatory agent. This substance could then act upon the vascular smooth 
muscle and cause relaxation. The molecule was named the endothelium derived 
relaxation factor, or EDRF. It is thought that NO is this a g e n t . ,30 This is still very 
much a disputed point and there have been suggestions that the EDRF may be a 
nitrosothiol or related compound.^!
The role that NO is thought to play in smooth muscle relaxation is the activation of the 
enzyme guanylate cyclase. This causes the conversion o f guanosine triphosphate to 
cyclic guanosine monophosphate (24).
( 2 4 ) :>ct B A S EG u a n y la te  C y c la se   ►N OO OHOH
OO T P
B A S E
OHcG M P
NO has been shown to interact with the haem component of soluble guanylate cyclase
(25). Coordination of the NO ligand to the iron causes a change in spin state of the iron. 
This forces the iron to move out of the porphyrin ring.
(25)
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The process of smooth muscle relaxation is initiated by the arrival of an endothelium 
dependent vasodilator such as acetylcholine. This triggers the opening of the calcium 
channels in the endothelial wall. The increase in Ca^+ in the cell activates NO synthase. 
The NO formed passes into the smooth muscle where it acts upon guanylate cyclase. 
The increase in cGMP results in the activation of a protein kinase. This enyzme 
facilitates the phosphorylation of proteins eventually leading to muscle relaxation.
1.5. N itric  oxide as a harm fu l agent
It has been obvious that NO was a very dangerous gas ever since the serious disasters^ 
which occurred from anaesthetists using cylinders of laughing gas (N2 O) contaminated 
with NO.
1 .5 .1 . As a c a r c i n o g e n 3 2 , 3 3
Just as NO can kill cancerous cells it would also appear to be quite capable of causing 
them. Where the dividing line between being a cytotoxic agent and a carcinogen lies is 
unknown. It thought that the carcinogenic activity lies in the formation of nitrosamines. 
NO itself will not react with amines, it requires to be oxidised to NO 2 . This occurs 
readily in the presence of oxygen. N 0+ will act as an electrophile and is attacked by 
secondary amines to give N-nitroso compounds. Many of these are known to be potent 
carcinogens. There is particular concern over the addition of sodium nitrite to meat as a 
preservative. The nitrite serves two purposes. Firstly it stops the meat from turning 
brown, by oxygenation of iron in myoglobin, and taking on an unattractive appearance. 
Much more importantly it prevents the growth of the bacterium which produces the 
botulinus toxin by interaction with electron transfer ferredoxins.34 When the meat is 
cooked the sodium nitrite and amines will react. Cooked bacon is known to contain N- 
nitrosodimethylamine and N-nitrosopyrrolidine. Under acidic stomach conditions nitrite 
and amines may also react. With this knowledge there was a strong campaign to ban 
nitrite from food. The fears were eased slightly when it was shown that our own 
intestinal bacteria produce nitrite in quantities which must be just as damaging as
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anything we obtain from food. It was also shown that nitrite occurs naturally in many 
other foods. As a compromise nitrite levels are now kept to a minimum. Cigarettes 
smoke also contains A-niü'osodimethylamine which may contribute to the cancer hazards 
of both smoking and passive smoking. In a more direct cancer inducing route, NO can 
cause mutagenesis by nitrosative deamination of DNA base pairs. This has been 
demonstrated in Salmonella typhinum}^
1.5.2. NO o v e rp ro d u c tio n
As a toxic agent it is logical to assume that too much NO, even when produced by the 
body, will be harmful
1 .5 .2 .1 . In f la m m a t io n
W hilst the NO produced by the macrophages is a vital part of the immune response, it 
can also cause gi*eat damage when released where it isn't needed. NO has recently been 
implicated in arthritis and rheumatism causing symptoms of inflammation as the joints 
are attacked by their own immune system. Inflammation is closely associated with the 
activation of iNOS and many anti-inflam m atory drugs will inhibit iNOS e.g. 
dexamethasone and other glucocorticoids.^^
1 .5 .2 . 2 . N e u ro d e g e n e ra c y
Probably the most dangerous place for excessive NO production to occur is in the brain. 
Nitric oxide has been implicated in cerebral damage caused by stroke, Parkinson’s 
disease and AIDS dementia.37 The overproduction of NO causing cell death in the 
central nervous system is thought to exist.
1 .5 .2 .3 . S ep tic  shock
Following illness or an accident it is possible for a condition known as septic shock to 
take hold. A progressive reduction in blood pressure occurs which is resistant to 
vasoconstrictors. It is now believed that excessive NO production is occurring and
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contributes to the fall in blood pressure. If unchecked, circulation will cease altogether. 
The usage of iNOS inhibitors to treat the condition has been demonstrated in a small 
number of cases.38
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C h a p te r  2 : Synthesis o f N itroso th io ls.
2.1. In tro d u c tio n .
The aim of all syntheses discussed in this report was the preparation of ^ -nitrosothiols. 
These were made for a number of reasons, including simply for the sake of seeing 
whether such a molecule could exist. However, the most important reason was to 
prépaie compounds which could be used in animal studies. This aim had a strong effect 
on how such syntheses could be performed and which reagents could be used. In order 
to prepare compounds on the scale required, the synthetic route had to be relatively 
inexpensive. It was for this reason that much effort was put into the usage of 
inexpensive leaving gioups such as mesylate and tosylate, when a triflate group could 
have been used under much simpler conditions and avoided much wasted time. Most of 
the syntheses encountered here are of a relatively simple nature, the type that could have 
been performed many years ago had there been reason to do so. This has been dictated 
by the interdisciplinary nature o f the project, where the aim was to make as many useful 
compounds as possible. Had innovative synthetic routes been used yields might have 
been enhanced but the number of compounds prepared would have been reduced. 
Likewise reaction conditions have not been modified to improve yields, as only the 
production of the final 5-nitrosothiol in large enough quantities to characterise and test 
was of importance. The usage of these compounds in human testing has also determined 
that certain reagents could not be used. Salts of silver, mercury and barium which might 
have been carried through into the final product and had a dramatic effect on the 
biological action. Also a product from a reaction involving such reagents would, in all 
probability, not have gained ethical permission for its usage. These factors have had 
considerable impact on the synthetic routes chosen. As with many reactions involving a 
thiol group, a number of the steps described create a very unpleasant odour and are 
pai'ticulaiiy antisocial to perform. Even with great care and attention, especially in the 
reactions involving a lengthy workup, it is very difficult to contain the odour. It has been 
found that merely inhaling such odours is sufficient to require a change of clothing and a 
shower, probably through the thiol finding its way into perspiration. It is for this reason
2 1
that a number of reactions may appear to have been terminated without a full investigation 
of the possibilities having been performed, simply because the end product was not 
regarded as being sufficiently important to warrant the trouble of synthesising it.
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2.2 . D iscu ssio n
2.3.1. 1 - 5 - N it r o s o th io s u g a r s
As a starting point for the preparations of new NO-donors based on carbohydrate 
residues it was decided that simple sugars were an ideal topic of investigation. There are 
well proven methods for the introduction of a thiol group at the anomeric position of a 
mono- or disaccharide. These methods can be used with a wide number of derivatives to 
produce a large range of characteristics. It was hoped that we would be able to change 
the substituents on the hydroxyl groups of the sugar to affect both the solubility of the 
molecule and the stability of the -SNO group. Thiosugars have the advantage of small 
size, allowing their usage in a number of different physiological conditions. Non- 
acylated thiosugars have been prepared in situ by Matthews and Kerr.l In physiological 
tests these were found to be very potent vasodilators. However, in solution these were 
found to be very unstable and a product was never isolated.
The anomeric position of a sugar is usually the easiest on which to cany out substitution 
reactions due to the formation of a carbocation as shown in figure 1. This gives the 
reaction a degree of S ^ l character. It is because of this that relatively mild conditions can 
be used in this series of reactions.
Figure 1
CMgOAcCH2 OAG ♦,
A cO
Ag o O A c
As preparations for a num ber of peracetylated thiosugars are available in the 
l i t e r a t u r e ,2 ’3 ,4  these were viewed as being a suitable point to begin our investigations. 
The route to the preparation of l-^-nitrosothioglucose tetraacetate (SNAG) is shown in 
figure 2
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Acétylations were carried out using acetic anhydride, either with sodium acetate at the 
temperature of a boiling water bath or with pyridine at room temperature. The base acts 
as an acid acceptor and moves the equilibrium in favour of acetylated product. In the case 
of pyridine /  acetic anhydride an adduct is fomied by the pyridine attacking the anhydride 
and it is this adduct which acts as the acetylating agent. Acétylation has the benefit of 
giving the product a low solubility in water, making isolation and purification easier. The 
reaction mixture is poured into ice water and the peracetylated product precipitated as a 
white powder in a high yield. The acetylated products of glucose [1], galactose [6 ], 
xylose [11], maltose [16] and lactose [22] were made in this manner. The p-form is 
predominant in the first four sugars listed. In the case of lactose a mixture of a  and p 
product is obtained.
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CHgOAc OAc
AcO
1 AcO AcOOAc OAc
[1] Rl=OAc, R2=H [6 ] Rl=OAc, R2=H [11] Rl=OAc, R2=H
[2] Rl=H, R2=Br [7] R l=H , R2=Br [12] R l=H , R2=Br
[3] R l=SC(N H 2 )NH.HBr [8 ] R l=SC(NH 2 )NH.HBr [13] R l=SC(N H 2 )NH.HBr 
R2=H R2=H R2=H
[4] R l=SH, R2=H [9] Rl=SH, R^=H [14] R l=SH , R2=H
[5] Rl=SNO, R2=H [10] R l-S N O , R^=H [15] Rl=SNO, R2=H
The bromination reaction was carried out using a 30 % solution of HBr in acetic acid. 
This can be used either as the solvent, in the case of lactose, or in smaller quantities with 
the peracetylated sugar dissolved in DCM. The workup to obtain the product, 
evaporation of the solvents which involves utilising toluene as an azeotrope and washing 
with large quantities of NaHCOg solution, was done with great care as the bromide is 
easily lost. It is preferable to convert the product to a more stable compound as quickly 
as possible. Evaporation of the solvent gives the bromides as fluffy white, or off-white, 
powders [2], [7], [12], [17], [23]. The instability of the bromide is responsible for the 
melting points and elemental analyses being inaccurate. The melting point is very much 
dependent on how rapidly the sample is heated and the elemental analyses dependent on 
how long the samples have been stored. It was found to be more expensive to buy 
acetobromoglucose than to make it by this method but as the crystallisation is often 
difficult, a lot less effort. The a-product is found to be the most common in all but the 
maverick lactose. This is due to the interaction of the dipoles involved. In the a  position 
the dipoles of the bromide and ring oxygen are in opposite directions making this form 
more favomable than the usually sterically favoured |3 form.
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CHgOAc
A cO
A cO CH2 OACO A c O
A cO O A c R'
O A c CH2OAC
CH2OAC
[16] R^=OAc, R^=H
[17] R^=H, R^=Br
[18] R^=SC(NH 2 )NH.HBr 
R^=H
[19] R^=SH, R^=H
[20] R^=SAc, R^=H
[21] R^=SNO, R^=H
[22] R^=OAc, R^=H
[23] R^=H, R^=Br
[24] R^-SC(N H 2 )NH.HBr 
R^=H
[25] R^=SH, R^=H
[26] R^=SNO, R^=H
Two convenient methods for thiolation were available. The one used depended upon the 
stability of the resultant thiol and whether it is acceptable to use heat during the hydrolysis 
step. Initially for all of the five sugars thiourea was used as the nucleophile. The 
bromosugar and thiourea are refluxed in dry acetone for fifteen minutes, after which the 
product should have precipitated. Difficulties were encountered in this reaction. In some 
cases reflux for an hour was required. Precipitation occurred only after the removal of 
solvent by evaporation or the addition of cold acetone to the reaction mix. Thiourea has a 
low solubility in acetone and does not go into solution until reaction has occurred. The 
product is formed as the isothiouronium hydrobromide salt which also has a low 
solubility in acetone and precipitates in the reaction mixture. Recrystallisation from 
acetone requires a large amount of solvent and a lot of patience. For glucose [3], 
galactose [8 ] and xylose [13] a white product was precipitated during the reaction and 
found to be the desired hydrobromide salt. No precipitation was seen in the reactions 
with the maltose and lactose bromides. In these cases the acetone was removed by 
evaporation yielding a white oil which slowly solidified. nm r spectroscopy
suggested that these were impure samples of the hydrobromide salt in view of the upfield 
movement of the anomeric carbon. The products were also soluble in water as expected. 
Attempted recrystallisation from acetone gave a white product found to be unreacted
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thiourea or its hydrolysis product urea. It is presumed that it is a higher degree of 
solubility in acetone rather than formation of a different product, which caused failure to 
obtain a product. Evaporation of the filtrate gave an oil. As the thiol could be obtained 
from this, the oil probably contained the thiouronium salt [18], [24].
Hydrolysis was carried out by adding the thiouronium salt to a hot solution of potassium 
metabisulphite. Addition of DCM to this, followed by stirring at reflux, allowed the thiol 
to move to the organic layer. Evaporation of the solvent gave a pungent oil which slowly 
solidified. Thioglucose [5], thioxylose [14] and thiomaltose [19] derivatives were 
successfully recrystallised from methanol to give large white crystals. Thiogalactose [9] 
and thiolactose [25] could not be recrystallised and remained as oils which slowly 
hardened. NMR studies revealed these to be fairly pure. O f these thiols it is noticeable 
that the most pungent, thioxylose, is also the least stable, whereas the least pungent, 
thioglucose is the most stable. Thioglucose and thiogalactose are stable in the long term 
under refrigeration but the other three thiols are prone to dimérisation even under such 
conditions.
The second method involves the preparation of the anomeric thioacetate from the 
bromide. Reflux of the bromide of maltose with potassium thioacetate in DCM /  ethanol 
gave a yellow oil which was recrystallised from ethanol to give a white solid [20] . The 
iR  nmr spectrum of a sample was extremely complex and it is really only necessary to 
identify the anomeric proton, to gain an idea of the substituent at that position and to 
determine the orientation of that substituent. However, as it is a good exercise in sugar 
chem istry, m ore com plete interpretations have been made. The thioacetate was 
hydrolysed using 1.5 equivalents of benzylamine in THE. Evaporation of the solvent left 
a yellow oil which solidified on cooling. The solid was stirred with ethanol and filtered 
and the product obtained by removal of the solvent. The thiol was found to be 
surprisingly stable and relatively odourless. The ^^C nmr spectrum of a two year old 
sample, presumed to have fomied a large quantity of disulphide, was compared to that of
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new product and no differences were seen. The nmr spectrum showed that the -SH 
peak at ô 2.25 was present.
Nitrosation is both the shortest and the most difficult o f the processes involved in the 
synthesis. A thiol can be nitrosated either by N2 O 3  gas or acidified nitrite. However it is 
isolation o f the product which was found to be difficult. The method used for the 
preparation o f the glucose derivative, SNAG [5], involved dissolving the thiol in 
methanol with a small quantity of water and chilling in ice. A small quantity of EDTA 
was added. This is to compensate for poor quality distilled water or sodium nitrite which 
may contain some copper ions. Excess sodium nitrite was added followed by the 
drop wise addition of conc. HCI to the mixture to give a red solution. The addition of 
more water to this caused the precipitation of the nitrosothiol, usually as dark red oil. 
The addition of a small quantity of HCI was then used to facilitate solid formation. A 
deep pink pow der was filtered o ff and dried under reduced pressure. Despite 
investigation of a number of different reaction conditions, this method is the only one 
which yielded a solid precipitate. Unfortunately it is not a particularly reliable method 
and frequently there is fomiation of a large amount of disulphide which contaminates the 
nitrosothiol. The presence of EDTA should reduce the effects of any metal ions in the 
reagents or solvents used. It has been noted that the use of freshly made thioglucose is 
necessary for successful nitrosation. Older samples, even when kept in the freezer, 
usually give large quantities of disulphide upon nitrosation.
W hen following this method glucose is the only sugar whose nitrosothiol can be 
precipitated as a solid. The preparation of the nitrosothiol for the other sugars involves 
extraction into DCM of the red oil produced. Evaporation of this gives a pale pink solid. 
None o f these products are stable however. Somewhat confusingly, when SNAG is 
prepared by this method it is also found to be unstable. When nitrosothiols are prepared 
by the other method, i.e. bubbling N 2 O 3  through a solution of the thiol in DCM, 
evaporation also gives an unstable pale pink powder as above. The anomaly is further
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compounded by the fact that the maltose [2 1 ] and lactose [26] derivatives are more stable 
in solution than SNAG, yet much less so in solid form. The only conclusion which can 
be drawn from this is that the method of isolation would appear to be vital in preparation 
of the nitrosothiol, with only immediate precipitation being successful. A third method of 
nitrosation, involving stirring the thiol in DCM with tertiary butyl nitrite, showed no 
nitrosation.
Totally satisfactory characterisation of all of these products has not been achieved. Only 
SNAG has been found to be stable enough to allow both and ^^C nmr spectra to be 
run. The spectrum shows the disappearance of the -SH doublet at Ô 2.3, whilst the 
l^C spectrum shows the downfield movement of the anomeric carbon as expected. ^^C 
nmr spectra have been obtained for the galactose [ 1 0 ] and maltose derivatives and these 
show the same trend. The ^H spectra for the sugars apart from glucose show the 
disappearance of the -SH doublet but are not very well resolved. This is due to the 
formation of disulphide. The protons of the disulphide have a very similar chemical shift 
to those of the nitrosothiol, causing a broadening of the peaks and giving unsatisfactory 
spectra. It was not possible to obtain a spectrum of the very unstable xylose derivative 
[15]. Infra red data show the disappearance of the -SH stretch at 2560 cm-1 and in, the 
case of SNAG, the appearance of an NO stietch at 1550 cm-1. Examination of the uv / 
visible spectra shows a strong absorbance in the 340 - 350 nm range. This is 
characteristic of other known nitrosothiols. Other commonly used identification 
techniques have not been possible. None of the compounds were stable enough to allow 
elemental analysis. FAB mass spectroscopy or other MS techniques cause sugar 
fragmentation giving no useful information. Attempts to examine purity using HPLC 
proved unsuccessful due to the highly non-polar nature of the compounds. The columns 
at our disposal were not polar enough to allow passage of the nitrosothiol. In view of the 
data we have and the purity of the precursor thiol we feel confident that the nitrosothiol 
has indeed been prepared in each case but, apart from SNAG, they are unstable and 
impossible to obtain in pure form.
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The preparation of a mannose derivative by the above reaction scheme was attempted. 
The pentaacetate [27] was found to be an oil. nmr specti'oscopy showed only one 
major product but spectra were indistinct and no interpretations could be made from 
them. The bromide [28] was prepared as before, giving a brown oil. The C-1 shift on 
the nmi‘ was as expected but no more information could be obtained. Reaction of the 
bromide with thiourea gave a white solid by precipitation. This solid was filtered and 
recrystallised from acetone. Somewhat surprisingly it was found to contain little or no 
organic material. It was clearly not [29]. The solvent was removed from the filtrate to 
give a white gum with a nmr as expected for [29].
CH2 OAG
A cO A cOO A c O A c
A cO O A c A cO S R
[27] [29] R=C(NH 2 )NH.HBr
[30] R=H
[31] R=NO
Hydrolysis of this with K 2 S 2 O 5  gave an oil which was assumed to be [30]. The 
movement of the C-1 in the nmr spectrum was as expected and the spectrum 
showed a doublet at 5 2.3 with a J value consistent with that o f the expected thiol. The 
product was nitrosated in methanol /  water with HCI /  NaN 0 2  giving a red oil [31]. The 
oil had a strong absorbance at 351 nm and showed no appreciable decomposition. 
However, 1%  nmr showed chemical shifts almost identical to those of the pentaacetate. 
As an alternative the bromide was reacted with potassium thioacetate to give a yellow oil 
but the l^C nmr spectrum showed this to be the pentaacetate also. Other studies^ suggest 
that mannose is very difficult to deal with and methods of a complexity outwith the time 
available would have been required to prepare the products in pure form. The major 
reason for the difficulties with mannose involve the orientation of the acetate at position 2
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[28]. This is set up perfectly for an elimination of the anomeric bromide as shown in 
figure 3.
Figure 3
AcO
AcOCH.
AcO
AcO
[28]
2.3.2. 1-Thiobenzoates. It is possible to displace a benzoate group with a bromide 
in the same manner as an acetate, thus allowing use of a similar procedure to prepare 1-5^ - 
nitrosothiosugar perbenzoates. The glucose and galactose products were investigated. 
Glucose was benzoylated in chilled DCM and pyridine by the slow addition of benzoyl 
chloride.
CH2 0 ^  O
O B z CHgOI^ Q
B zO
[32] R=OBz
[34] R=SAc
[35] R=SH
O B z
[36] R=OBz
[38] R=SAc
[39] R=SH
Rem oval of the solvents gave an oil [32] which slowly hardened and could be 
recrystallised from acetone /  water. Bromination, as for the acetates, gave a white 
powder [32] which was identified from its and nmr spectra but had a poor 
elemental analysis and a low melting point.
O B z
B zO
B zO O B z
[33]
B zO O B z
[37]
[33] was reacted with potassium thioacetate in DCM /  ethanol to give a yellow oil, [34], 
which solidified on heating in methanol. The 1-thioacetylgalactose tetrabenzoate [38]
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was prepared in the same manner. Subsequent reaction gave the pentabenzoate [36] and 
bromo compounds [37] as gums. The thioacetate was also a white powder. Attempts at 
hydi'olysis of both thioacetates using benzylamine in THF under N 2  were successful in 
producing the thiols, [35] and [39], but these rapidly dimerised and disulphides were 
formed. TLC showed the disappearance of the starting material and a strong thiol smell 
was noted during reaction. Once exposed to the air, TLC showed the formation of 
another compound which was accompanied by a disappearance of the thiol smell. 
Reduction of the disulphide with DTT was attempted. Again a thiol smell was noted 
during reaction but this faded as soon as the mixture was exposed to air. Only disulphide 
could be isolated despite a very careful workup. The lack of mention of the thioacetates 
in the literature is perhaps a demonstration of the instability of the thiol and their lack of 
use as synthetic precursors.
2,3.3. 3 - 0 -M e th y lg lu c o s e . To investigate the effect o f a partial change of 
protecting group an attempt was made to introduce a methyl group at position 3, amongst 
the acetate groups at 2, 4 and 6  and to compare this compound with SNAG. This 
procedure involved the use of diisopropylidene glucose [40] as described later. The 
hydroxyl group at position 3 was m ethylated [41] with dim ethyl sulphate. The 
diisopropylidene groups were removed by overnight reflux in acid to produce 3-0-methyl 
glucose [42] and the product acetylated using acetic anhydride and pyridine to give the 
tetraacetate [43] as a viscous oil. The oil was found to be a mixture of the a  and (3 
products. Bromination was performed as before to give a brown oil [44]. Addition of 
ether caused precipitation of a white solid. When filtration was attempted the solid 
become a brown intractable gum, either on contact with air or with moisture. Attempts to 
purify the gum proved unsuccessful. W e felt that this study was a fairly good indication 
of the unpredictability of sugars and that a change from an acetate to a methyl at a distant 
site could make an easy reaction nigh on impossible.
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CH2 OR® Q
[41] [42] Rl=OH, R2=H, R3=H
[43] Rl=OAc, R2=H, R3=Ac
[44] Rl=H, R2=Br, R3=Ac
2.4. 3 -5-N itroso th iosugars . O f the three accessible positions on a sugar ring, the 3 
position is the most shielded. The anomeric position has the influence of the ring oxygen 
whereas the 6  position is at a primary site outwith the ring. The 3 position is readily 
accessible in both glucose and fructose with the use of diisopropylidene groups to block 
the other positions and leave the 3- position available for reaction. 1,2:5,6- 
Diisopropylidene glucofuranose [40] was prepared by stirring glucose in acetone with a 
ZnCl2  dehydrating agent and a catalytic amount of H 3 PO4 . Yields are quite low (-50  %) 
with much of the glucose remaining unreacted. In view of the low cost of the materials 
involved, this is not a great problem.. The unreacted glucose was filtered off and the zinc 
removed as Zn(OH ) 2  by addition of NaOH. Upon evaporation the product formed as a 
hard lining inside the flask which had to be chiselled out with care, giving the product in 
the form of hard sheets. In order to permit further substitution introduction of a number 
of leaving groups was investigated.
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[40] R=H [48] R=Ac
[45] R=Ms [49] R=H
[46] R=Ts [50] R=NO
[51]
[47] R=Tf
The mesyl [45] and tosyl [46] derivatives were prepared using mesyl or tosyl chloride in 
pyridine to give white solids in high yields. These groups proved very difficult to 
displace. Initially mild conditions were attempted in order to introduce a thiolate 
nucleophile. Predictably only starting material could be isolated from the reaction 
between the mesylate and thiourea in acetone or with potassium thioacetate in DCM / 
ethanol. Attempts to displace the mesyl and tosyl groups with iodine by way of reflux 
with sodium iodide in DMF also proved unsuccessful giving an impure product. l^C 
nm r spectroscopy dem onstrated that the leaving group rem ained but that an 
isopropylidene group had been lost. The method of Nayak and Whistler^ suggested that 
the tosyl group could be displaced by heating with potassium thioacetate in DMF, at 
115°C for 3 days. Several attempts were made to copy this reaction, including heating to 
120'*C for 6  days under N 2  with a five-fold excess of thioacetate. At best a 25 % 
conversion was obtained. Generally only unreacted starting material could be isolated. 
This method, apart from the inconvenience of the harsh conditions involved, produces a 
foul smelling dark brown sludge. Workup involved repeated precipitation of unwanted 
salts in xylene and cannot be recommended for maintaining a pleasant lab atmosphere. A 
M itsonobu type reaction using thioacetic acid with triphenylphosphine and diethyl 
azodicarboxylate was attempted. A grey solid was isolated but found to be neither
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starting material nor the desired thioacetate. Other workers have verified that this reaction 
is not viable on a starting material such as this. The leaving group is simply not labile 
enough to compensate for the steric crowding around the 3-position. Despite the expense 
it was concluded that the use of a triflate leaving group was necessary. 1,2:5,6- 
Diisopropylidene 3-0-triflylglucofuranose [47] was produced using triflic anhydride and 
pyridine well diluted with dry DCM. Despite the fact that this molecule is fairly unstable 
at room temperature, turning black within a day, the triflate displacement was not found 
to be easy. Reflux with potassium thioacetate in DCM / ethanol yielded only starting 
material. Attempts at displacement of the triflate with a more labile iodide [51], using 
tetrabutylammonium iodide in refluxing toluene, were successful but yields were very 
low (<15 %). Attempts to displace the triflate using potassium thioacetate in DMF at 
110°C gave only a dark brown tar. This was extracted with hot hexane but no product 
was observed upon evaporation. Successful displacement of the triflate was achieved 
using tetrabutylam m onium  thioacetate (from tetrabutylam m onium  hydroxide and 
thioacetic acid) in refluxing toluene. Evaporation of this gives a thick dark brown sludge 
and a more pale brown liquid. This liquid was decanted and lar ge crystals of 3-6-acetyl- 
l,2:5,6-diisopropylidene glucofuranose [48] formed in the liquid. These were repeatedly 
recrystallised from hexane to remove the thioacetate starting material. The dark brown 
sludge was also repeatedly extracted with hexane to give an impure product which 
required many subsequent recrystallisations. Despite all this effort, the yields remained 
very low (<30 %). Attempts at deacetylation using 1.5 equivalents of benzylamine in 
THF, under N 2 , initially produced a mixture of thiol and disulphide. The disulphide was 
successfully reduced using excess DTT in DCM. The reacted and unreacted DTT were 
washed out with water to leave the pure thiol and evaporation gave an oil. The 
hydrolysis method was later perfected; the procedure was addition of three portions of 
benzylamine, each of 1.5 equivalents, over a week and progress was monitored by TLC. 
Flash column chromatography gave the 3-thio product [49] as a pale yellow oil. 
Attempts to isolate the thiol as its sodium salt using 1 equivalent NaOMe were only 
partially successful. An orange oil was isolated and this could be nitrosated to give a red
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oil. However, the orange oil was not soluble in water and nm r spectroscopy 
revealed the presence of an extra peak casting doubt upon the identity of the compound. 
Hydrolysis using a catalytic amount of sodium metal in methanol was also attempted but 
after stirring for three days, under N 2 , only disulphide was detected. 3-Thioglucose was 
niti'osated in methanol /  water with HCl /  NaN 0 2  to give a red solution. Extraction into 
DCM  and evaporation gave a red oil. The oil maintained its colour during long term 
storage but large amounts of disulphide were detected by nmr spectroscopy. A clean 
nmr spectrum could be obtained only from a preparation of the nitrosothiol obtained 
by bubbling N 2 O 3  through a solution o f the thiol in DCM. This process is difficult to 
control and even slight over-nitrosation gave a brown solution which rapidly 
decomposed. 6"-Nitroso-3-thio-1,2:5,6-diisopropylidene glucofuranose [50] can be 
prepared as a seemingly stable molecule but cannot be isolated in its pure form.
1,2:5,6 diisopropylidenefnictose [52] was prepared by stirring fructose in acetone with a 
catalytic amount of H 2 SO 4 . As with glucose, the product was isolated as hard white 
sheets covering the inside of the Buchi flask. Some confusion was caused upon 
examination of the nmr spectrum as the C-2 is quaternary and therefore gives a 
much smaller peak than the other sugar carbons and it was seen only with difficulty. The 
3-0-tosylate [53] was prepared by the standard method using tosyl chloride and pyridine 
to give a white powder. As with glucose, attempts at the displacement of this tosyl group 
with a thiolate nucleophile proved unsuccessful and only starting material could be 
isolated.
OR
[52] R=H
[53] R=Ts
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Following the same recipe as for glucose, the preparation of the 3-0-triflyl derivative was 
attempted. A white powder was isolated with some difficulty as it had a higher than 
expected solubility in water. This powder showed the same blackening at room 
temperature as the glucose derivative. nmr spectroscopy showed that only one 
isopropylidene group remained, explaining the relatively high solubility in water. A 
possible product is [54]. Study of the reaction was not continued.
2.5. 6-5-N itrosoth iosiigars. It has been noted that the nitrosoderivative of a tertiary 
thiol, such as penicillamine, is much more stable than that of a primary thiol such as 
cysteine. This would suggest that the derivative of a secondary thiosugar, e.g. at 
positions 1 or 3, would be more stable than that of a primary derivative, at position 6 . In 
order to study this, various routes toward the preparation of 6-5^-nitrosothiosugars were 
investigated. The 6 -position in most sugars is the second m ost reactive, after the 
anomeric position and is therefore readily accessible once the anomeric position is 
blocked. In a similar manner to the preparation of 3- substituted glucose, a 6 - substituted 
galactose can be prepared using isopropylidene protecting groups to block the 1,2,3 and 
4 positions.
\
[55] R=OH
[56] R=OTs
[57] R=SAc
[58] R=SH
[59] R=SNO
The reaction of galactose with acetone using ZnCl2  and H 2 SO 4 , gave the l,2 :3 ,4 -0- 
diisopropylidenegalactopyranose [55] as a sticky brown syrup. Tosylation of the oil 
gives the 6 -tosyl [56] product as a white crystalline solid. Attempts at displacement of 
the tosyl group using tetrabutylam m onium  thioacetate in refluxing toluene were 
unsuccessful. However the tosyl group was displaced by potassium thioacetate in DMF.
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Distillation of the dark brown gum gave a pungent orange oil shown to be 6 -thioacetyl 
l,2:3,4-0-diisopropylidenegalactopyranose [57]. This method of isolation is particularly 
effective for this com pound. The isopropylidene groups give the molecule a rigidity and 
stability which allows it to be heated to such a high temperature (up to 175“C) without 
suffering decomposition. The use of DEPT nmr spectroscopy was applied to 
identify the chemical shift of the C-6 . Conversion to the thioacetate caused it to move 
upfield by 38 ppm. The thioacetate was hydrolysed to the thiol [58] using a catalytic 
amount of sodium in methanol. Evaporation and extraction into ether gave the 6 -thio 
product as a pale yellow oil. This very simple method of hydrolysis can be used as the 
isopropylidene groups, unlike acetates, are resistant to base hydrolysis. The oil was 
nitrosated to give a red semi-solid [59]. Although this appeared to be stable it was found 
to be mainly composed of disulphide. This was confirmed by direct oxidation of the thiol 
to give an identical product. Repeats o f the reaction gave increased degrees of 
dimérisation during the hydrolysis stage. It was found to be impossible to obtain the 
nitrosothiol in any gieater than -25  % purity.
Tosylation of com mercially available 1,2,3,4-0-tetraacetylglucose gave the white 
crystalline 6  tosyl product [60] in good yields. This was stirred in DMF at 120°C with 
potassium thioacetate to give a thick brown slurry. The solvents were removed by 
evaporation and the residue stirred with ice cold xylene. The residual salts were filtered 
off and the solvent evaporated from the filtrate. The process repeated to give a pale 
brown semi-solid. nm r spectroscopy of this revealed only the presence of 
thioacetate. No sugar ring carbons or O-acetates were observed. It is very unlikely that 
the desired 6-5"-acetylglucose tetra-(9-acetate would have been insoluble in xylene, 
suggesting that reactions other than its formation have occurred. A previous study^ 
involving the preparation and usage of a number of monosaccharide triflates suggested 
that the 6 -trifiylgalactoses were stable but that their glucose counterparts were not. The 
difference is probably that the galactose involved diisopropylidene protection whereas the 
glucose used acetate protecting groups. It may be that instability which caused loss of the
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tosyl group was accompanied by acetate rearrangement. This reaction could have been 
attempted using less harsh conditions, such as potassium thioacetate in ethanol, but in 
view of the unpleasant smell, the difficulty in selective hydrolysis o f the thioacetate and 
the difficulty of purification without causing O-acetate hydrolysis, it was decided not to 
pursue this reaction further.
2.4.3. A more elaborate procedure for the preparation of a 6 -thio substituted glucose 
starts with methylglucopyranoside and involves the use of a halide leaving group. 
Bromination at C - 6  was accomplished using NBS and PhgP in DMF, probably by the 
mechanism shown.
O O
PPhs
N — Br
Succinimide
O
^OH
O RCH2
R -O -P P h s
CHzBr 
Phgpo j —— q
HO .OH 'OMe
OH
[61]
During evaporation of the solvent it is important not to overheat the solution or the 
bromide can be easily lost. The product was dissolved in DCM and extracted into water. 
This is a very easy way of removing the phosphine oxide which can often be a difficult 
process. This remains in the organic phase. The sugar [61] was then acetylated in acetic 
anhydride and pyridine and the succinimide washed away with water. Evaporation of the 
solvents gave a thick brown oil. Recrystallisation from ethanol /  water gave a well 
crystalline white product [62].
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[60] [62] R=Br
[63] R=SAc
[64] R=SH
[65] R=SC(NH 2 )NH.HBr
Substitution of the bromide with thioacetate is an easy process. Potassium thioacetate in 
DMF (or acetone) is effective as is tetrabutylammonium thioacetate in toluene. The 6  
thioacetyl sugar [63] can be isolated either by distillation, to which the sugars are 
surprisingly resilient, or by precipitation of unwanted salts using xylene. Both methods 
gave a pure product but in a very low yield (20 - 30 %). Hydi'olysis of the thioacetate 
proved very difficult. Matched and Roberts^ reported the preparation of the thioacetate as 
a pale yellow glass, from which a thiol containing compound was obtained by hydrolysis 
with NaOMe. For this they reported an IR stretch consistent with a thiol but the 
elemental analysis was not as expected, suggesting large amounts of disulphide may have 
been present. The use of benzylamine in THF successfully gave only one product by 
TLC and no starting material. Flash column chromatography, under the same solvent 
conditions, gave no product. The disulphide has a much lower rf value so it is thought 
that dimérisation had occurred on the column. The usage of thiourea as a nucleophile has 
also been found to be successful. The thiouronium bromide salt [65] is precipitated upon 
reflux of the bromide with thiourea in acetone. Hydrolysis with K 2 S2 O 5  gave a pungent 
smelling white powder [64]. ^H nmr spectroscopy showed a doublet characteristic of 
thiol. However, the spectrum revealed the product not to be pure and disulphide was 
observed. Following two days storage, under refrigeration, the thiol smell had 
disappeared, suggesting that most of the thiol had oxidised. In view of the difficulties 
experienced in isolating pure thiol [64] in these reactions it was felt that a C - 6  S- 
niti'osothiosugar would not be a stable or viable prospect. Finally, as the C - 6  is reactive.
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it is possible to mesylate methylglucopyranoside selectively using 1 equivalent of mesyl 
chloride. This was done, followed by acétylation with acetic anhydride /  pyridine to 
allow isolation of the product. The product was found to contain no mesylate and to be 
fully acetylated. This suggested that either mesylation was unsuccessful, or that the 
mesylate was unstable and decomposed allowing acétylation of the C-6 .
2.6. 2,5-DianhydroaIditols. The shape of dianhydroalditols make them interesting 
to study. A substituent may be either exo or endo due to the bent and rigid shape of the 
molecule. Upon substitution the positioning is reversed. In the case of 1,3,4,6 
dianhydromannitol (isomannide) [6 8 ] the two hydroxyl groups are endo. An attacking 
nucleophile approaches from the "outside" o f the structure which is relatively easy. In 
the case of 1,3,4,6-dianhydroglucitol (isosorbide) [75], one hydroxyl group is exo and 
the other is endo. The endo group is easily displaced but the exo group can only be 
displaced under forcing conditions as an attacking nucleophile has to approach from 
"inside" the stincture. There is a third derivative, 1,3,4,6-dianhydroiditol [80], in which 
both of the hydroxyl groups are exo and substitution requires veiy harsh conditions.
RO
OR
HORO
OHOR
[6 8 ] R=H [75] R=H [80]
[69] R=Ms [76] R=Ms
[70] R=Ts [77] R=Ts
[71] R=Tf [78] R=Tf
It had been hoped that the 5-nitrosothio derivatives for all three could have been made, 
this would have allowed investigation into the differences in stability between a shielded 
SNO group and an exposed one. It was also hoped that these molecules would facilitate 
the preparation of a di-5-nitrosothiol and studies into whether this would be twice as
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active as a mono derivative. The dimesyl [69], [76] and ditosyl [70], [77] derivatives of 
isomannide and isosorbide were prepared. These are easy reactions and gave white 
crystalline products. A variety of thiolation methods were attempted in order to displace 
the mesyl and tosyl groups viz. thiourea in acetone, potassium thioacetate in DCM / 
ethanol, thioacetic acid with ZrCl^ in DCM, tetrabutylammonium thioacetate in toluene 
and phase transfer using tetrabutylammonium hydrogensulphate and finally thioacetic 
acid and sodium hydroxide in ethyl acetate/water. Unfortunately none of these conditions 
was strong enough to cause reaction and starting materials were isolated each time. Two 
harsher sets of reaction conditions involve the use of potassium thioacetate in acetonitrile 
or in DMF. In both cases a foul smelling brown sludge was produced from which no 
identifiable product could be obtained by either precipitation or by colum n 
chromatography. Distillation of the product from the DMF reaction gave an orange oil. 
This was found to be the 2,5 dithioacetate [72].
RS
SR SR
[72] R=Ac [79] R=Ac
[73] R=H
[74] R=NO
Following the methods of Bladon and Owen,9 the thioacetate was refluxed in a 2.5% 
HCl solution in methanol. Evaporation gave a pungent brown oil. The authors claimed 
that the product is stable enough to allow removal of the HCl by evaporation followed by 
distillation of the product to give a clear low melting solid (35 - 37 °C). Storage of the oil 
under vacuum with NaOH removed most of the remaining HCl and left a brown semi­
solid. This was distilled under vacuum to give a pale orange oil with a very strong 
odour. The oil solidified under refrigeration. Nmr studies showed it to be a pure sample 
of [73]. The thiol stretch at 2560 cm’l was seen by i.r. spectroscopy, showing that the
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pure thiol has been formed. The thiol would appear to be perfectly stable under acid 
hydrolysis conditions and remarkably stable towards heat. Considering our apparent 
inability to prepare the thiol under base hydrolysis condition we had initially supposed 
this to be a very unstable thiol, prone to oxidisation or polymerisation. These,results 
indicate that the instability is more towards basic conditions. The dithiol was nitrosated 
to give an impure but seemingly stable red oil. In view of our earlier failures to displace 
m esyl and tosyl groups, the usage of a triflate leaving group was investigated. 
Isomannide ditriflate [71] can be prepared from isomannide using triflic anhydride and 
pyridine in dry DCM. Evaporation gave a yellow oil. Solidification followed by 
recrystallisation from ethanol produced long needle crystals. The triflate is much more 
reactive than the mesylate or tosylate and reaction with potassium thioacetate in DCM /  
ethanol to gave the 2,5-dithioacetylisomannide [72] as an oil. The deacetylation proved 
difficult. The use of two equivalents of NaOMe lead to the formation of a white solid 
found to be insoluble in all common laboratory solvents. This was assumed to be the 
polysulphide polymer. Acetate hydrolysis with benzylam ine in THE under N 2  
successfully removed all starting material and during the reaction a strong thiol smell was 
noted. TLC showed the fonnation of a large number of different products as the reaction 
continued. Attempts to separate these by flash column chrom atography proved 
ineffective. The thioacetate was also directly produced from isomannide using a 
Mitsonobu type reaction as shown in figure 4 This produced the desired thioacetate but 
left a vast amount of PhgPO. For 3 g of the product over 20 g of phosphine oxide is 
formed. Isolation of the pure product from this requires an excessive amount of time and 
effort involving repeated crystallisations of phosphine oxide from ethyl acetate.
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Figure 4
H 3 C -C
PhaPO +
H S -C
Q> H H .C -N -N -C ^
EtO OEt
The ditriflate of isosorbide [78] was also produced by the same method as for isomannide 
and gave a low melting solid. Displacement with potassium thioacetate in DCM /  ethanol 
gave an oil. nmr spectroscopy gave a clean-looking spectrum but showed 13 major 
peaks for the ring carbons instead of the expected 6 . Two thioacetate peaks were seen. 
A number of spots were shown by TLC. It is assumed that the endo triflate will 
substitute readily but it is thought possible that, with the exotriflate, elimination may 
occur more readily than substitution. A possible product from this reaction is [79]. A 
similai* nmr spectrum was obtained for the reaction of the ditosylate with potassium 
thioacetate in DMF. The hydrolysis of this impure thioacetate was attempted using 
benzylamine in THF. A strong thiol smell was noted during the reaction but a number of 
side reactions were indicated by TLC and isolation of the thiol proved impossible. Our 
results show that an exo thiol group is reactive and prone to dimérisation. If a thiol group 
could be inti'oduced at an endo position, without causing elimination, then a compound of 
greater utility for our purposes might be prepared.
2.7. Thioglycerols. Nitroglycerine is not only a very effective nitric oxide donor but 
it is also a very effective transdermally delivered molecule. It was hoped that S-
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nitrosothiol derivatives of glycerol might exhibit the same qualities. Thioglycerol (3- 
m ercapto-1 ,2 -propanediol) [81] is readily available and provides a very useful and 
inexpensive starting material. The nitrosation of thioglycerol was previously performed 
by Matthews and Kerr^ without isolating the product. The nitrosothiol was discarded as 
too stable and therefore inactive. It has now been shown to be of great interest and other 
groups are now investigating the route o f decomposition. The ^-nitrosated product 
(SNOIL) [82] was prepared by nitrosation of with HCl /  NaN0 2  in methanol /  water.
H2 C
HC
HgC-
■SR
OH
OH
[81] R=H
[82] R=NO
H2C-
HC-
H2 C-
SR
OAc
OAc
[84] R=Ac
[85] R=H
[8 6 ] R=NO
This was then repeatedly extracted with DCM to give a deep red oil in low yields, most of 
the product remaining in the aqueous phase. A better nitrosation procedure involves 
dissolving the thiol in DCM and passing N2 O 3  (from HCl dripped onto NaN0 2 ) through 
the solution. This reaction is difficult to control but it should be possible to follow the 
loss of thiol using basified nitroprusside as a marker. A purple adduct forms in the 
presence o f thiol. Overnitrosation leads to the formation of a brown solution which 
decomposes giving none of the desired product. Various reasons for this have been 
considered including the foimation of CINO, a powerful oxidising agent, from impurities 
in the solvent. Under-nitrosation obviously leads to unreacted thiol being present. A 
complex twist to our study of this compound is that in solution SNOIL is a very stable 
compound. On the other hand, as a pure oil it can be very unstable. When stored in a 
sealed container in a freezer it can be explosive. Our studies suggest that the isolated pure 
nitrosothiol is unstable, but material still containing small quantities of unreacted thiol
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impurity is indefinitely stable. As far as our transdermal studies were concerned, the 
water solubility of the non-protected glycerol meant that it was not of use to us. It was 
hoped that acétylation would allow its use. Three different methods were investigated for 
the preparation of the diacetyl product. The first involved the initial preparation of the 
disulphide. D ioxygen was bubbled through a solution of the thiol basified with 
triethylamine. The disulphide was then acetylated with acetic anhydride /  sodium acetate 
to give the tetraacetate [83] as an oil. This was then stirred in methanol with 1 equivalent 
of the reducing agent dithiothreitol under N2  in an effort to regenerate the thiol. Only 
starting material could be isolated from the reaction. The second method involved direct 
acétylation of the thioglycerol to give the triacetate [84]. An 5-acetate is less stable than 
an D-acetate and can be deprotected by selective hydrolysis. This involved stirring the 
thioacetate in dry THF, DMF or diethyl ether with an amine (1.5 eq). After 3 days 
stirring under N2 , benzylamine in THF showed 100 % 5-deacetylation, hydrazine acetate 
in DMF showed 50 % reaction and diethylamine in ether showed no reaction. Due to the 
difficulties in removing DMF without causing disulphide formation the hydrazine acetate 
reaction was not further investigated. The diethylamine reaction would have been an 
obvious choice had it been successful as both the ether and amine are easily removed by 
evaporation. The by-product, diethylamine acetate, also has a low boiling point and is 
easily removed. The benzylamine in THF method was the preferred choice. Flash 
column chromatography is required to remove the benzylamine acetate and unreacted 
benzylamine. This produced the pure thiol [85] as a pale brown oil. The thiol was 
indefinitely stable in a refrigerator. The thioglycerol diacetate was nitrosated by both the 
N 2 O 3  and the HCl /  NaN0 2  methods. Evaporation gave the nitrosothiol as a deep red oil
[8 6 ]. The oil required to be kept in the freezer, decom posing overnight under 
refrigeration. The final method involved the direct acétylation of SNOIL. It was hoped 
that the high stability of the nitrosothiol might allow acétylation and purification without 
showing any significant decomposition. The red oil was acetylated in acetic anhydride /  
pyridine. The product was dissolved in DCM and the unwanted acid and base washed
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out.. Evaporation produced a thick red oil. NMR revealed that a substantial degi’ee of 
decomposition had occurred (~30 %). The oil decomposed within 24 h of refrigeration.
Attempts were made to synthesise the dibenzoyl derivative of thioglycerol using benzoyl 
chloride. This gave a range of products with could not be adequately separated by 
column chromatography.
2.8. M ercaptosucciiiates. Mercaptosuccinic acid is one of the more stable thiols and 
is found to be quite resistant to disulphide formation. 5-Nitrosothio derivatives of this 
were investigated in the hope that the acid group, next to the SNO, might shield the SNO 
from  decom position. M ercaptosuccinic acid [87] is a crystalline water soluble 
compound. In order to lower the solubility the methyl and ethyl esters were prepared. 
Several methods for this were investigated including acétylation followed by méthylation. 
These would have required hydrolysis of the thioacetate produced. These studies were 
stopped when it was discovered quite how easy it was to make the esters by standard 
methods. Mercaptosuccinic acid was heated at reflux in the relevant alcohol with H 2 SO4  
and a few molecular sieves. The methyl [8 8 ] and ethyl [90] esters were successfully 
prepared as unpleasant smelling oils.
\  \
C CO2 H H*— C C02Me C-----C02Et
H S —  C —  C O 2H R S -------- C —  COglVIe R S —  C  C 0 2 E t
H H H
[87] [8 8 ] R=H [90] R=H
[89] R=NO [91] R=NO
No reaction at the thiol centre is seen. The nitrosation of these using either N2 O3  or HCl 
/  NaN 0 2  methanol /  water gave a deep red oil. These oils [89], [91] appeared to be 
almost indefinitely stable, one having been left on a bright fume cupboard window 
showed very little decomposition. Unusually for a thiol, if anything the odour becomes
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more unpleasant upon nitrosation. The smell, quite the worst encountered in these 
studies, curtailed any further studies on these com pounds, w hether kinetic or 
physiological. If not for the smell then these compounds would have been of great 
physiological interest to us due to their stability.
2.9. Pen icillam ine derivatives.
2.9.1. A-Acylated penicillamine derivatives. 5-N itroso-A -acetyl penicillam ine 
(SNAP) is a well known nitrosothiol. It is very stable as a solid but in solution it usually 
decomposes fairly rapidly. This has been shown to be due to the fonnation of a complex 
with Cu(I), a species which undergoes rapid decomposition. The preparation of similar 
compounds containing longer acyl chains is of interest for several reasons. It is hoped 
that the long chain may "shield" the -SNO group and prevent the complexation of copper, 
giving a much enhanced lifespan to the molecule. It is also a possibility that a long acyl 
chain will be soluble in the lipid membrane. The rest of the molecule would not be and 
so the acyl chain would act as an anchor holding the molecule in place and distributing 
NO in a much less random fashion than a "free" NO donor. This may have the effect of 
greater activity, with less NO being lost. It may also give a longer lasting effect with the 
donor being absorbed onto the membrane rather than passing rapidly through. Three 
different chain lengths have been prepared alongside the two membered acetyl group seen 
in SNAP: the 3, 5 and 7 membered propionate [99], valerate [103] and heptanoate [107] 
derivatives. These are prepared by a similar procedure to that of Martin et for the 
acétylation of cysteine. The thiol precursors to all three could be isolated but the S- 
nitroso products for the propionate and heptanoate were more easily prepared without 
isolation of the thiol.
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HaC-rf {? HsC ' Y  5 H a C n  {?
/ \  /CH3 / \  / C ^  ^CH3 /C x  /CHs
HOgC N C HO2 C N (CH2)3 HO2 C N (CH2)5
H H2  H H
[99] R=H [103] R=H [107] R=H
[100] R=NO [104] R=NO [108] R=NO
A-Propionylpenicillaniine was prepared from stirring penicillamine in aqueous THF with
1 . 2  equivalents of propionic anhydride and 2  equivalents of sodium propionate under N2 . 
After standing overnight the THF was evaporated to leave a thin oil. The oil was 
dissolved in water and conc. HCl was added until precipitation began. The mixture was 
chilled and a large amount of white solid was obtained. The solid could be recrystallised 
from hot water. However, an easier purification route was to stir it with hexane, where 
impurities taken out to leave the A-propionylpenicillamine in pure form. The V-valeryl 
and A-heptanoyl derivatives can be made in the same manner using the appropriate 
anhydride and sodium salt. The valeryl derivative has a particularly nasty smell. In the 
direct preparation o f 5-nitroso-A-propionylpenicillamine [ 1 0 0 ] the thin oil from the 
acylation was dissolved in water and nitrosated with an excess of HCl /  NaN 0 2 . A deep 
red liquid was produced. This was chilled in ice and a green solid appeared. An HPLC 
study showed only one product present. The ^H nmr spectrum showed a paiticularly 
clear NH - CH coupling. The valeryl derivative [104] was prepared by dissolving the 
thiol in water and nitrosating as above. The slow addition of excess acid with chilling 
caused a dark green solid to precipitate. The nitrosothiol was only slightly less pungent 
than the thiol. The heptanoyl derivative [108] was, like the propionate, prepared via the 
thin oil from the acylation reaction. The oil was nitrosated in water as above and a red oil 
was precipitated. The oil was dissolved in DCM, washed and dried. The major impurity 
was found to be heptanoic acid. The nitrosothiol was very soluble in base, mling out the 
use of NaHCOg as a means to remove the acid impurity. The solvent was evaporated to 
give a red /  green dichroic oil. Refrigeration for several days caused a green solid to form
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in the oil. The semi-solid mixture was stirred with hexane and a dark green solid was 
precipitated, nmr spectroscopy showed the powder to be a mixture of nitrosothiol 
and unreacted thiol. This was dissolved in DCM and re-nitrosated with N 2 O 3 . 
Evaporation and trituration with hexane gave the pure nitrosothiol. Further studies 
confirmed that this is a relatively slow nitrosation. W hilst all o f these products were 
green and showed the same red/green dichroism  as SNAP, their colours were 
significantly different to that of SNAP, all being of a lighter shade. There also appeal's to 
be an increase in the value with increasing chain length. This is also shown in the 
results from the penicillamine derivatives coupled to glucosamine. All derivatives 
showed a similar stability to SNAP and a similar response to copper. The chain length 
appears not to give protection against copper catalysed decomposition and so probably 
does not prevent copper complexation. The propionyl and heptanoyl derivatives have a 
very similar physiological activity to that of SNAP, whereas the action of the valerate is 
startlingly different as described in chapter 3.
2 .9 .2 ,  P e n ic in a m in e -s u g a r  c o u p lin g  reac t ion s. Results in chapter 4 
demonstrate the possibilities for the transdennal delivery of an acetylated sugar moiety 
and that a compound as such is a much more effective vasodilator than SNAP when 
delivered transdermally. Since SNAP is a much more stable nitrosothiol (in the solid 
phase) than SNAG, it was thought that it might be possible to combine the two structures 
to create a molecule containing the good features of both. Various methods have been 
looked at for the prevention of copper complexation, and the decomposition this causes, 
in penicillamine based NO donor compounds (see above). The free acid group plays an 
important role in this complexation . Were the acid to be linked to a bulky group there 
was the possibility of inhibiting this copper promoted decomposition. From this came 
the idea of linking an amino sugar to a penicillamine residue via an amide bond. The 
most readily available aminosugar is glucosamine (2 -amino-2 -deoxy glucose) bought as 
the hydrochloride salt. This otherwise synthetically difficult molecule is extracted from 
such sources as crab shells. The free base may be prepared by reaction with sodium
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dissolved in methanol, the hydrochloride salt going into solution as the free base whilst 
sodium chloride is precipitated and can be filtered off. Attempts to use this in coupling 
reactions with V-acetylpenicillamine, either by the mixed anhydride or DCC methods, 
were thwarted by the lack of a suitable solvent in which to carry out the reaction. This 
was not of great importance as the coupled product would have had too great a solubility 
in water to have been of any interest to us. In order to prepare a suitable compound it 
was necessary to acetylate the product and then selectively remove the 5-acetate. Whilst 
this is not overly difficult it did suggest that it would be simpler to introduce the acetate 
groups onto the sugar prior to coupling with penicillamine. The method of Bergmann 
and Zervas^^ has been widely used for this, involving the use of an anisaldehyde 
protecting group for the amine.
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HCI.NH2
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NaOH OHHO
HC [93]
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I HCI.NH2 I
[95]
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[96]
N-acetyl .  ^  
P en ic illam ine
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0 = c (  SH [97]
H N ^  H3C 
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H3C
The glucosamine hydrochloride [92] was dissolved in sodium hydroxide solution and 
shaken with anisaldehyde. Initially the anisaldehyde remained as an oily suspension but 
eventually reacted. Chilling at -20°C gave large quantities of product [93]. It was 
necessary to dry the product, under vacuum over P2 O 5  at 45“C, for 3 days, before 
acétylation can be carried out. In the presence of water acetic anhydride will react to form 
acetic acid. The acid will hydrolyse off the anisaldehyde group allowing unwanted N-
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acylation to occur. An N-acetate is particularly difficult to remove, being more stable 
than an O-acetate. The dry anisol-glucosamine was acetylated in acetic anhydride /  
pyridine. W hen poured into ice water a high yield o f acetylated product [94] was 
obtained. The method of Bergmann and Zervas for the removal of the anisaldehyde 
group involves dissolving the acetylated product in boiling acetone and the addition of 1 
mole of 5 M HCl. This should lead to the precipitation o f large crystals. Repeated 
attempts at this method gave no precipitate. However, the deprotected amine was 
prepared by a simpler method. The acetate was dissolved in acetone with heating. A 
small quantity of water was added, followed by drop wise addition of conc. HCl until 
precipitation of [95] occurred. Chilling caused the precipitation of large amounts of solid 
until the mixture could no longer be stirred efficiently. Repeated washing and stirring 
with chilled ether removed the oily yellow anisaldehyde precipitate. The solid material 
was dried and dissolved in water. The free base [96] was prepared by the addition of 2 
equivalents NaOAc. Extraction with DCM gives a white solid in moderate yields. 
Coupling with N-acetylpenicillamine was carried out using the DCC derivative shown in 
figure 5.
Figure 5 
+/C H 2 — C H 2 — N =C =N -
O '
CH3C0H4SO3
This method has the advantage that the urea by-product is insoluble in DCM and can be 
filtered off after reaction is complete. Glucosamine acetate, A-acetylpenicillamine (1.5 
eq) and the DCC agent (1.5 eq) are stirred under overnight. The reaction follows a 
particular profile when successful. The reaction mixture is initially cloudy due to the low 
solubility o f A-acetylpenicillamine in DCM. After about 15-30 minutes it begins to react, 
goes into solution and the reaction mixture becomes clear. This lasts for about 5 minutes 
before the urea begins to precipitate and the solution again becomes cloudy. Washing 
with acid, base and water removes any remaining starting materials and by-products to
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give a white powder. The powder is washed with dry ether to give a very clean product
[97]. nmr spectioscopic studies were complicated by the use of D, L-penicillamine 
as a starting material. This produces two distinctive enantiomers in the product, shown 
by each peak being doubled or being twice the expected height. The use of a 300 MHz 
nmr spectrometer and DEPT was successful in assigning each peak. The nmr 
spectrum proved difficult to interpret. For nitrosation the thiol was dissolved in methanol 
/  water, nitrosated with excess NaN 0 2  /  HCl and extracted with DCM. Evaporation gave 
a dark gieen oil which was triturated with dry ether to give a dark green powder [98]. 
The yield is low (-30  %) but it is interesting that this should be so similar to the yields 
obtained by Waiig^^ for the preparation of the non-acetylated derivatives by a completely 
different method. Frequently it has been found that the product is not fully nitrosated and 
still contains large quantities of the thiol precursor. Nitrosation can be completed by 
passing N 2 O 3  through a solution of this in DCM. The nitrosothiol was found to be 
stable, more resistant towards copper catalysed decomposition and of great physiological 
interest to us (chapter 3). This compound and its derivatives have been patented for use 
as a vasodilator, involving a range of substituents.
CHO2R'
RO OR'
NH
S R
CH
HN,
Where R^=Ac and
[97] R'=H, R^=CH3
[98] r ‘=NO, R^=CH3
[101] r '=H, R^=CH2CH3
[102] r '=NO, R^^CHzCH)
[105] R*=H, r2=(CH2)3CH3
[106] R'=N0, R^=(CH2)3CH3
[109] R'=H, R^=(CH2);CH3
[110] R^=NO, R^=(CH2)5CH3
Compounds containing other alkyl groups were synthesised. The same methods as 
above were used to link N-propionyl, N-valeryl and N -heptanoylpenicillam ine to 
glucosamine [101], [105], [109]. The reaction with the propionoate is similar to that of 
the acetate. The heptanoate was prepared as a white oil which required trituration and
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chilling with dry ether in order to obtain a solid product. The valerate showed the same 
profile as the heptanoate but appeared to be more soluble in ether. Trituration gave a 
product but only in very small amounts. These three were nitrosated as above [102],
[106], [110], the heptanoate again proving very resistant to nitrosation. The three have 
similar stabilities to RIG 200 but the longer acyl chain leads to solubility problems which 
has made physiological testing difficult. The nomenclature of these, RIG 200 etc, was 
created due to a seminar being presented on the physiological results before the patent had 
been finalised. The original name "GLUPEN" was felt to give an idea on the structure 
and, as prior disclosure can invalidate a patent, it was decided to use the original 
experiment number, IRG 200, as the name. A mistake lead to this being changed to the 
more pleasing RIG 200. This somewhat conveniently refers to a compound with a 2 
carbon chain. The other com pounds, RIG 300, 500 and 700 have been named 
accordingly as have their thiol precursors.
2.9 .3 . Synthesis of 1-aminosugars for glycopeptide preparation. Having 
successfully prepared glyco-ami noacids based on 2 -aminoglucose we were interested in 
preparing other similar derivatives. The possibility of other acyl groups on the 
penicillamine residue has been discussed above. Another possibility was to move the 
penicillamine-sugar linkage to a different part of the sugar ring. This has been done in 
the study performed by Wang et al on related compounds. It should be noted here that 
our study was begun 6  months before the publication of the above work and the patent 
for RIG 200 also submitted before that work. As in Wang's study we felt that the 1 and 
6  positions were the most worthy of investigation. Both of these positions are very 
different from positions 2, 3 and 4. They are also the most easily accessible. In order to 
couple the sugar to the penicillamine moiety it is necessary to introduce an amine group 
into the structure. One of the easiest methods is via the azide. The bromides of per- 
acetylated glucose, galactose and maltose were stirred in DMF at 100°C with excess 
sodium azide for several hours. The 1-azido products [111], [115], [117] were
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precipitated when the mixture was poured into ice water. Recrystallisations from 
methanol gave attractive pale yellow crystals.
CH gO A c1
A cO O A c
CH gO A c
A cO
A cO CH2 OACO A c O
A cO O A c
[111] Rl=OAc, R2=H 
[115] R 1=H ,R 2=0Ac
N3
[117]
Hydrogenation of the azide was attempted using Raney Nickel in ethyl acetate but only 
starting m aterial was isolated. The three 1-azido products were successfully 
hydrogenated using 10 % Pd on carbon in a large volume o f methanol, under an 
atmosphere of hydrogen. In the cases of glucose [112] and galactose [116], filtration and 
evaporation gave a clear oil which slowly solidified. Recrystallisations from ethanol gave 
the 1-amino sugars as white solids. In the hydrogenation of 1-azido maltose the amino 
sugar was precipitated during the reaction. DCM was added and the mixture heated until 
solution occurred. The catalyst was removed by filtration through hot celite. As the 
solution cooled the amine was re-precipitated as a white powder [118].
CHgOAc
A cO
A cO CH2 OACOAc
A cO NH2 OO A c
A cO NH2O A c
[112] R1=OAc,R2=H
[116]R1=H,R2=OA c
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The coupling reactions were carried out in the same manner as for 2-aminoglucose. The 
reactions usually followed the same pattern as before, whereby the penicillamine goes 
into solution and the urea by-product is precipitated. Both these factors, along with the 
strong thiol smell, suggested a successful reaction [113]. In the cases of glucose and 
galactose a thick oil was produced. Unlike the 2-aminosugar coupling, this was found to 
be soluble in ether. nmr spectroscopy revealed most of the desired peaks to be 
present along with a number of major peaks which could not be assigned. No suitable 
solvents could be found for a successful tiituration.
A cO  NH
CHa
CH3  Q
O H
[113] R=H
[114] R=NO
The oil was nitrosated in methanol /  water with HCl /  NaNÛ 2  and a green /  brown oil 
produced. Again the oil was soluble in ether and trituration was not possible, nmr 
spectroscopy of the nitrosothiol [114] revealed it to be impure and gave few indications 
as to the structure of the molecule. In the case of maltose the reaction followed the same 
pattern but a white solid was isolated in large quantities (>70 % yield). Despite the 
strong thiol smell, this was found to be starting material. It is not clear why products 
with analyses resembling those expected, with the expected odour, from reactions 
following very distinctive profiles should prove to be non-isolable. The products from 
the 2 -aminoglucose reactions me insoluble in ether, which provides a very convenient 
method for the removal o f im purities. W hy a sim ilar com pound based on 1- 
aminoglucose should have a completely different solubility is not readily apparent. It is 
possible that the desired product has not been prepared due to a molecular rearrangement 
of an undefined nature.
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2.9.4. Syn thes is  o f  6 -am inosu gars  for g lycopep t ide  preparation . 6-
Aminogalactose was prepared from 6 -bromomethyl glucopyranoside tiiacetate via the 
azide by the same route as the 1-amino sugars. The azido product [6 6 ] was a crystalline 
white solid and the amino product [67] a clear oil which eventually hardened. The 
coupling followed the same pattern as those above, giving a pungent oil which could not
be purified. Similaiiy niuosation gave a green oil which could not be characterised
A cO Ago
Ago O M e A cO O M eO A c O A c
[66] [67]
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2.10. Sum mary.
We have made a variety of interesting products and investigated a number o f different 
routes toward the synthesis of such compounds. The compounds prepared have fallen 
into a number of different categories:
a) Stable compounds which may be of use for physiological studies and which may have 
potential therapeutic usage. These include SNAG, SNOPP, SNVP, SNOPHE, RIG 
200, RIG 300, RIG 500 and RIG 700.
b) Stable compounds which cannot be used due to their unpleasant odour. These are the 
mercaptosiiccinates.
c) Semi-stable compounds of which some usage may be made but their full potential is 
difficult to assess without further study concerning their mode of decomposition. In 
particular these are the thioglycerol derivatives.
d) Semi-stable compounds which cannot be prepared to the degree of purity necessary for 
physiological usage, such as the S-S-nitrosothiol derivatives of glucose, the 6 -5 "- 
nitrosothiol derivatives of galactose and the 2,5-5-nitrosodithioisomannide.
e) Unstable compounds of no possible physiological usage due to this instability, such as 
the S'-nitrosothiol derivatives of galactose, xylose, maltose and lactose.
f) Compounds for which the S-nitrosothiol derivative could not be made either because of 
thiol instability or because pure thiol could not be obtained. These include the derivatives 
of benzoylated glucose and galactose, the derivatives of isosorbide and isomannide, the 
coupled products of the 1 -penicillam inyl ami nosugars and the 6 -penicillam inyl 
aminosugars.
g) Synthesis which failed after a few steps. These include reactions involving fructoses 
and 3-0-methyl glucose.
Many different nitrosothiols have been prepared but it is convenient that the most 
interesting products developed all came from relatively easy, user-friendly reactions. 
These gave products in a solid form which were easy to handle. The products which 
could be obtained from the more difficult and less user friendly reactions appeared to be
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of little interest as either the reagents were too expensive, the yields were too low, the 
products too unstable or simply the products were unsuitable for testing.
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Chapter 3: Vasodilatory Properties of N itric Oxide Donors.
3.1. Introduction.
Am ongst the many roles nitric oxide is known to play, or thought to play, the 
maintenance of vascular tone is possibly the most important. As discussed in chapter 1, 
nitric oxide is responsible for relaxation of the smooth muscle which surrounds blood 
vessels. By this method blood pressure can be controlled. Nitric oxide is produced by 
the thin layer o f cells lining the vessels, the endothelium. Endothelial dysfunction, 
resulting in a reduced level of nitric oxide synthesis, is thought to play a major part in a 
number of disorders such as atherosclerosis. Nitric oxide acts as an inhibitor of platelet 
aggregation and of muscle cell proliferation. When it is not present in sufficient 
quantities the walls of the blood vessel are susceptible to a build up of platelets which 
form clots and allow the deposition of fatty substances which narrow the blood vessel. 
Similarly, an increase in muscle cells in the vessel also acts to nanow  the artery. The 
reduction in vessel diameter restricts the amount of blood which can pass through and 
causes an increase in blood pressure. This places additional strain on the heart and 
increases the risks of a clot forming and blocking the artery. This may then cause a heart 
attack. A common treatment for this condition is percutaneous tiansluminal angioplasty. 
This involves the insertion of an inflatable tube into the artery via the blood vessels at the 
top of the leg. The tube is then inflated to fill the artery and forcibly removed. This act 
of removal scrapes away the deposits lining the artery, but also destroys the very delicate 
endothelium. The lack o f endothelial production of nitric oxide to inhibit platelet 
aggregation, allows further deposits to gather in the artery and frequently leads to a 
reoccurrence of the problem. ^  Following angioplasty it is common for the endothelium 
to take as much as two weeks to fully recover. During this period a hardening and 
scarring of the vessel, known as restenosis, may occur. Without the continual changes in 
dimension encountered by a normal blood vessel, in response to nitric oxide, the vessel 
may lose its ability to dilate. Consequently it would be desirable to supply nitric oxide to 
the afflicted areas during this healing period to prevent damage to the arteries. GSNO has 
been used for this purpose, inhibiting platelet aggregation as well as acting as a
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vasodilator.^ This usage, whilst patented, is not terribly effective as the GSNO is not 
very stable and gives only veiy short term relief. The other drawback encountered is the 
difficulty in containing the response to only involve the desired blood vessels. If a non­
specific NO donor, such as GSNO, is used then it will cause a general increase in blood 
flow throughout the body. As there is no overall increase in blood volume, there is no 
benefit to the damaged areas. In practice a systemic response may be positively hamiful 
due to vascular steal. When a damaged area is in competition with a healthy area it will 
receive a smaller blood flow, the blood taking the route of least resistance. When a non­
specific vasodilator is given, the healthy area will be able to respond more efficiently, 
dilating more rapidly and to a greater degree than the damaged one. Due to this the 
healthy area will steal an even greater proportion of the available blood and, instead of 
helping, the situation will be exacerbated. This highlights the necessity of developing a 
specific NO donor. GSNO is a stronger inhibitor of platelet aggregation than SNAP, 
however it is a poorer vasodilator,^ showing a useful degree of specificity. If this could 
be exploited and a more stable derivative prepared, then it could be of therapeutic benefit. 
Another useful avenue o f investigation is the preparation of NO donors which exhibit 
tissue specificity, showing a greater degree of activity towards damaged tissue. It is 
these compounds we have concentrated upon. The addition of a long aliphatic chain to a 
stable NO donor was thought to have the possibility of being absorbed into the tissue 
lining the blood vessel. A possibility for this involves the preparation of bipolar 
molecules with a stiongly hydrophobic portion and a strongly hydrophilic portion. It 
was envisaged that the hydrophobic area would be taken into the tissue whilst the 
hydrophilic part would remain on the surface in the lumen. The NO donor part could be 
on either the hydrophobic or hydrophilic portion of the molecule giving two completely 
different types of donors. Nitric oxide, delivered intra-arterially from a compound 
remaining in the blood flow, can only have a transient effect upon the blood vessels as it 
will move through them at such great speed. Were the molecule to be held in place, 
delivering the nitric oxide to one particular area, then it could have a much higher 
potency. This effect would be even greater were the NO to be released inside the tissue
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rather than in the blood and so another line of investigation is to create a molecule with 
the correct solubility as to pass into the surrounding tissue in its entirety. In a similar 
manner to RBS (chapter 1) this could act as a long tenu local supply of nitric oxide.
Another important vascular use for nitric oxide donors is the treatment of angina pectoris, 
the intense pain caused by the spasmic contraction of the cardial muscles. The organic 
nitrates nitroglycerine, isosorbide mononitrate and isosorbide dinitrate as well as amyl 
nitrite have been used for this for many y ear s. ^  Their usage is limited by the 
development o f tolerance (chapter 4). This is probably due to depletion of the body 
supply of thiols, which are thought to be used in the metabolic processes involved in the 
production of nitric oxide from organic nitrates. A nitrosothiol, not requiring metabolic 
processing, is a viable alternative. This could provide a continuous supply of nitric oxide 
without the need for rest periods as for organic nitrates. It may also be possible to 
alternate between the two types of donor to provide full and effective treatment for more 
serious sufferers. In order to do this a nitrosothiol with a greater degree of stability than 
those previously known would be required. It is probable that this would involve 
resistance to copper ion catalysed decomposition whilst maintaining the thenual stability 
of SNAP. A final usage for these donors is in the field of heart by-pass surgery. This 
involves an artery being ti'ansferred from the leg to act as a new vessel in the area of the 
heart. A problem frequently encountered in this area is that the vessel may suffer an 
irreversible contraction during this transferral period. A donor which could be absorbed 
into the vessel and keep it dilated during the process, would obviously be of great benefit 
in these operations.
With very able support from a number of physiologists we have been able to investigate 
the possibilities for fulfilling these requirements from the nitric oxide donors that have 
been prepared. These have been tested upon isolated rat arteries. Early studies were 
perfomied on the tail artery. This is a relatively large and easily accessible artery. The 
drawback of this, as a large artery, is that it has little relevance to the control of blood
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pressure. It is changes in tone o f the smallest blood vessels, the resistance vessels, 
which are responsible for major alterations in blood pressure. Therefore it is preferable 
to use the smallest possible vessels which can be handled. Perhaps a more valid 
complaint is that humans don’t have tails and therefore no valid comparisons can be 
made. Later studies were performed using the smaller rat femoral arteries. Further work 
may involve use of the even smaller mesenteric arteries. Several delivery methods for the 
donor to the artery were investigated. The donor may be delivered as a bolus injection, 
whereby increasing doses are passed through the artery where they remain for only a 
very brief period o f time. The artery is allowed time to recover between doses. From 
this a dose response cuiwe for each compound can be constructed. The donor may also 
be delivered by supeifusion, where the donor is added to the Krebs buffer and the artery 
is continually bathed in it. Increasing doses are then added to the perfusate without the 
ai'tery recovering to its original level of contraction. The artery can then be washed out 
with fresh buffer to detennine the time taken for a full recovery to be made. It is also of 
im portance to add a nitric oxide scavenger, such as haemoglobin or an L-arginine 
analogue to the perfusate to determine that the dilation is NO mediated. The co­
superfusion of the donor with a scavenger is a valuable method of separating a sustained 
response from a ti'ansient one. With this method the transient response may be seen but a 
sustained one is suppressed by the scavenger.
The most important aspect of these studies was found to be the difference in vasodilatory 
activity between arteries with an intact endothelium and those with the endothelium 
removed. In order to validate the relevance of these studies limited testing upon humans 
has been done. Ethical permission for the use of the more promising compounds has 
been obtained and so full in vivo studies on humans will be perfonned in time. A lack of 
time, and other commitments for those involved, has determined that only a select 
number of our compounds have been tested. It is felt that these are probably the most 
likely to show results of interest to us.
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From  these studies we have shown our compounds to be active as NO mediated 
vasodilators. We have gained an idea of their relative potencies and the length of time the 
response may be sustained.
3.2. Isolated rat tail artery studies.
In order to carry out any kind of a study on a nitric oxide donor, it is necessary to first 
ascertain that it does indeed act as a vasodilator. Our initial studies were carried out using 
SNAG as the vasodilator and the animal model studies solely to support the results 
obtained from  human testing. Later studies, perform ed by a more experienced 
physiologist using blood vessels more closely related to those found in humans 
represented full studies in their own right.
Experimental set-up
A set-up depicted below (figure 1) was used. In this case it was the tail artery rather than 
the femoral that was used in this experiment. The perfusion system used is similar to that 
previously described.^
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Figure 1
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Segments o f tail artery ( 1 - 2  cm long) were dissected from normotensive male wistar rats 
(300 - 400 g) following cervical dislocation. These were cannulated and perfused 
internally with pre-warmed Krebs solution pH 7.3 - 7.4 (composition in mmols dm'3: 
NaCl, 118; KCl, 4.7; NaHCOs, 25; NaH 2 P 0 4 , 115; CaCl2 , 2.5; MgCl2 , 1.1; glucose, 
5.6 and purged with 95 % O2  /  5 % CO2 ) at a constant flow rate of 2 ml /  min. A Gilson 
Minipuls peristaltic pump was used to draw the internal perfusate (Krebs) from a 
reservoir. The temperature was maintained at 32 ± 2“C by superfusing the prepai'ations 
with pre-warmed Krebs solution, drawn from a second reservoir (flow rate 8  ml /  min) 
by means of a peristaltic pump.
The perfusion pressure was monitored using a differential pressure transducer (sensym 
type s e x  150 NC, Parnell Electronic components, Leeds) located upstream from the 
vessel. The electrical output from the vessel was fed to a MacLab type 4e A/D converter 
and printed out. The printer traces were analysed by hand as described later. A short
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side-tube, which teiminated in a resealable rubber spectrum, allowed bolus injections of 
SNAP and SNAG to be delivered into the internal perfusate. The transit time from the 
injection site to the lumen was three to four seconds. Each bolus injection remaining 
inside the artery for approximately 0.3 seconds.
Experim ental protocol
The experiments were performed in a darkened laboratory using low intensity lighting 
(red 15 W  lamps) as the nitrosothiols are light sensitive. Phenylephrine ( 1 - 7  pm) was 
added to the Krebs internal perfusate to precontract the artery, generating perfusion 
pressures of 100 - 120 mmHg. Phenylephrine is an analogue of noradrenalin and 
stimulates Ca^+ influx allowing contraction to occur. Stock solutions of SNAP and 
SNAG (1 X lO'^M) were made up in 50 % aqueous ethanol and diluted serially to give a 
range (10’  ^ - lO'^M) of concentrations in aqueous ethanol. The ethanol was necessary 
due to the low solubility of SNAG. Injections using only the solvent were given and 
found to have little effect upon the level of arterial tone. Bolus injections (lOpl) of the 
nitrosothiols were then delivered. These produced transient responses which were 
allowed to recover fully between successive injections. The vasodilator responses were 
calculated by expressing the drop in internal pressure as a percentage of the pressure 
immediately prior to injection (active pressure). The passive pressure (pressure before 
the vessel was precontracted with phenylephrine) is used as the baseline rather than zero 
pressure. Representative traces are shown in figure 3
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Both nitl'osothiols were tested upon the same piece of arteiy to allow direct comparison. 
The combined dose response results (where n = 12 for each) are shown in figure 2. The 
two response cui*ves are very similar and demonstrate that the two drugs are fairly closely 
m atched in vasodilatory activity. The addition of haem oglobin to the perfusate 
completely inhibits the vasodilatory action of SNAG on the arteries at all concentrations 
below 5 X 10"^M and greatly reduced the activity at the highest concentrations. This 
indicates that the vasodilatory action is due to the release of NO.^ These results are 
conclusive in showing that SNAG is an effective vasodilator.
3.3. Rat fem oral artery stud ies.
Selection o f com pounds.
Problem s with solubility determined that only a small selection of the compounds 
prepared were suitable for testing. The femoral artery, when used with this system, was 
found to be sensitive to both DMSO and ethanol. Both of these caused substantial 
dilation o f the artery and so, with the time available, we were only able to use such 
compounds as could be dissolved in an aqueous system at concentrations of 1 0 "^  and
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below. In this series of experiments we used the iV-acyl penicillamines, SNOPP, SNVP 
and SNOPHE, the derivatives bearing 3, 5 and 7 membered chains respectively. We 
were also able to use RIG 200, which was at its solubility limits at -2 .5  x lO '^M. 
Sonication was necessary to dissolve these compounds. Absorbance studies verified that 
this did not cause any loss of the NO group. In each of these studies the artery response 
to the 5-nitrosothiol was compared to that of SNAP.
M eth od s.
A protocol similar to that of 3.2 was used. Experiments were carried out on isolated 
segments o f femoral artery from adult male W istar rats (400 - 550 g; n=36). The 
perfusion system was as described for rat tail tirtery perfusion. The animals were killed 
by cervical dislocation and the femoral arteries exposed and canulated immediately distal 
to the epigastric arterial branch. Cannulated arterial segments ( 7 - 8  mm long) were 
dissected free and transferred to a perspex organ bath chamber ( 1  ml volume) at 37°C. 
The rest o f the procedure was as 3.2, except that the signal from the converter was fed to 
a Macintosh LCIII computer as to make data storage and analysis easier.
Endothelial denudation.
The endothelium is an essential part of the arterial machinery for the production of NO. It 
is of interest to note any differences in response to NO donors in the presence and 
absence of the endothelium. The endothelium is easily damaged during exposure and 
cannulation of the artery but can be surprisingly difficult to remove intentionally. In 
human studies it is enough to pass water through the blood vessel, whereby the osmotic 
pressure kills the endothelium. In animal model studies it is easier to pass air through the 
artery which also kills the endothelium. In order to determine the endothelial viability, 
the pressure after denudation is compared to that of the healthy artery in the presence of 
an NO scavenger such as haemoglobin. In both cases there should be no nitric oxide and 
so the pressure should be identical.
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The apparatus allows the use of three different modes of ^-nitrosothiol delivery to the 
vessel:
a) Bolus injection (10 |il)  through a resealable rubber septum into the perfusate 
immediately upstream of the vessel. The artery is exposed to the drug for -300ms.
b) Addition o f the drug to the perfusate, allowing the inside o f the artery to be 
continuously exposed to the drug.
c) Addition of the drug to the superfusate, continuously exposing the outside of the artery 
to the drug.
Bolus injection studies.
Bolus injections of 5-nitrosothiol (lOpl; 10'^ - lO'^M) were made sequentially into the 
perfusate of the precontracted arteries. The was performed on endothelium intact and 
endothelium denuded arteries. The responses were deemed to have recovered once 
pressure was maintained for more than 2 ^ 2  min. Following the highest dose (IQ-^M) the
arteries were allowed to recover for periods of between 15 min and 5  h before being 
perfused with haemoglobin (10 |iM).
R e su lts .
Experiments using endothelium intact artery showed the nitrosothiol to have only a 
tiansient effect. Injections of all of the nitrosothiols showed dose dependent vasodilation 
which rapidly recovered to their original pre-injection pressures, as expected. The 
results for endothelium denuded vessels varied substantially between compounds and 
will be dealt with separately, in comparison with SNAP.
3.3 .1 . RIG 200
Injections of RIG 200 into endothelium intact arteries gave a dose dependent increase in 
dilatory response. The arteries recovered fully to their pre-injection pressures. The 
studies showed it to have a lesser effect than that caused by SNAP. Bolus injections of
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RIG 200 into endothelium denuded arteries showed a full recovery following 10'^ and 
10‘^M injections but thereafter failed to recover to pre-injection pressure. There appears 
to be no difference in the sensitivity to the NO donors between the endothelium denuded 
arteries and those with intact endothelia. The results are shown in figure 3. The upper 
trace shows the bolus injection o f increasing doses of SNAP. At all but lO’^M the 
pressure recovers fully. The trace shows the recoveries to be rapid. At the lO'^M dose 
there is a rapid initial recovery which then tails off. The addition of haemoglobin, via 
perfusion, gives a rapid return to original pre-injection pressure.
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The lower trace shows the bolus injection of RIG 200 in increasing doses. The recovery 
between injections is much less rapid and to a lesser degree, leading to a sustained 
depression of tone Typically recovering to only about 50 % of pre-injection pressure 
following a lO'^M bolus injection. The perfusion of haemoglobin gives a very slow rise 
in pressure. The difference between the recovery periods for SNAP and RIG 200 is 
dem onstrated by the traces in figure 4. Trace a) relates to RIG 200, a slow and 
incomplete recovery, trace b) relates to SNAP, a full and rapid recoveiy of tone.
F igure 4
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The comparisons between SNAP and RIG 200 are shown in figure 5 below. The gi’aph 
gives the maximum dilation (as a percentage of perfusion pressure) caused by increasing 
doses of each drug. The gi aph also shows the degree of recovery shown by the artery at 
each dose. From the graph we can see that there is a sti’ong dose dependency for both 
drugs, with an increase in peak amplitude with increasingly concentrated bolus injections. 
SNAP (filled circles) is shown to be more potent at all but the highest dose than RIG 200 
(filled tiiangles). Following bolus injections of SNAP the artery is shown to recover 
fully (100 %) at all but the highest doses (empty circles). The artery shows a dose 
dependent decrease in recovery following doses of RIG 200 (empty triangles) and only 
recovers fully at the lowest doses.
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3.3 .2 . P en icillam ine der ivatives.
As the penicillamines prepared are close analogues of SNAP it is reasonable to expect that 
their activities and stabilities should be of similar magnitudes to that of SNAP. The acyl 
chain, increasing the lipophilicity of the molecule, enhances prospects of entering the 
tissue lining the lumen. However, unlike RIG 200, they still retains some degree of 
hydrophilicity through the free acid group. This makes the handling of the compound 
somewhat more simple. It is easier to get these derivatives into solution than RIG 200 
and consequently it is possible to use them in higher concentrations.
Pen icillam ine derivatives
HO2C N
H
C
H2
SNOPP: R = GH3  
SNVP: R = (GH2 )2 CH3  
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74
Figure 7
Peak amplitude (endo. intact)
125
1 0 0 -
SNAP
O h SNOPP
SNVP50
SNOPHE
25  -
O n es
log Dose (M)
F ig u re  8
Recovery (endo. intact)
120
1 1 0 -
SNAP100
SNOPP
9 0 -
SNYP
SNOPHE
7 0 -
60
log Dose (M)
75
Bolus injections of the nitrosothiols gave transient dilations as expected. When vessels 
with intact endothelia were used, very similar patterns for the penicillamines and SNAP 
were seen. Figure 7 demonstrates the increase in arterial dilation with increasing doses of 
nitrosothiol. The graph shows very little difference between any of the derivatives..
Figure 8  shows the recovery of the arteries with increasing dose. The arteries recover to 
their initial pressures at all but the highest doses. Statistical analyses have shown the 
differences to be non-significant.
A similar pattern to that shown for the endothelium intact vessels (figure 7) is shown for 
the dose dependent dilations of endothelium denuded vessels (figure 9). There are no 
significant differences in the activities of any of the four nitrosothiols. In view of the 
variance in the stabilities o f the four compounds, especially with respect to copper 
catalysed decomposition (chapter 6 ), it is perhaps surprising that there is not more of a 
difference in the activities of these compounds. This suggests that there are possibly 
m ore factors involved for in vivo decom position than those used in our model 
decomposition studies and that these are of a significant importance. The amplitude of 
the response to each nitrosothiol was very similar, however, when looking at the 
individual response traces (figure 1 0 ) it is appaient that there is a very significant trend in 
the response of the endothelium denuded artery to each drug. As was hoped, the longer 
chain did appear to allow the nitrosothiols to be taken into the lining of the blood vessel in 
a similar manner to that of RIG 200.
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Figure 10 demonstrates that the response is more sustained with increasing chain length. 
The heptanoyl derivative showing the lowest degreee of recovery, the valeryl derivative 
giving a slightly lesser response (greater recovery) and the propionyl and acetyl 
derivatives giving the most transient responses. The results are discussed individually.
3 .3 .2 .1 . SN O PP.
The propionyl derivative, with only one carbon more in the acyl chain than SNAP, 
shows very similar results to SNAP. In endothelium denuded tissue there is a less o f a 
recovery at the highest two doses. It is a stable compound which is easy to use and 
prepare, but, as a vasodilator, shows only slight benefits over SNAP.
3 .3 .2 .2 . SN V P.
Figures 9 and 10 demonstrate that SNVP is a very good vasodilator and also acts as to 
give a sustained response. Figure 11 shows an individual trace comparing the effects of 
increasing bolus injection doses of SNVP on endothelium intact and endothelium 
denuded vessels. The full recovery of the artery to pre-injection pressure, and above, 
after microinjections of SNVP to an artery with its endothelium intact is shown in the 
upper trace. The substantial increase in pressure at the end of the run marks the addition 
of l{iM haemoglobin. The lower trace shows the lack of recovery of an endothelium 
denuded vessel to the highest dose for SNVP. The artery only recovers to its initial 
pressure with the addition of haemoglobin. This recovery is noticeably slower than that 
shown in the upper trace.
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The heptanoyl derivative is shown by figure 10 to be the best of the four nitrosothiols as 
regards degi’ee of recovery of arterial tone. The long chain makes it less soluble and 
therefore less easy to use than the other three. It was also noted that the shelf-life of 
SNOPHE was not as great as those for the other derivatives. This is possibly due to the 
more hygroscopic natui*e of the compound.
3.4. Current and future stud ies
This work represents an on-going project and the bolus injections studies, regarded as the 
most valuable, are the only ones fully investigated thus far. The end to these studies will 
involve testing upon human subjects. Preliminary trials have already been carried out. 
These have shown RIG 200 to be an active dilator of human blood vessels. The studies 
remained incomplete due to difficulties in fully removing the endothelium from the vessel 
and verifying its complete removal.
Trials investigating the transdermal capabilities of these compounds will also be 
performed, probably in a similar manner to those described in chapter 4. Preliminary 
studies have been earned out involving the addition of RIG 200 and SNAP to the
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superfusate reservoir. Whilst this does not show the ability of the drug to be delivered 
transdermally, it does demonstrate the ability for it to pass through the outside covering 
of the blood vessel to the muscle cells. The results shown below (figure 12) demonstrate 
the effects of superfusing ICb? - 10‘^M SNAP and RIG 200 into the artery. Superfusion 
of SNAP gives a dose dependent decrease in pressure, which is rapidly reversed upon 
washing out with fresh buffer or on addition of haem oglobin to the perfusate. 
Superfusion of RIG 2(X) gives a dilation of lesser magnitude to that of SNAP. Following 
superfusion with lO ^M RIG 200, the vessel remained dilated for over 4 h, showing no 
recovery of pressure. These results suggest that RIG 200 has the ability to pass all the 
way through the blood vessel in order to reach the elastic lamina where it is absorbed 
(3.5). Superfusion with haemoglobin or L-NAME was required to obtain a recovery to 
the pre-injection pressure.
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3.5. S u m m ary
These results suggest that the endothelium acts as a physical barrier preventing the 
nitrosothiol from entering the tissue. The layer under this, known as the internal elastic 
lamina, is composed of cells embedded in a glycoprotein matrix. It is possible that the 
nitrosothiols, particularly RIG 200 with its sugar component, have an affinity to this 
extracellular fluid. Our results strongly indicate that the more hydrophobic compounds 
have a higher affinity for this layer and are therefore more soluble in it. The more
SO
hydrophilic donors with the shorter chains, SNAP and SNOPP, appear to be unable to 
penetrate this layer. RIG 200 and SNOPHE are being used at the limits o f their 
solubilities, i.e. they are about as hydrophobic as we can utilise with this delivery 
system. From this it is fair to say that these compounds will remain in the elastic lamina 
for as long as any compounds we could use and it is only the potency that we could 
improve on. From these compounds we have tested, the best sustained response is seen 
with SNOPHE. However this compound is relatively difficult to handle due to its 
hygroscopic nature. The next best donor compound is SNVP, which can be made in 
large quantities and is very stable. The one drawback with this compound is the 
unpleasant smell from the valerate portion of the molecule, which may be a factor against 
its use in human testing. Despite being less potent and having a slightly less well 
sustained response, RIG 200 is the most useful of these compounds, especially for 
human testing. Further work may also involve the other similar derivatives, RIG 300, 
500 and 700. These have been shown to be more stable than RIG 200 (chapter 6 ) and 
may prove useful for inducing long term vasodilation. This will require a slightly 
different delivery system to overcome the solubility problems.
3.6 . C onclus ions
A number of new NO donor drugs have been prepared. These have been found to be 
active vasodilators of about the same potency as SNAP. Three of these have been found 
to be taken into the tissue lining the blood vessel when the endothelium has been 
removed. This has very important medical implications especially in the treatment of 
conditions where the endothelium has been damaged. The usage of these drugs for the 
treatment of patients following PCTA, for removal of atherosclerotic plaque, has been 
envisaged. As the endothelium is removed in this treatment, the donors prepared here 
would be of particular benefit. As these compounds are only taken into the tissue when 
the endothelium is removed, it is feasible that following delivery they would pass 
hamilessly through the healthy tissue, where the endothelium is intact. These could then 
gather in the damaged areas, where the endothelium is damaged or removed, and act as
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the source of nitric oxide no longer available to the blood vessel. In this they would act 
as tissue specific donors, specific to damaged tissue and hopefully allow recovery of the 
endothelium without the blood vessels sustaining any more damage. As effective long 
term NO donors these compounds also have the potential to be used in a number of other 
roles such as the treatment of cardiovascular disorders. The work on these compounds 
will continue, both to determine the potential of those already prepared and to synthesise 
similar compounds which may prove to be more effective.
Many thanks to Dr Ian Megson of Western General Hospital, Edinburgh, for carrying out 
the bulk of this work
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Chapter 4: Transderm al Delivery Stud ies^ ^
4.1. Introduction
There are many ways of introducing a therapeutic agent into the body. Commonly dr ugs 
are delivered orally or inti'avenously. A method which has shown great promise in recent 
years is that of transdermal drug delivery (TDD). In this the drug is delivered directly 
through the skin and into the bloodstream. The main advantages that accompany the use 
of TDD are:
1. Avoidance of breakdown of the dr ug in the stomach and hepatic first pass metabolism, 
e.g. the bioavailability of nitroglycerine is reduced to 1 % by its short half- life and first 
pass metabolism.^
2. A constant rate o f drug delivery and consequently a sustained plasm a drug 
concentration can be attained.
3. Ease of delivery and reduction of dosing frequency.
4. Avoids the pain and possibility of infection associated with injections."^
5. The drug can be delivered in a lower dose or less often. However this may be offset 
by the initial cost of the TDD system compared with the costs of oral delivery.^
There ai’e many considerations necessary in TDD, particularly as it involves transporting 
a substance across a bai'rier specifically designed to resist such a process:
1. The skin is a very effective barrier and so the drug must be very potent.
2. The di'ug must have the correct solubility to pass through the skin. It must be a small 
molecule, generally under 1000 Da. The molecule must have a low solubility in water, 
though some degree of water solubility appears to be necessary.
3. The di’ug must not irritate the skin.
4. The drug must have the correct diffusion and partitioning characteristics as it is 
necessary for the drug to: i) Diffuse through the delivery system, ii) Partition from the 
system to the stratum corneum, iii) Diffuse through the stratum corneum, iv) Partition 
from the stratum corneum into the viable epidermis, v) Diffuse through the viable tissue
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and finally, vi) Enter the cutaneous microcirculation. These are complex demands to 
place on the shoulders of any prospective candidate for TDD.
Despite the fact that topical drug application has been used since Egyptian times, most 
topical drugs are intended for local action and not for the general circulation. TDD has 
been mostly ignored as demonstrated by there having been only two drugs licensed in the 
USA for transdermal delivery in 1985. By 1994 there were seven marketed transdermal 
systems. These were for: nitroglycerine, oestradiol, clonidine, fentanyl, nicotine, 
scopolam ine and noresth isterone acetate.^ The usage o f these, in particular 
nitroglycerine, will be discussed later.
W hilst there are a sizeable number of deliveiy systems, most are similar and follow the 
same basic design:
a) Drug reservoir - the required amount of drug for the prescribed program is stored in a 
stable form.
b) Rate controlling element - maintains the prescribed rate of drug administration 
throughout the operating life of the system.
c) Energy source - effects the transfer of the drug molecule from the reservoir to the 
selected point of entry in the body.
d) Delivery portal - provides an exit for the drug from the delivery module so that it can 
reach the target organ.
e) Platform - houses the drug and delivery modules. This must be compatible with the 
local tissues, i.e. it must not irritate the skin.
The system is attached to the skin by an adhesive which contains a priming dose designed 
to saturate skin sites before establishment of a steady state input of drug from the 
reservoir. The rate controlling microporous membrane is chosen to ensure that the 
delivery rate of the drug reservoir is much less than the rate at which the impermeable 
skin can absorb the drug. This ensures that the system, and not the skin, determines the
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rate of delivery. Were this not so then patients with high skin permeabilities or damaged 
skin might receive a harmfully high dose.
A good example of a delivery system is Ciba-Geigy's "Transderm-Nitro" for the delivery 
o f nitroglycerine. The reservoir is composed of nitroglycerine absorbed onto lactose and 
dispersed in a colloidal suspension of silicon dioxide and silicone medical fluid. The 
amount of nitroglycerine contained in the medium is five times that delivered to the body 
and thus serves as the energy source for drug diffusion. The microporous membrane is 
composed of ethylene vinyl acetate co-polymer. The membrane pores are of such a size 
as to limit in vivo delivery from the reservoir to 0.5mg/cm^/24hrs. The surface area of 
skin covered by the membrane detemiines the total amount of drug diffused. The system 
is attached by a hypoallergenic adhesive which is protected during storage by a non- 
permeable peel strip. Approximately 8 % of the nitroglycerine diffuses into the adhesive 
layer during storage . Upon application, this amount of drug in the adhesive may serve 
as a priming dose. Finally the reservoir is protected by an outer layer of aluminised 
plastic which is impeimeable to the nitroglycerine housed in the adjacent reservoir. The 
system which we have used in testing involves a less complex setup where the skin 
controls the rate of adsorption. This will be discussed later.
As nitric oxide donors are already used for transdermal delivery, nitroglycerine and the 
other organic nitr ates are obviously of great interest to us.
Organic nitrates are safe, effective and relatively inexpensive for the management of 
ischaemia related to coronary heart disease.^ The benefits of these have been known for 
over 1 0 0  years, with the usage of nitroglycerine in the treatment o f acute attacks of 
cardiac angina.^ There is considerable evidence to suggest that the site of the metabolic 
conversion to produce NO occurs in the vascular smooth muscle.^ However the actual 
mechanism by which this occurs remains u n d e f i n e d . O r g a n i c  nitrates are known to 
cause vasodilation and vasorelaxation of coronary arteries. A platelet aggregation
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inhibitor role has also been suggested. There are three nitrate compounds currently 
available in the USA: nitroglycerine, isosorbide dinitrate and isosorbide mononitrate. 
These are available as rapid acting but short-lived sublingual and transmucal doses for the 
relief from angina pectoris attacks, or as longer lasting oral and transdermal formulations 
for the relief of chronic ischaemia and myocardial infarction. Transdermal nitroglycerine 
is more effective than oral nitroglycerine for cardiovascular therapy, though it does lead 
to a higher incidence of adverse effects such as headaches, dizzinesss and skin irritation.^ 
Tolerance to the organic nitrates, rendering them useless, can be a major problem: a once 
daily application of isosorbide dinitrate cream produces tolerance and a complete lack of 
efficacy within a week. Nitroglycerine patches are claimed by the manufacturers to 
provide 24 hr anti-ischaemic and anti-anginal efficacy, provided the use and dosage is 
strictly controlled. Despite this it is more commonly thought that a drug free resting 
period is required to avoid tolerance. Removal of the patch during the night appears to be 
a favoured option.^ Transdennal delivery of nitroglycerine has been used in the treatment 
of Raynaud's Phenomenon. It was found to be effective in reducing the number and 
severity of the attacks, but was found to induce frequent headaches making it an 
unsuitable ti*eatment.l^
In recent years nicotine patches such as nicorette and nicotinell have become popular 
cigarette substitutes for those "requiring" nicotine. These deliver nicotine into the body in 
a manner currently thought to be less harmful than smoking. The usage of transdermal 
nicotine has been shown to double the success rate of smoking cessation. However the 
patches are costly and should only be recommended for smokers unable to quit by 
simpler means and those likely to suffer severe nicotine withdrawal symptoms.
Two of the other TDD systems involve the use of clonidine, a mild hypertensive agent, 
and oestradiol, used in female honnone treatment.
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One of the first TDD systems was for scopolamine. This is a powerful narcotic and 
sedative commonly used for the prevention of motion sickness and also as a wartime 
truth drug. In a slightly unusual study, transdermal scopolamine has been shown to 
reduce drooling in developmentally delayed children. In one third of the subjects a 
complete cessation of drooling was observed whilst the patch was being worn.l^ Whilst 
few scientists would regard this as a major development, it does show the range of 
possiblities for the usage of TDD.
The range of drugs which can be delivered ti'ansdermally is limited to smaller molecules. 
In general this means that larger molecules cannot be passed through the skin. However, 
laboratory techniques have been developed to either push drugs through the skin (such as 
iontophoresis) or to make the skin more permeable, (such as sonophoresis). In 
iontophoresis, a potential difference is set up through the skin so that a charged molecule 
can be pushed through. This can be used for the delivery of sodium nitroprusside or 
acetylcholine as well as many other drugs. Sonophoresis"^ involves the usage of low 
frequency ultrasound (1 MHz) to increase the permeability of the skin. This has been 
used for the delivery of insulin (-6000 Da) and erythropoeitin (-48000 Da). The 
ultrasound increases the size of air pockets in the stratum corneum. This allows these 
drugs, to which the skin would normally be an impermeable barrier, to pass through. 
Upon termination of treatment the skin quickly regains its normal properties. At present 
these methods of delivery are possible only under laboratory or medical supervision but 
in future years it may be possible to make use of these techniques for drug delivery.
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4.2. Selection of a Transderm al Agent
In order to initiate a series of studies involving transdermal delivery on humans, a 
number of criteria had to be met. The compound being used had to be relatively easy to 
synthesise on a moderately large scale. It had to be easy to handle, preferably a solid and 
stable enough to be stored for prolonged periods of time. Most importantly it had to be 
shown to be com pletely safe in order to obtain perm ission for its usage. S- 
niti'osothioglucose tetraacetate (SNAG) was felt to satisfy these criteria. It is a pink 
powder (stable under refrigeration) and can be synthesised from commercially available 
acetobromoglucose in three short steps. The first step involves the usage of thiourea, a 
known carcinogen. There is no chance of any of this being present in the final product. 
Any thiourea not removed by recrystallisation of the first product is likely to be 
hydrolysed to urea or washed away during the second and third steps. In a sample of 
SNAG the only likely impurities are unreacted thiol (TGA) and the disulphide foimed by 
n itrosothiol decompostion. In vivo the thiol may also be produced by enzymatic 
reduction of the d i s u l p h i d e . it i s  also probable that in the body the acetyl groups are 
lost by enymatic cleavageK) to give the free thiosugar (TG).
Consultation of a number of toxicological databases has not suggested any notable 
adverse effects of any of the above compounds. Further to this TG and TGA have been 
put to a number of physiological uses. TGA is used in a the treatment of rheumatoid 
arthrits as a ligand in the gold complex aurafin.l^ TG and TGA complexed to copper 
have been tested sucessfully as antiinflammatory agents. The use of TG and TGA as 
detoxification agents have been suggested and p a t e n t e d . Thioglycosides, are found 
in a number of plants used in human foodstuffs, such as sprouts, horseradish and 
mustard. In the cooking of these it is likely that some TG is formed. No haimful effects 
have been noted, in fact sprouts are regarded as being a particularly healthy food.
With this information began the lengthy process of obtaining ethical permission for an 
initial pilot testing on humans. After a long delay this was finally granted. The delay
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was necessary in order to determine legal responsibilities for any side effects, to make 
sure all involved parties had the necessary insurance and also to satisfy the commitee that 
the identity of the compound was as stated. It is because of this timespan that we have 
not been able to investigate other NO donors for their transdermal delivery capabilities.
It is not certain whether it is SNAG passing through the skin and decomposing internally 
to deliver NO, or SNAG decomposing externally and NO passing through the skin. 
Negative results obtained using a very hydrophilic NO donor suggest that it may be the 
former explanation which is correct.
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4,2. Prelim inary studies.
Studies were carried out in collaboration with members of the Department of Medicine at 
Ninewells Hospital, Dundee. Large amounts of time were spent working out a suitable 
protocol for a full scale trandermal study on SNAG. The situation was somewhat 
complicated by the change from a "single point" to a "scanning" laser Doppler flowmeter 
which changed the methods used. Laser Doppler flowmetry is a useful non-invasive 
m ethod for studying the skin.^1 It is commonly used for studying a number of 
conditions:
a) Rheumatology. Many painful conditions involve changes in skin blood flow. The 
microvascular changes disorders such as Raynaud's phenomenon are easily observed by 
laser Doppler imaging.
b) Burns. Laser Doppler Images help the plastic surgeon to assess burn depth, the 
regions most affected and the regions where blood flow has been sufficiently maintained 
as for recovery to occur without surgery. Following treatment, graft progress can be 
monitored.
c) Dermatology. The degree and involvement of irritant and allergic responses can be 
monitored over a number of sites to determine the extent of the reaction and to determine 
the nature of the irritant.
d) Other studies include monitoring post angioplasty subjects and wound healing.
Both single point and scanning LDF work on a simple principle involving the differences 
between transmitted and reflected light. A beam is emitted from the probe and is reflected 
back off the skin to a detector in the probe. The beam is powerful enough to penetrate 1 
mm into the skin. It is the microcirculation in this area that is of interest to us. If the 
laser beam comes into contact with a moving object i.e. a blood cell, then the frequency 
will be changed. The probe measures the frequency differences between the transmitted 
and reflected beams and from this calculates a figure temied the "flux". Flux is made up 
from the product of two values: the number of cells passing a point per unit time and the 
average velocity of these blood cells. It is possible to break the arbitrary figure into its 
individual components. For our purposes this is unnecessarily complex and an increase
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in flux can be regarded as an increase in blood flow. As suggested by their names, the 
single point Doppler flowmeter measures over a very small area and gives the flux as a 
continuous readout. The scanning Doppler imager has a beam which passes rapidly back 
and forth in lines across the desiied area until it has taken a reading over every part. This 
gives a colour coded picture made up o f individual pixels. Each pixel represents the 
blood flow in a volume of skin approximately equal to 1 mm^. The scanner can be set to 
take readings at any time interval to build up a series of pictures of blood flow changes 
with time. It is also possible to obtain and follow the exact readings for any individual 
pixels, but it is more infomiative to look at the whole picture.
4.2.1. S ingle Po int Studies.
Measurements were made using a M oor MBF3/D laser Doppler Flowmeter (MOOR 
Instruments, Axminster, UK). The perpex well had an outer diameter of 30 mm, a 
central chamber, responsible for holding the probe, of 3.5 mm diameter and an inner 
chamber, in which the solution is held, of 8  mm diameter. The laser records the blood 
flow for a 1 mm3 volume.
To detector
Laser emitter and 
receiver 732nm
— Well, containing 
substance in solution
To arm (needed only 
for iontophoresis) .. Attached to ann by peelstrip
Our original, technique involving the use of the single point apparatus, had a number of 
flaws. We now know that some human subjects will always show a very low response
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to vasodilatory drugs, age often playing an important role in this. There are many other 
factors which may influence the result such as the emotional state of the volunteer and the 
weather outside. It was also found that some ususally responsive subjects could show 
little or no response at times simply because of items they may have eaten or drunk. The 
picture generated by the scanner often contained "rogue" pixels. These are single pixels 
in which the blood flow, often quite different to that o f surounding areas, does not 
change in spite of any drastic overall changes in the skin blood flow. Whilst this is not a 
problem when using the scanner, it is quite possible that some of our early negative 
results, using the single point apparatus, were caused by attempts to study such an area. 
Initial studies were carried out using ethanol as the solvent. SNAG (1 % in ethanol) was 
placed in the small plastic well into which the probe is inserted. The well is attached to 
the inside of the forearm with double sided adhesive rings prior to this. Areas on the 
forearm with no large underlying veins were chosen and cleaned with ethanol wipes. A 
second probe, in a holder containing only ethanol, was used as a baseline control. A 
suitable area of skin is one with a stable blood flow which falls within a range of flux 
values, typically 20 to 40 arbitrary flux units. A maximum possible blood flow, seen by 
heating the skin, is usually between 200 and 250 units. Once the solutions have been 
added the blood flow is displayed as a continuous reading on a monitor screen as shown. 
When the trace has filled the monitor screen it will begin to overwrite the previous trace. 
This makes it easy to see any changes in the blood flow. The major problem with this 
system is its sensitivity. The patient cannot talk, laugh, change their position or even take 
a deep breath without having a disruptive effect on the blood flow trace. The position in 
which the amis must be held, outstretched with forearms at heart level facing upwards, is 
incomfortable and difficult to maintain for long periods of time.
Figure 1 shows the increase in blood flow for a 1 % solution of SNAG compared with a 
control. Very little increase in flux was observed over the first six minutes. The flux 
then gradually climbed to give a maximum eight - fold increase after 20 minutes. At this
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stage a plateau was usually reached and the flux value levelled off, sometimes with a 
slight decrease until the end of the experiment at 30 minutes.
F ig u re  1
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SNAG was compared with solutions o f SNAP, isosorbide dinitrate and isosorbide 
mononitrate (all 1 % in ethanol). Neither of the nitrates gave any response. An increase 
of up to three-fold was observed with SNAP. This lower response to SNAP may be 
due to it being a poorer transdermal agent - less able to pass through the skin, or if it is 
NO passing thiought he skin (see 4.1) it may be because SNAP has a higher stability and 
is simply giving off NO at a reduced rate.
A dose dependent study was set up, involving concentrations of 0.25, 0.5, 1.0, 1.5 and 
2 % SNAG in ethanol. However it was now found that none of these gave any 
response. In several successive tests no positive results were seen. An explanation for 
this could not be given until it was noted that there was a discolouration of the skin near 
to the site of observation. A red ring at distance of up to 2 cm from the site under study 
was being produced despite the negative result of the test. A reddening of the skin is 
usually indicative of an increase in blood flow, suggesting that vasodilation is occurring
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but not in the area under scrutiny. Simple experiments involving holding a vial 
containing a solution of SNAG in ethanol upturned against the skin also demonstrated 
this phenomenon. Little or no reddening was seen for the areas in contact with the 
solution but a very distinctive and persistent red ring around the area was noted. These 
very basic tests were very important in showing that the vasodilator was indeed active but 
that our delivery system was at fault. The ethanol, by some hitherto unknown route, was 
transporting the vasodilator away from the site, either across the surface of the skin or 
through the microvessels. It is not understood why a ring is observed rather than a 
general reddening of the skin ai ound the site.
For human usage there are generally thought to be three possible solvents, water, ethanol 
and DMSO. We discounted DMSO due to the problems with absorption through the skin 
and the subsequent unpleasant taste the patient experiences. SNAG is not soluble enough 
in water and ethanol had proved ineffective for our purposes. Despite the simplicity of 
the idea, changing from neat ethanol to an ethanol /  water mix was a major step. Using 
this system the results were not only reproducible but faster to obtain. With the ethanol 
system an initial lag phase was seen. This was impossible to distinguish from a study in 
which no increase in blood flow was going to occur. A lot of time was often spent 
waiting to determine whether it was a negative result or merely a prolonged lag phase. 
With ethanol /  water an immediate result increase in blood flow was seen. The addition 
of a drop of his solution to the skin led to a reddened patch, at the site of the drop, within 
30 s. This made for shorter testing times and therefore more acceptable to the subject. 
Upon removal of the probe and holder a reddening at the site was obseiwed. A ring, 
distant to the site, was no longer seen. Despite the succès of these results it was decided 
to move our studies onto the newly aquired scanning apparatus.
4.2.2. Scann ing Studies
The scanning laser Doppler Flowmeter is pictured in use on page 17. It gives a blood 
flow over a much larger area than the single point apparatus and so probably provides us
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with a more accurate indication of the blood flow variation. As readings aie only taken at 
various time intervals it is only necessary for the subject to remain completely quiet and 
still when the actual scan is being done. This method also lends itself to other possible 
delivery methods such as a KY jelly base.
In order to fit both a baseline and an "active" area under the scanner at once, only one arm 
was used in this study. In this we make the assumption that any changes in blood flow 
will be local and will not influence one another.
The plastic wells, larger than for the single point study, are attached to the forearm and 
filled with a solution of SNAG in a 1 : 1 ethanol : water mix. All other areas of skin and 
exposed plastic are covered with black material to avoid confusion and to visually 
improve the results. On the monitor screen is displayed two circles , each filled with 
coloured pixels. Each colour represents a particular flux level, according to a scale on the 
screen. Increases are easily observed as the basal flow is usually shown as a daik blue 
colour. An increase in the blood flow leads to a lightening of these colours, becoming 
more vibrant as the flow further increases. The computer with dedicated software can 
then be used to calculate the average blood flow for the designated area. This is actually 
taken as the median rather than the mean value. The reason for this concerns problems 
encountered with reflections leading to enormously high flux values. It was possible to 
obtain a photographic image from the DC signal of the area being studied. This shows 
clearly where any reflecting areas may be. These can then be isolated and such areas 
removed from the calculation. Even with this there are still anomalous regions which will 
give an incorrect estimate of the blood flow were the mean value to be taken. Usage of 
the median value is an approximation based on the assumption that there will be as many 
abnormally high values as abnormally low values and that these will cancel each other 
out. The laser scans over the desired areas, through the solvent, giving a series o f 
images on the monitor screen. Figure 2 (page 98) shows the gradual increase in blood 
flow on an area of forearm skin. The dark blue of the early pictures developes into the
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lighter and brighter colours of the later pictures as the vasodilatory effects occur. A dose 
dependent study was carried out using 0.25, 0.5, 1.0 and 1.5 % solutions of SNAG in 1: 
1 ethanol : water. The results, shown in figure 3 demonstrate a sizeable increase in skin 
perfusion with increasing dosage.
F igure 3
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An eight-fold increase with the 1.5 % solution is the maximum obtained. A more 
concentrated solution cannot be prepared due to solubility problems. The results from a 
study of blood flow against time for a 1 % solution are shown in figure 4. This 
demonstrates an immediate effect, which builds up to its full intensity over a period of 15 
to 20 mins. This maximum effect is then sustained for over 10 minutes. These
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results are also shown pictorially in figure 2 (page 98). The scale at the bottom of the 
page explains that the blue dots represent the areas of lowest bloodflow, seen at the 
beginning o f the experiment. The pink and white dots, seen at the end of the experiment, 
represent areas of higher blood flow. This picture clearly shows the development of an 
increase in bloodflow following the application of SNAG.
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In a study more relevant for therapeutic purposes, we also tested SNAG delivered in KY 
jelly. In order to do this SNAG was dissolved in a small quantity of ethanol, 10 % of 
final volume. This was then mixed with KY jelly  to make up the final desired 
concentration, giving a pink gel. The gel is rubbed gently onto the skin and can then 
either be scanned through or wiped off prior to scanning. In the picture shown (figure 5, 
page 100) a sizeable area of the forearm has been studied (5 cm x 4 cm). Half of this was 
smeared with KY jelly : ethanol 9 : 1 and the other half with a 1 % SNAG solution in the 
same solvent system. These were scanned through over a period of 20 minutes. The 
initial flux levels were the same on both halves. Figure 5 shows a very distinctive
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increase in flux on the side bearing the SNAG solution. When these were wiped clean it 
was noted that the skin on the SNAG covered area was bright red whereas the control 
side showed no discolouration. This is a good example of how localised the vasodilatory 
effects of this system are.
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Figure 6 shows the variation of flux with time in graph format from the above study. 
When spread over a large area as above the increase in flux is much smaller (3-fold) then 
when the same quantities are used over a smaller area (8-fold). It should be noted that an 
8-fold increase has been seen with all three delivery systems, suggesting that this may be 
the maximum obtainable with this compound. It is a surprise to find such closeness 
between the differing systems as there are many factors which should inhibit 
comparisons between the methods. When KY jelly is used it is difficult to quantify the 
amount or degree of "rubbing" given, though this will be the same for the control site. 
The rubbing is necessary for the jelly to pass through the skin. The uneven thickness of 
the jelly may also be of importance. This may affect the laser ti ansmission and also the
1 0 1
amount of SNAG locally available to the skin at the particular site. W e must also take 
into account the cooling effects of ethanol used in the solvent and the probable variation 
in stability of SNAG in these different solutions. In an ethanol solution there will 
probably be fewer of the copper ions present than in a water /  ethanol mix. The stability 
of SNAG in KY jelly has not been studied but all in all three systems SNAG visually 
decomposes, i.e. loses its colour, at an equivalent rate.
4.3. Stud ies on blood flow  variance in human cutaneous tissue follow ing  
transderm al delivery of an NO donor.
As part of a trial in collaboration with Ninewells Hospital, funded by the Arthritis and 
Rheumatism Council, we are required to perform a study investigating the localised 
effects of nitric oxide, delivered transdermally from SNAG, on human skin blood flow. 
The full tests will involve fifteen healthy volunteers and thirty primary and secondary 
Raynaud's patients. The tests will not be completed in the lifetime of this study and 
therefore only prelim inary results, from a smaller sample, can be reported here. 
However, with six healthy patients and nine Raynaud's patients, a sufficient number of 
tests have been performed for the results to be viable. The results o f the tests on 
Raynaud's patients and their comparison with the data from healthy patients will be 
discussed in chapter 5. The results and implications of the trials on healthy volunteers are 
reported in this chapter. The study on the six healthy volunteers was reported as a full 
paper in its own right. W hilst this has been rewritten, it will be reported in a similar 
form.
4.3 .1 . Introduction
Skin ischaemia, with possible tissue necrosis, ultimately results from a blood flow 
problem in the nutritive microvessels. 80 - 90 % of the blood flow in the skin serves a 
thermoregulatory purpose, with only the small percentage remaining being involved with 
nutrition. However it is this remaining component which is important clinically and a 
failure at this level which may lead to a number of vascular problems as encountered in
1 0 2
disorders such as diabetes m e l l i t u s ^ ^  and Raynaud's phenom enon.^^ Since the 
endothelium and NO aie important regulators of vascular tone, it is therefore essential to 
determine the responsiveness of cutaneous microvessels to nitric oxide. In order to 
investigate this, different areas o f cutaneous tissue with different thermoregulatory to 
nutritive vessel ratios have been studied. NO is known to be an important regulator of 
vascular tone at a number of different levels of circulation. However it is questionable 
whether cutaneous microvessels are responsive to it. This uncertainty arises from the 
variable effects of L-NMMA, an inhibitor of NO production, in cutaneous blood vessels. 
Coffman^^ showed that the brachial artery infusions of L-NMMA significantly reduced 
basal skin blood flow at the dorsum of the finger and the foreann. In contrast. Noon et al 
demonstrated that L-NMMA did not reduce basal skin blood flow at the dorsal surface 
o f the finger but did at the pulp where thermoregulatory arteriovenous shunts are 
abundant. However, a role for NO in the thermoregulatory control of skin blood flow in 
humans has been refuted. Thus while NO may be involved in the basal regulation of skin 
blood flow, the stimulated release of NO from cNOS appears to be small. Indeed Khan 
et al 23 have shown that L-NMMA does not inhibit cutaneous vascular responses to 
acetylcholine or methacholine. Studies have demonstrated that providing more L-arginine 
for NO production does not improve cutaneous vascular reactivity. Known vasodilators 
such as acetylcholine and sodium nitroprusside have been shown to have a relatively 
small effect on cutaneous blood flow. Even when sodium nitroprusside is infused intra­
art erially, the cutaneous vascular response tends to be s m a f i 2 6  or even completely 
absent.27 Of the previous studies concerning the effects of transdermally delivered NO 
upon cutaneous tissue, the donors have usually required m etabolism , such as 
nitroglycerine, rendering them ineffective in the vascular beds being studied. These do 
not contain the necessary apparatus to effect this transformation (chapter 4.1). Others, 
such as sodium nitroprusside, require active transport across the skin. One method for 
this is via iontophoresis, whereby the current used may also be having an effect on the 
skin. Nitroprusside may also require extensive metabolism (chapter 1 ) and so results 
obtained may not be relevant to our studies.
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Therefore, in this study, we me reporting for the first time the effect of an NO donor drug 
requiring no metabolic conversion to produce NO, on the cutaneous microvasculature in 
human subjects. From this we aim to highlight any variance in the response to NO 
between thermoregulatory and nutritive blood vessels.
4.3 .2 . M ethods  
Subjects.
Six healthy adult males were recruited as volunteers for the study. Ethical approval was 
granted from the Tayside Committee on Medical Research Ethics and informed consent 
was obtained . The mean age o f the sample was 29 yem's (range 24 - 41). Blood 
pressure was 123/77 ± 14/12 mm/Hg and heart rate was 69 ± 13 beats per minute.
M easurem ent of skin erythrocyte flow.
The levels of blood flow in cutaneous tissue shows a considerable level of variance over 
any given area. To overcome this potential problem we used scanning laser Doppler 
imaging. Skin perfusion was measured in ambient light conditions using the MoorLDI 
scanning laser Doppler imager (Moor Instruments, Axminster, UK) which scans a low 
power laser beam (1.5mW helium neon , wavelength 632.8 nm) in a raster pattern over 
the skin surface. Moving blood in the microvasculature causes a Doppler shift which is 
processed to build a colour coded image of blood flow (erythrocyte flow). The image is 
stored on a computer which uses dedicated Windows software for image processing and 
analysis. The colour image is processed to give a blood flow in arbitrary perfusion units 
(PU). The scanner was placed 50 cm above the measuring area for all scans. The spatial 
resolution for the scan area was set at 100 x 100 pixels and the scan speed was 
4ms/pixel. The median value was determined for each scan area.
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M easurem ent o f Skin Oxygenation
Oxygen saturation in the skin was measured with micro-lightguide spectrophotometry 
(EMPHO II, BGT, Gmbh, Germany). In this technique the absorption spectrum of the 
light reflected from the skin, between 500 and 620 nm, is analysed to provide an estimate 
of the concentration of the oxygenated haemoglobin, expected as a percentage of total 
haemoglobin. One optical fibre, of 250 |im  internal diameter, transmits light to the skin 
and six similar fibres detect the reflected light. The catchment volume of the instrument is 
estimated to encompass predominantly capillary blood. For each measurement, the probe 
was scanned evenly over the skin and a set o f 20 spectra were recorded continuously at a 
rate of one per second. The absorption spectr a for haemoglobin and oxyhaemoglobin are 
visually quite different (figure 7) allowing interpretation of the spectra obtained. These 
spectra were analysed by fitting with set spectra o f known oxygen saturation, to produce 
20 values of blood oxygenation, from which the mean was calculated.
F igure  7
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Changes in skin perfusion and oxygenation were determined using one-way analysis of 
variance (ANOVA) for repeated measures, followed by post-hoc paired t-tests for 
individual concentration when a significance was found. The null hypothesis was 
rejected at p<0.05.
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4.3.3. E x p e rim e n ta l P ro to co l.
The subjects were seated comfortably in a slightly cooled room (19°C) and allowed to 
equilibrate over a 20 minute period. The right arm was supported on a table at about 
heart level. Measurements were made over three different areas, the volar forearm, the 
dorsum of the finger and the finger pulp. Each site was cleaned gently with alcohol 
wipes. The first site to be studied was the forearm. The subject’s arm was set up as to 
have the forearm facing upwards. Two circular perspex wells (diameter 2 cm, height 0.7 
cm) were attached to the forearm with double sided adhesive tape. The edges of the wells 
were and all external areas of skin were covered with black material. The scanner was set 
to cover an area of skin containing both wells and for the scanning time to be 
approximately 45 seconds. The scans were taken every one and a half minutes, allowing 
time for the skin oxygenation readings to be taken in between. A scan was over each area 
to obtain a "dry" baseline for skin perfusion and oxygenation. The wells were then filled 
with 50 % aqueous ethanol and "wet" baselines for perfusion and oxygenation recorded. 
This was to assess the influence of the solvent on readings, as regards cooling etc. One 
well was then emptied and refilled with a solution of 0.5 % SNAG in aqueous ethanol. 
Scans were then recorded over a period of 15 - 20 minutes, until no more increases in 
readings were observed. The wells were then emptied, moved to a different site, and the 
process repeated using 1 % and then 1.5 % solutions of SNAG. After the tests were 
complete, the subject was allowed 5 minutes to stretch the arm and normalise the blood 
flow. The aim was turned over as to have the back of the hand facing upwards and the 
fingers flat on the table. Three wells were constructed for the fingers out of caulking 
compound. Blu-tac was found to be the most effective substance for this purpose. 
These wells, of 1 cm diameter and 0.8 cm height, were firmly attached to the dorsum of 
the middle three fingers using double sided adhesive tape. As before, both dry and wet 
baselines for perfusion and oxygenation were recorded. The aqueous ethanol was dried 
from the wells and these were then filled with 0.5, 1.0 and 1,5 % solutions of SNAG. 
These were then scanned as for the foreami. Care needed to be taken to avoid a leakage 
of the contents from the well. In order to avoid the choice of finger having any bearing
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on the results, different concentrations of SNAG were used on different fingers with each 
volunteer. Finally the same procedure was repeated on the pulp of the middle three 
fingers. This is a relatively uncomfortable position for the patient to maintain and the 
hand requires to be supported for the fingers to be at the correct angle.
4 .3 .4 . R e su lts  
Sk in  e ry th ro c y te  flux.
Baseline skin erythrocyte flux was not significantly different at any of the three sites. 
F igure I shows that transderm al application of SNAG produced significant 
concentration-dependent increases in skin erythrocyte flux at both the forearm (p<0.01, 
ANOVA) and dorsum of the finger (p<0.005, ANOVA). For the forearm, post-hoc t- 
tests showed significant increases in skin erythrocyte flux from baseline at all three 
concentrations (p<0.02 for all concentrations, figure 1). At the 1.5 % concentration, skin 
erythrocyte flux increased from 27 ± 3 PU to 86 ± 21 PU. With the 0.5 % solution it 
was difficult to observe any increase in flux by way of a colour change on the computer 
screen. The increase was visually noticeable at the higher concentrations. At the dorsum 
of the finger, post-hoc testing showed a significant increase in skin erythrocyte flux at 
1% (p<0.02) and 1.5% (p<0.02) concentrations with no significant increase at 0.5 %. 
Skin erythrocyte flux increased from a baseline value of 29 ± 3 PU to 52 ± 7 PU after 
application of 1.5 % SNAG. The results for erythrocyte flow in the pulp shown in figure 
8 suggest that SNAG has caused an increase. However, statistical analysis demonstrates 
that the increase is not significant. The increase shown was mainly due to an outlier from 
one subject who showed some increase in blood flow. Visually there was no increase in 
flux during the experiments on the other subjects.
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The application of aqueous ethanol was found to produce no changes in skin erythrocyte 
flux at any of the sites in question.
Sk in oxygenation
Figure 9 shows that at the forearm SNAG produced a 40 % increase in oxygen saturation 
(p<0.001, ANOVA) and post-hoc testing showed this to be significant for all three doses 
(p<0.05 for 0.5 % and 1.5 %, p<0.01 for 1.0 %, paired t-tests). In practise the value for 
oxygen saturation probably reached its maximum with the 0.5 % dose and no further 
increase was possible. At the dorsum of the finger, plots of oxygen saturation over time 
for individual subjects showing highly fluctuating values but with no significant change 
overall. At the finger pulp there was no significant increase in oxygen saturation from the 
baseline at any concentration of SNAG. It is shown (figure 9) that the baseline was 
higher for the pulp than forearm or dorsum and this may have had some bearing on the 
results. Were the saturation already at its maximum then we would not have seen an 
increase even had the vessels been responsive.
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4 .3 .5 . D iscussion
The three areas of cutaneous tissue were selected as they represent good examples of the 
two different blood vessel functions. The perfusion in the forearm and dorsum of the 
finger serves a mainly nutritive role and plays little part in the control of body temperature 
via dilation or constriction. The fingertips, however, are rich in arteriovenous shunts. 
These can be viewed as channels which may divert large quantities of blood through them 
to help in thermoregulation. The increase in perfusion flux in the forearm and dorsum, 
with no increase in the pulp, shows a very definite difference in the responsiveness of the 
different types of cutaneous microvessels. Our results demonstrate conclusively that 
nutritive microvessels are responsive to exogenous NO. The significant increase in 
oxygen saturation of the forearm is also suggestive of an increase in capillary perfusion. 
The catchment volume for this technique is thought to encompass mainly capillary 
flow ,28 where the oxygen is being consumed. The initial levels of oxygen saturation, 
upon entering the capillary system, should be the same irrespective of the blood flow. 
However, the tissue may only use a certain amount of this oxygen as the blood passes 
through, therefore the percentage consumed from a higher blood flow will be less than 
that consumed from a lower blood flow. It is because of this that we see an increase in 
the levels of oxygen saturation rather than an increase in the uptake of oxygen by the
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blood. From this we can equate a higher blood flow with a higher level of oxygen 
saturation of haemoglobin. To explain this increase a decrease in oxygen consumption is 
unlikely. Results from the dorsum of the finger are more difficult to interpret. No 
overall change in capillary oxygen saturation is seen but individual values fluctuated 
between high and low values throughout the period of measurement. This gives an 
average zero response. These results, alongside the increase in perfusion flux, suggest 
that SNAG is having an effect on the dorsum cutaneous microvessels. From these 
results we cannot say exactly what the effect is. Despite the confusing nature, the 
fluctuating values for oxygen saturation did turn out to be of significance when compared 
with the corresponding results from Raynaud's patients (chapter 5). The results from the 
tests upon the finger pulp suggest that microvessels with a themioregulatory function do 
not respond to exogenously delivered NO. This interpretation was hindered by the 
suggestion that the skin at the finger pulp site may be of a different nature to the skin on 
the forearm and the dorsum and that this may be the factor causing this difference. If this 
skin were tougher or thicker or have a thicker layer of dead cells covering it then it might 
affect the results. To try and answer this, a number of methods for removing any dead 
cells were investigated. Sticky tape was applied to the fingertips and sharply removed to 
pull off any loose tissue. The perfusion and oxygenation results were similar to those 
above. It is possible to shave off large amounts of dead skin from the fingertip with 
cai'eful usage of a scalpel blade. This was performed the evening before testing to allow 
the finger time to recover. When SNAG was applied, the results were identical to those 
seen before. Finally the injection o f a very small quantity of SNAG solution into the 
finger pulp was tried. This proved very painful and the area surrounding the injection 
site showed a large degree of trauma, disguising any potential vasodilation. As 
suggested above, the lack of rise in the oxygenation of the finger pulp blood flow may 
have been due to the levels already being at their maximum. To investigate this we 
cooled the subject (room temperature of 14°C) to obtain a lower baseline. Despite the 
low baseline we did not see any increase upon addition of 1.5 % SNAG solution. From
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our results we felt we could confidently say that the microvasculature in the finger pulp 
was not being affected by the exogenous NO being supplied to it.
4 .3 .6 . C o n c lu s io n s
The finding that SNAG causes significant concentration dependent vasodilation of 
nutritive cutaneous microvessels is consistent with these blood vessels being responsive 
to exogenous NO. SNAG has a considerable advantage over other commonly used 
donors such as nitroglycerine in its mode of action and its mode of delivery. It is rapidly 
metabolised such that the vasodilatory effects remain local and there are no systemic side 
effects such as headache, flushing and nausea. Considering the small scale applications 
involved it has been no surprise that we have not encountered any problems with 
tolerance. With the apparent thermal decomposition of SNAG, without the need for 
transnitrosation, we do not expect tolerance to develop were SNAG to be used for 
therapeutic purposes. A com pound such as this may have im portant therapeutic 
implications in several areas o f microvascular dysfunction. The ability to increase 
nutritive capillary flow through NO may be of particular importance in patients with 
diabetes mellitus who are prone to skin ulceration and infection. It has been suggested 
that vascular sensitivity to NO is diminished in patients with diabetes m e llitu s ,p e rh a p s  
due to oxidative stress^^ or quenching of NO by the formation of advanced glycosylation 
end-products.^® Providing NO transdermally to compromised areas of tissue may enable 
NO levels to be elevated sufficiently to overcome its inactivation. Furthermore, local, 
transdermal application of an NO donor could limit the "steal" phenomenon seen with 
other non-specific vasodilators. In the "steal" phenomenon ischaemia can be worsened 
due to the diversion of blood through non-nutritive thermoregulatory vessels but also to 
existing healthy blood vessels. With direct application of SNAG to an affected area it 
should be possible to avoid this occurrence.
The rapid action of SNAG makes it an ideal compound upon which to base these studies. 
W ork carried out on isolated rat-tail arteries has shown it to be an effective NO donor.
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The vasodilatory action is inhibited by the addition of haemoglobin, demonstrating that it 
is indeed the NO and not some other facet of the molecule having this effect.
4.4. O ther transderm al delivery stud ies.
As stated in 4.2, a lack o f time has prevented us from obtaining permission for full 
transdermal tests on other compounds. We were able to carry out preliminary tests, 
using ourselves as volunteers, on other compounds which showed potential.
The two derivatives o f thioglycerol, known as SNOIL and SNOIL-acetate were 
investigated. We were particularly interested in these compounds due to their structural 
similarity to nitroglycerine, one of the most effective transdermal agents and one of the 
most efficient NO donors. Despite their apparent similarities, the two thioglycerol 
derivatives have very different solubilities. SNOIL is very hydrophilic and SNOIL - 
acetate is fairly hydrophobic. They are both very stable compounds under certain 
conditions but are sometimes found to be very unstable, explosively so at times. 
Solutions of the two compounds (1 % in ethanol /  water) were placed in the plastic wells 
and the blood flow investigated using the scanning laser Doppler. The results (figure 10) 
demonstrate a completely different effect between the two. SNOIL has no effect on the 
blood flow whereas SNOIL - acetate has given a rapid and vast increase, larger than we 
had seen for any vasodilatory compound. This is in accordance with suggestions that a 
molecule must have a low degree of water solubility to pass through the skin. It is hoped 
that further work, both on the kinetics and the physiological usage of these compounds 
will be possible and that their potential be fully investigated.
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Chapter 5: Investigations into Raynaud's Phenom enon.
5 .1. Introduction
Also known as symmetric gangrene or local asphyxia, this was first described by 
Raynaud in 1862. However, despite the disease being known for over 130 years, the 
etiology remains an enigma. Between 1991 and 1993 at least 38 different therapies were 
advocated and seventy different theories put forward as to the underlying cause. 1 These 
will be discussed later. Interest in the disease has increased di amatically over the last few 
years with over two hundred papers published each year and a well supported charity. 
As more is learnt about the disease and its importance and relevance to other disorders its 
significance receives greater appreciation, especially as the disruption to the individual 
and to society becomes apparent.
It is a disease that afflicts approximately five percent of the population, though the figure 
varies drastically, depending on the exact definition of the disease.^ O f these up to 80 % 
are females.3 This may be due to the observation that women have a lower hand blood 
flow than men.4 The disease tends to be prevalent in those under the age of about forty 
years. Not surprisingly it is most common in the colder parts of the world.^
Raynaud's Phenomenon (RP) is a paroxsymal or intermittent spasm of the digital 
arteries^ and possibly involves other factors such as platelet aggregation^ disrupting the 
blood flow. The symptoms encountered by a sufferer involve a loss of blood circulation 
to the affected area, usually the hands. This leads to the hands becoming numb and 
useless. Intense pain is felt when the circulation is restored. Sufferers tend to have 
lower blood flow in the digital microcirculation than normal healthy subjects and have a 
lengthier recovery period. The skin microvessels contract and the blood flow is blocked. 
This is most usually caused by exposure to the cold and em otional stress. In a 
susceptible individual temperatures as high as 17°C can cause an onset of the symptoms.^ 
In the most severe cases temperatures of 25°C can be sufficient to initiate an attack, i.e. 
well above the noimal maximum temperature both outside in northern Europe and indeed
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inside a normal house. In a mild case of the disorder the only symptoms are pale and 
numb linger s. 8 Sufferers may have dry, cracked hands with ulcers on the fingertips and 
skin with a prematurely aged appearance.^ In a more advanced case the extremities 
become painful and useless, taking on a livid red colour accompanied by a throbbing 
pain. In the most serious of cases, cyanosis and superficial gangrene can occur. The 
gangrene can be of a moist or dry nature and can lead to the loss of the digits involved. 
Damage caused generally takes a long time to heal and can leave the fingers looking 
shiny, smooth and c la w - l ik e .  While the fingers are the most frequently affected part of 
the body, it is also possible for the toes, ears, nose and tongue to be afflicted.
RP is a heterogeneous disorder with many different stimuli producing the same 
symptoms. The name is generally used to describe the symptoms of loss of circulation 
irrespective of the cause. RP can be divided into primary and secondaiy. Secondary is 
taken to mean RP is associated with an underlying disease, whereas Primary RP is taken 
to mean that no underlying disease co-exists. This is referred to as Raynaud's Disease 
(RD) which is often hereditary. RD is usually diagnosed when there is an absence of any 
symptoms or signs of systemic disease that might account for the occurrence o f RP. 
There are two main theories to explain RP: an increase in sympathetic nervous activity or 
a local fault such as a drop in CGRP-like nerves or an increase in a-adrenoreceptor 
activity. The cause of these is as yet unknown.
O f  the many prospective causes of R P , one is not in dispute. In early 1 9 9 6  miners 
suffering the disorder won the right to compensation in the c o u r t s .^9 Workers suffering 
R P  through the long term usage of vibrational tools were recognised as victims of the so 
called Vibrational Induced W hite Finger (VWF).ri,12 This is very common amongst 
workers exposed to excessive vibration which damages blood vessels. This includes 
miners, chainsaw operators and those involved in polishing metal especially in the 
aerospace industry. This may frequently demand a career change, particularly difficult 
for some professions such as secretaries involved in typing. The disorder often affects
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piano players in later life. There are also a number of chemicals implicated in the onset of 
RP such as PVC. Similarly those exposed to the cold on an intense or long term basis 
stand a good chance of developing RP. Prolonged changes in environmental temperature 
may alter thermosensitivity in humans. A good example is shown in that after 10 or more 
years of daily exposure to iced fish, 90 % of frozen fish filleters developed RP.^^
Patients with RP have been shown to have abnormally increased platelet activity. 
Hyperactive platelets may further impede blood flow in the already contracted blood 
vessels of the sufferers and platelet aggregation may have a pathophysiological role in 
RP. Exposure to silica^^ and silicone^^ from breast implants has been shown to lead to 
an incidence of RP much above the average. Patients receiving chem otherapy, 
particularly antineoplastic agents, cis-platin and bleomycin as used in the treatment of 
testicular cancer, are very likely to develop RP. 17,18 Other commonly suggested triggers 
include an enhanced response to catecholamines 1^  and female sex hoimones.^ll
The suggestion that nitric oxide is involved is not a new one. In tests the response to 
nitroprusside, a well known, if inadequately studied, NO donor, has not been diminished 
in Raynaud's sufferers, whereas that o f bradykinin has. This suggests that endothelium 
dependent venodilation is im paired in peripheral vessels in RP, possibly due to 
dim inished release of nitric oxide and may contribute to the pathogenesis o f the 
d i s o r d e r .  19 Levels of cGMP (involved in the pathway leading to smooth muscle 
relaxation and hence increased bloodflow) increased in a control group after exposure to 
the cold but levels rem ained constant in RP sufferers, suggesting they lack the 
physiological response of cGMP to cold exposure.7^1 A deficiency of immunoreactive 
CGRP nerve fibres has been demonstrated in the digital cutaneous micro-vasculature of 
patients with RP. The distribution of other nerve fibres seems to be unaltered. 
Raynaud's suggestion that RP is caused by overactivity of the sympathetic nerves is still 
regarded as being a possibility. 13
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A final contributing factor toward RP would appear to be lifestyle itself, attacks are more 
common in smokers and those taking oral contraceptives and are often brought on by 
stress and other strong emotions.
When stress management and relaxation training fail to control symptoms then various 
medications may be prescribed. These include calcium channel blockers such as 
nicardipine.^^ This is generally well tolerated and can give effective improvement in RP 
patients provided there are no underlying d i s e a s e s .^ ^  A well tested treatment is the 
prostacyclin analogue iloprost.^^ The action of this is not defined but it is known to 
inhibit platelet aggregation and provide cytoprotection.26 Giving evidence of the nitric 
oxide involvement, L-arginine, from which NO is produced in the body, has been shown 
to be of some use in the treatment of RP^^ although recent studies have conflicted with 
this conclusion.28 The most commonly used treatment at the moment involves a 
sympathectomy, whereby doses of phenol are given to the affected areas. This basically 
kills the nerve endings, removing their ability to cause vasospasm. This is a fairly 
effective treatment but usually leads to a reoccurrence of the problem within a short 
period of time.
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The lack of suitable treatment is highlighted by some of the more comical suggestions 
seen for the control of RP symptoms. The Sunday Times^^ suggests massaging the feet 
with a few drops of essential oil of black pepper diluted in a tablespoon of almond oil.
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This is probably as effective as any other suggestion yet put forward. Finally the 
suggestion o f Raynaud him self involving, "a galvanic current with the positive pole 
applied over the fifth ceiwical vertebra and the negative over the last lumbar vertebra 
W ith a moderately strong current applied for five to ten minutes daily this treatment 
appeared to be effective in some cases. Whilst this is not a common treatment at present, 
the usage of spinal cord stimulation has been proposed for the treatment of RP "because 
of the high probability of failure of other medical or surgical therapy.
Treatment of the disease is limited in that the most effective drugs for vasodilation are 
ineffective on the skin microcirculation. The most commonly used vasodilators are 
glyceryl trinitrate and isosorbide dinitrate. However these are compounds that require to 
be metabolised in order to release nitric oxide. The necessary machinery to metabolise 
these is only contained in micro vessels of diameter larger than about 100 |im. The skin 
surface microvessels are only about 20 {im in diameter. Therefore a nitric oxide donor 
which can spontaneously emit NO is preferable. In these compounds the decomposition 
is caused thermally, photolytically or by transnitrosation or metal ion catalysis. It is on 
this basis that we feel it worthwhile synthesising a nitric oxide donor which has similar 
characteristics to glyceryl trinitiate and isosorbide dinitrate in size and solubility but will 
emit nitric oxide spontaneously. These, it is hoped, will aid our understanding of the 
disease and assist in the formulation of a successful treatment by showing whether the 
defect lies in a lack of nitric oxide production, a lack of ability to use it, or neither.
However, the most vital information this may supply will be the connection of RP to 
other vascular disorders where a deficiency in NO production is involved. RP often 
heralds connective tissue disorder,^! in fact 50% of secondary RP sufferers are likely to 
develop a connective tissue disorder such as CREST (calcinosis, Raynaud's oesophageal 
dysmotility, sclerodactyly, telangiectasia) and other collagen vascular diseases including 
scleroderm a.32 RP can also be used as an early warning of an underlying problem, 
notably testicular cancer.33 The prevalence of migraine is significantly increased in
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subjects with RP,34 with as much as twice the normal incidence.35 This suggests that 
these conditions may share a common pathogenic defect or mechanism.
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5.2. V asod ilatory R esponses o f R aynaud’s Patients.
As stated in chapter 4, the aim o f the ARC funded trial was to study a number of 
sufferers of Raynaud’s disease and their skin blood flow responses to the vasodilator 
SNAG. These were then to be contrasted with the results from tests upon healthy 
volunteers. From this study we hoped to learn a little about the disease and possibly 
suggest a treatment for it and similar conditions.
5.2.1. Selection o f C andidates.
Ten volunteers from the Tayside area, suffering from Raynaud’s disease, were accepted 
as part of the trial. Out of these, four showed primary Raynaud’s and six showed 
secondary Raynaud’s phenomenon. The ages ranged from 16 to 65. A number of these 
candidates had visible symptoms of Raynaud’s, such as the pinched appearance of the 
face, particularly the mouth. Some of the secondary patients also suffered from systemic 
sclerosis and had slightly deformed hands. It is possible that a thickening of the skin in 
some o f the sufferers may have affected the ability of the drug to pass through to the 
living tissue. It is also fair to postulate that we are dealing with a different type of skin in 
the volunteers with such conditions as scleroderma and systemic sclerosis. However, 
comparisons between these patients and those with primary Raynaud’s and no other 
symptoms, suggest that it has had little influence upon the results. The degree to which 
each of the patients was affected by the disorder varied dramatically, from those who 
suffered several attacks per week, to those who only found problems during periods of 
cold weather. The stimuli causing the attacks also showed considerable variation, some 
subjects were affected by emotional stress and others found it had little or no bearing on 
the onset o f an attack. For the completed study (n = 45) there will be an equal number of 
primary and secondary sufferers. Each of these will be matched with a healthy patient of 
the same age as to eliminate the natural changes in circulation which occur with increasing 
age. The full study will eliminate the errors caused by the heterogeneous nature of the 
sample. W ith the smaller numbers discussed in this report we can only look at the 
general pattern of response.
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5 .2 .2 . M ethods
The effects of SNAG upon the cutaneous blood flow were as discussed in section 4.3. 
The blood flow in the forearm, dorsum of the finger and pulp o f the finger were 
investigated at 0.5, 1.0 and 1.5 % solutions of SNAG using scanning laser Doppler 
Imaging. The % oxygen saturation was also followed using m icro-lightguide 
spectroscopy. The overall time for the tests was between 1V2  and 2 h per patient.
5 .3 . R esu lts
The results of the study are shown in comparison to those from the tests carried out upon 
healthy patients from chapter 4.
5.3.1. Skin erythrocy te flux.
The results shown below compare the blood flow changes in response to SNAG for 
healthy patients and Raynaud’s sufferers. These have all been calculated as % changes 
relative to the baseline rather than as individual flux values shown in chapter 4. It is 
because of this that some of the values appear to be contrary to those already shown.
Figure 1 shows that transdermal application o f SNAG produces a dose dependent 
increase in blood flow in the Raynaud’s patients. However it is noticeable that this 
increase is dramatically smaller than that obtained in healthy patients. At the 0.5 % dose 
the increases for Raynaud’s and healthy patients were 29.5 and 44 % respectively. The 
differences are greater at the 1.0 (40 and 123 %) and 1.5 % concentrations (59 and 144 
%). A similar pattern is seen on the dorsum of the finger at the higher concentrations 
(figure 2). At the 0.5 % concentration, the % increase for blood flow for the Raynaud’s 
and healthy patients were 3.8 and 2.0 % respectively. A large difference in the % 
increase was seen at 1.0 (10 and 60 %) and 1.5 % (-1.2 and 84 )%. The results for the 
erythrocyte flux in the pulp are more difficult to interpret (figure 3) as they show no 
pattern and were not found to be of statistical significance (p>0.05 for all values).
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Figure 3
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5.3.2. Skin O xygenation. The results below com pare the levels of oxygen 
saturation in the skin of Raynaud’s sufferers and healthy patients. The results are shown 
as actual levels o f skin oxygenation rather than % increases to highlight important 
differences, especially in figure 6. Statistical analysis was carried out as chapter 4.
The effects o f transdermally delivered SNAG on the forearm are shown in figure 4. 
These demonstrate a similar pattern between both sets o f patients, both showing a 
significant increase in p02  upon application o f SNAG (p<0.001). The 0.5 % dose 
causes relatively high increases in p02  of 57 and 51.5 % for the Raynaud’s and healthy 
patients respectively. In healthy patients this would appear to be about as much of an 
increase as is possible, the 1.0 and 1.5 % SNAG doses giving p 0 2  increases of 54 and 
46 % respectively. In the Raynaud’s patients a further increase in saturation is seen with 
p02  levels of 74.5 and 76.5 % for the 1.0 and 1.5 % solutions respectively. Whilst there
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does appear to be a trend showing a higher O2  saturation in the Raynaud’s patients, this is 
not borne out be rigorous statistical analysis (p>0.05).The results shown in figure 5 
compar e the change in oxygen saturation in the dorsum of the finger between the two sets 
of patients and demonstrate a lack of any significant change in p02, (p>0.05). This is 
explained in 5.4.
The changes in p02  levels in the pulp of the finger for the two sets of patients are 
compared in figure 6. The results demonstrate that there were no significant changes in 
the levels of oxygen saturation for either the healthy patients or the Raynaud’s sufferers, 
in fact the graphs show a slight decrease. It is noticeable that there is a markedly higher 
level of PO2  in the finger pulp of healthy patients. These patients showed an average 
initial p02  level of 56 % whilst the Raynaud’s patients had an average initial reading of 
39 4L
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5.4 . D iscu ssio n
The results show that the two groups of patients show very different responses to 
exogenous nitric oxide. This response is quite difficult to quantify and the results have 
shown that there may be little correlation between the two methods that have been used. 
This is most obvious in the results for the forearm, whereby the healthy patients show a 
much larger increase in blood flow, but the Raynaud’s patients show a slightly larger 
increase in p02. The blood flow differences are very dramatic and cannot be discounted, 
demonstrating that Raynaud’s patients have a lesser ability to respond to exogenous NO. 
The micro-lightguide spectroscopy technique studies the blood at a very superficial 
vascular level and the ability of Raynaud’s patients to respond at this level may have little 
bearing on the disorder. As this technique is not as fully tested as laser doppler imaging, 
connections between the two sets of results cannot be made with 100 % certainty. The 
results from the dorsum for both sets of patients showed no significant increase in the 
levels of saturation as shown in 4.3. However, though not described by the graph, the 
results were very different. The p 0 2  figure is calculated from the mean of a number of 
values as described previously. With the Raynaud’s sufferers there was very little 
deviation from the mean and it was obvious that SNAG was having little or no effect 
upon the area studied. With the healthy patients there was a large variation in the results 
with alternating high and low readings being recorded. This suggested that SNAG was 
having an effect upon the subject. Therefore calculation o f the mean, giving a non­
significant change in p 0 2  for both sets of patients, does not accurately reflect the effects 
of SNAG upon the levels of oxygen saturation in the dorsum. From this it is possible to 
say that there is a difference in the dorsum response between Raynaud’s and healthy 
patients, with Raynaud’s patients giving a lesser response. However it is not possible to 
quantify what this difference may be. In view of the lack o f response in the pulp of 
healthy patients it was not surprising to note the lack of response in Raynaud’s patients. 
Though the p02 did not change during the experiments, there was a much lower starting 
value in the Raynaud patients. This low value in the finger pulp may turn out to be of
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m ajor im portance in the etiology o f Raynaud’s Phenomenon but, as the pulp is 
uni'esponsive to exogenous NO, this will be difficult to investigate.
These results have highlighted that the ability to respond to exogenous NO is an 
im portant factor in the defect involved in RP and that there is a marked difference 
between sufferers and non-sufferers. From these we can suggest that the blood vessels 
of Raynaud’s patients either have a diminished ability to dilate, in response to nitric 
oxide, or that there are other factors which over-ride this external stimulus, such as 
sympathetic nerve activity.
5 .5 . C o n c lu sio n s
Despite our hopes that an NO donor could be of therapeutic benefit in the treatment of 
skin disorders, it became apparent from an early stage that SNAG would not be a suitable 
candidate for this purpose. SNAG has too low a stability to be used as a drug and the 
vasodilatory responses it causes are much too transient. However, this rapid action, 
short term response characteristic makes SNAG an excellent compound for a study such 
as this. It has no known side effects and the vasodilation caused is very much localised, 
allowing many sites to be tested without affecting each other another. It also gives a rapid 
response allowing patients to be tested quickly. This has allowed us to carry out the first 
study investigating the effects of exogenous nitric oxide on Raynaud’s patients. It has 
also allowed us to make the first study that directly compared the differences in the 
response between Raynaud’s sufferers and healthy patients. From an investigative point 
of view the nature of the results were unimportant as long as they were reproducible. 
Two of the possible causes of RP involved the sufferer either not producing sufficient 
quantities of NO, or the blood vessels not having the ability to respond to it. It is 
possible that the two are connected, a long term lack of NO leading to damage of the 
tissue and so reducing its capability to dilate when exposed it NO. From our point of 
view the first cause would have been of more interest as it would have allowed for the 
possibility o f using an NO donor in the treatment of RP. As it was, our results point
130
toward the second cause being of more significance. This dictates that NO donors are 
unlikely to be a particularly effective treatment for RP.
Despite finding our compounds to be of little value in the treatment o f RP, the study has 
been instrumental in demonstrating one of the defects present in sufferers. It has, 
however not told us how this has come about. Further studies clarifying the effects of L- 
ai'ginine in both RP and healthy patients, as well as investigations into the levels of L- 
arginine in RP sufferers, will be necessary to determine how much of the NO pathway is 
damaged. It may be that it is only the lack of NO induced vasodilation which is different 
in RP patients or it may be that there are several defects in the pathway. This information 
will be o f use in the continuing search for a treatm ent or cure for Raynaud’s 
phenomenon.
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Chapter 6 : K inetic Studies
6.1. Introduction
In recent years a large amount of the work performed with nitrosothiols has involved 
investigations into their mode of decomposition.! When studying the decomposition of 
SNAP, in order to determine the mechanism of NO release, it was often difficult to obtain 
reproducible values for the half life. In view of the fact that SNAP is very stable as a 
solid and yet sometimes decomposed very rapidly in solution, it was concluded that 
something about the solvent must have been responsible for causing the decomposition. 
Differences in the half life were shown to occur for different batches of distilled water, 
suggesting that some carried a higher level of impurities. When EDTA, a metal chelating 
agent, was added to a solution of SNAP, the rate of decomposition was greatly reduced. 
Studies, using a range of metal salts, revealed copper to be the major influence upon 
decomposition.2 A number of later studies showed that it was in fact the Cu(I) ion which 
was responsible.3 This was found to be slightly peculiar in that Cu(I) is unstable and is 
rapidly oxidised to Cu(II) under physiological conditions. The addition of neocuproine, 
a specific Cu(I) chelator, dramatically reduced or even halted decomposition.^ A reaction 
mechanism for this is shown in figure 1.
Figure
(1) RSH + OH' RS' + HgO
(2 ) RSNO + 2 0 H' ^  RS’ + NOg’ + HgO
(3 ) RS- + Cu^ -" = = f = ^ [ RS Cu + ] — RS'+ Cu+
(4) RSNO + Cu+ ^  [RSNOCu-^]-EA§I*_ pg- + Ql|2+ + nO ’
(5 ) 2 RS' ► RSSR
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The first steps involve the production of RS'. This may be from a thiol impurity (1) or 
from the reaction of the nitrosothiol with OH" (2). These steps may be regarded as the 
initiation stages, whilst the concentration of RS" is building up. During this, a lag phase 
in the decomposition is sometimes seen. W hen thiol is added to the solution, or an 
impure sample used, a more rapid decomposition, without a lag phase is seen. The 
reaction is autocatalytic, regenerating RS" and Cu(II) so that the reaction may continue 
producing NO. Finally thiyl radicals will combine to produce disulphide. Despite the 
complexity of the full reaction scheme, the rate of decomposition remains dependent upon 
the concentrations of RSH and Cu(II). When step (3) is slow and step (4) fast there is 
zero order dependence on RSNO concentration. In the human body there is about 0.1 g 
of copper per 75 kg body weight.^ This is mostly present in a bound form, as serum 
albumin. Very little copper is present as free ions. Experiments have been carried out 
using bound copper as a model for serum albumin. These have shown the rate of 
decomposition of SNAP to be increased by bound copper, though not to the same degree 
as when using free copper. These results suggest that the copper catalysed 
decomposition might also be relevant in vivo. Possible Cu-nitrosothiol complexes are 
shown in figure 2.
F igure 2
N = 0  N = 0
OH,
°  OH,
The formation of these are favoured by the attraction of the electron rich NH2  or CO2  
groups to the copper and the stability of the six membered ring intermediate. The 
im portance of the amine and acid groups is verified by experiments involving the 
blocking of these groups. The S-nitroso derivatives of N- or O- protected penicillamines 
aie more stable than the unprotected molecule.^ When these sites are blocked, typically 
with an V-acetyl and an 0-m ethyl, it is more difficult for the copper to coordinate and it
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therefore has a smaller effect. However, the fully protected derivative has a low 
solubility in water and is of little use in physiological studies. Another important factor in 
the stability involves the other groups on the thiol-bearing carbon. The penicillamine 
derivative is much more stable than the cysteine derivative,^ for instance. It is fairly easy 
to envisage the methyl groups of the penicillamine hindering coordination to the copper. 
The effect of these is more notable in the solid forai, where SNAP is stable but S-nitroso 
acetyl cysteine (SNAC) is not. This suggests an electronic influence of the methyl 
groups as logic would suggest that more steric crowding would be more likely to lead to 
displacement of the NO to ease this crowding. In solution it is also possible to halt the 
decomposition of SNAC using a Cu(I) chelating agent^ i.e. the lack of dimethyl grouping 
does not appear to make the nitrosothiol more susceptible to copper catalysed 
decomposition.
.SNO .SNO
h - T  O H.C’Y  o
^ C H  Q C H ^ C
HO2 C HO2 C CH3
H H
SNAC SNAP
There are of course other factors involved in S-nitrosothiol decomposition. The most 
important are themial and photolytic. Most RSNO compounds are theiTnally unstable and 
most will rapidly decompose when exposed to light. Another route for NO production is 
transnitrosation, whereby the NO is transferred to a thiol which will give a less stable 
nitrosothiol (figure 3). This may then spontaneously decompose to produce NO.^>^
F ig u re  3
STABLE LESS STABLE
R’ SNO + R^SH R^SH + R^SNOI
R^S'h- NO'
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6.2. Decomposition Studies.
The original intention had been to study the effect o f copper ions on the rate of 
nitrosothiol decomposition in aqueous buffer. However, this has been performed only 
for a small number of the nitrosothiols prepared, due to problems with impurities and 
instability. The compounds can be divided into two classes: those based on penicillamine 
and those based on thiosugars. The decomposition of the penicillamine derivatives have 
been fairly easy to investigate and are covered in 6.2.2. The thiosugar derivatives were 
more difficult to study as they were often impossible to obtain in a pure form and 
decomposed so rapidly as to be difficult to follow the decomposition using our apparatus.
6 .2 .1 . D ecom position of 1 -5 -n itro so th io su g a r s.
The compound was dissolved in 50 % aqueous methanol and the disappearance of the 
SNO absorbance at 340 nm monitored. Routinely samples were made up in four separate 
cuvettes. Into each was placed 1 ml of either: buffer pH 7.4, EDTA 2 x 10"'  ^M in pH 
7.4 buffer, Cu^+ 2 x 10‘4m  in buffer or Cu^+ 2 x lO'^M in buffer. A sample of the 
nitrosothiol ~1 x 10"^M was made up in methanol. Immediately prior to scanning, 1 ml 
o f the nitrosothiol solution was added to each cuvette, to give a final nitrosothiol 
concentration of ~5 x lO'^M. The results for all four sugars other than SNAG [5] were 
found not to be reproducible but suggested little difference in the rate of decomposition 
between the four samples. The results of the decomposition of SNAG are shown below, 
indicating a small rate increase for the copper containing samples, the slowest rate being 
found for the sample containing the least copper (EDTA x lO’^M) and the fastest rate for 
the sample containing the most copper (Cu^+ x lO'^M).
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Likewise, the sample containing Cn^+ at the lower concenti ation still shows a faster rate 
of decomposition than the sample containing only buffer. A large increase in the rate of 
decomposition was seen when the temperature was increased from 20 to 30“C, the half 
life falling by 50 %. This, and the obseiwation that the removal of copper does not halt 
the decomposition as with SNAP, suggests that the decomposition of SNAG is mainly a 
thermal process, with only a small role for copper.
Other compounds studied include SNOIL-acetate [86], 3-5-nitrosothioglucose [50], 6-S- 
nitrosothiogalactose [59] and di-5-nitrosothioisomannide [74]. Results for these were 
difficult to interpret. The variable levels of disulphide already present probably retarded 
the decomposition rate by complexing Cu^+, making the results meaningless.
Further studies of a range of compounds is necessary to determine the effects of copper 
on 5-niti’osothiosugar decomposition. Various studies of interest which should be 
carried out include com parisons between 3-5-nitrosothioglucose [50] with its
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diisopropylidene protecting groups which should not show any copper complexation, 
and the acetylated form which may.
F igure 4
. 0 .
o
SNO O,
Ago
CH20AC Q
OAc OAc
SNO
[50]
This would possibly highlight the involvem ent of the therm al reaction in the 
decomposition. A study involving the mercaptosuccinates (figure 5) would have been 
very informative, comparing the decomposition of the unprotected derivative, containing 
two acid groups, and the protected derivatives with their two ester groups.
F igure 5
H H
HI CO2 H HI CO2 R
ONS C CO2H
H
ONS C CO2R
H
Studies by associated groups are in progress, studying the decomposition of SNOIL [82] 
and SNOIL-acetate [85], figure 6.
F igure 6
H2Ç SNO H2C--------SNO
HC OH HO OAc
H2 C" OH H2 C" OAc
[82] [85]
These are showing some interesting results which may further our understanding of the 
groups necessary for copper chelation to occur.
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The study of copper ion catalysis is incomplete because of competing demands as the 
research developed. However, this work is necessary before a complete understanding 
of this class of NO-donor compounds can be obtained
6 .2.2. P en icillam ine D er ivatives
The decomposition of SNAP has been studied in great detail and a full understanding of 
the mode of breakdown elucidated only fairly recently. A number of new derivatives of 
penicillamine have been prepared. These show interesting variations in physiological 
activity (chapter 3) and so it was of interest to learn if the added groups had an effect on 
either the rate of decom position or the mechanism of decom position. The new 
derivatives all had an acyl chain, of various lengths, attached to the amine group of 
penicillamine. One possible complex between the amino acid and the copper ion involves 
the amide of SNAP. Therefore it was expected that a long aliphatic chain in this region 
might inhibit the complexation to a degree. This might occur either by inhibiting an 
interaction between the nitrogen and the copper, or in the case of longer chains which 
could coil around the molecule, inhibit complexation to other parts of the molecule. A 
long chain might also act as a ‘cage’ around the SNO group and prevent the loss of nitric 
oxide.
The three derivatives preptued were the propionyl, valeryl and heptanoyl derivatives of 
penicillamine. These have been named SNOPP, SNVP and SNOPHE respectively.
H3 C.
H3C - V  O SNOPP: R = CH3
CH C R SNVP: R = (CH2)3CH3
HOaC^ ''C ' SNOPHE: R = ( C H 2)5 0 H3
H Hg
Decomposition studies for these were carried out and comparison of these with SNAP 
were made. The decomposition curves are shown below. Nitrosothiol (1 ml, 3 mM in 
methanol) was mixed with either buffer (pH 7.4), EDTA 2 x IQ-^M in buffer solution or
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Cu^+ 2 X 10‘^ M in buffer (1 ml). The fall in absorbance at 340 nm was recorded. SNAP 
was synthesised by the method described by Field et al.^
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The above graphs demonstrate the similarities between the four compounds. All show a 
high stability in the presence of the metal chelating agent EDTA. All show a marked lack 
o f stability in the presence of Cu^+ ions. The results, summarised in table form below, 
indicate that the longer chain does appear to confer a higher degree of stability toward 
decomposition catalysed by trace amounts of copper. When only buffer is present the 
decomposition of SNOPP, SNVP and SNOPHE is each significantly slower than that of 
SNAP. The decomposition catalysed by larger quantities of copper appears not to be 
hindered by the longer chain with SNOPP and SNOPHE having shorter half-lives than 
SNAP in the presence of 10‘'^M Cu^+. It is not obvious how the longer chain would aid 
complexation. The fact that the five membered chain, seen in SNVP, appears to give a 
more stable molecule than the three or five membered chains seen in SNOPP and 
SNOPHE, suggests that there is not necessarily a logical or simple reason for the way 
this series of compounds decompose.
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8  (mol-ldm^cm-l) ti/2 /mins in buffer t i / 2 /mins with [Cu^+J
= 10-4M
SNAP 1360 350 105
SNOPP 1370 620 90
SNVP 1550 720 120
SNOPHE 1360 560 80
Decomposition after 400 minutes at 20° C
Buffer EDTA x 1(MM Cu2+ X 10-4M
SNAP 55 % 8.3 % 79%
SNOPP 40% 5.9 % 96%
SNVP 35 % 4.6 % 7 8%
SNOPHE 36% 9.1 % 100%
The decomposition rate is very much affected by the purity o f the sample and the 
concentration of thiol. The stability will also be affected by the position of the 
equilibrium between the nitrosothiol and thiol + NO+ as well as the stability of the pure 
nitrosothiol. Because of this, these numbers can only give a very inaccurate impression 
of nitrosothiol stability.
The complexation of copper to the penicillamine moiety of SNAP can occur through the 
carboxyl or the amine groups. The above results have indicated to us that blocking the 
amine group with a longer chain is of limited value in reducing the influence of copper on 
the rate of decomposition.
We had also prepared another series o f compounds, containing the same selection of 
chain lengths on the amine, but also with a sugar ring attached to the carboxyl group. 
One of these has proven to be of great physiological interest (chapter 3).
145
AcO
CHO2 AC
o = c
AcO
RIG 200; R = CH3 
RIG 300: R= CHgCHg 
RIG 500: R = (CHajaCHa 
RIG 700: R = (CHajsCHa
^ c = o
R
The limited solubility of derivatives with an acyl chain other than the acetate, determined 
that these could not be tested under the same conditions as other NO donors investigated. 
Due to this we were unable to get any idea o f their potential as NO donors. Whilst it is 
not as satisfactory a study, an investigation into the decomposition of these molecules has 
been very important in assessing their potential. The results obtained show that the 
addition of a longer chain gives a quite different type of NO donor. The results are 
shown in the gi’aphs below.
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RIG 500 continued
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The above graphs appear to split the four compounds into two very distinctive categories. 
RIG 200 and RIG 300 give very similar profiles whilst RIG 500 and RIG 700 show the 
same pattern of decomposition. RIG 200 is very similar in stability to SNAP in both half 
lives and % decomposition for the three solvent conditions examined. RIG 300 shows 
the same decomposition pattern but is very much more stable toward trace copper 
catalysed decomposition. The limitations of both half life and % decomposition values 
are demonstrated here in comparing RIG 200 with RIG 300. They have similar half lives 
for the decomposition in the presence of lO’^ M copper and yet the % decomposition for 
RIG 300 at 400 minutes is much lower than for RIG 200. This is probably due to the 
rate slowing down as the decomposition continues, in the same manner as shown for 
RIG 500 and RIG 700. Both compounds show a significant lag phase at the start of the 
decomposition curves for the buffer and Cu^^ samples. This can be explained as the 
period whilst the levels of thiol are building up as shown in figure 1. The decomposition 
of RIG 500 and RIG 700 is much slower than for the first two compounds. In the case
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of RIG 500 the decay appears to proceed smoothly, but when the study is continued for a 
longer period ( > 1 0 0  min) it is noted that absorbance levels out and no further 
decomposition is seen. This is shown more dramatically in the case o f RIG 700 where 
this levelling off is seen after only a very small degree of initial decay. This is also seen 
in investigations into the decomposition of GSNO. The decay of GSNO is very complex 
but involves inhibition of the decomposition by the disulphide which halts the reaction.. 
The addition of 1 mmol cysteine to the halted RIG 500 decomposition causes an instant 
response and rapid breakdown of the nitrosothiol. At 30°C the initial decomposition of 
RIG 700 proceeds to a greater degree before the decay is halted. An increase in 
temperature appears to cause no further decomposition. The addition of 1 mmol cysteine 
allows the reaction to continue but does not increase the initial rate.
The data from these experiments are summarised in the tables below.
£(m ol' Mm^cnr ^  ) tl/2 /m ins in tV2 / rïiins with tV2  /  mins with
buffer [ C u 2 + ] = 1 0 - 4 M [cysteine]=10’^M
RIG 200 1 1 0 0 300 1 1 0
RIG 300 1150 1 0 0 0 105 350
RIG 500 1280 >24 h 1140
RIG 700 1 2 2 0 N/A N/A 400
Decomposition after 400 minutes at 20°C 
Buffer EDTA x lO'^M Cu^+ x lO'^M
RIG 200 63.5 % 11.9 % 100 %
RIG 300 29,5 % 21.8 % 57.4 %
RIG 500 21.9 % 12.1 % 36.6 %
RIG 700 3.1 % 2 .1 %  3 .0 %
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6.3. Conclusions
Our results show no obvious pattern between the blocking of the acid and amine groups 
of penicillamine and the inhibition of copper catalysed decomposition. The addition of 
various groups to penicillamine does appear to increase the thermal stability i.e. the rate 
o f decom position in the absence o f copper is reduced. It is presumed that the 
decomposition is a mainly thermal process in these cases. The rate of decomposition in 
the presence of only trace amounts of copper is also reduced. However, it is only in the 
cases of RIG 500 and RIG 700 that the rate of decomposition in the presence of larger 
amounts of copper is reduced. This suggests that we have not hindered the complexation 
of copper to the nitrosothiol to any major degree.
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C h a p te r  7:
E x p e rim en ta l
p-D -G lucose p e iitaace ta te  [1] was prepared by stirring D(+) glucose (10 g, 55 
mmol) with anhydrous sodium acetate ( 8  g, 97 mmol), dissolved in acetic anhydride (50 
ml, 0.52 mol), in a boiling water bath for 1.5 h. The resultant mixture was poured onto 
500 ml crushed ice and scratched to induce crystallisation from the oil formed. The 
white solid produced was washed with copious amounts of water and dried, yielding 
white crystals (18.2 g, 84%), m.p. 129-130°C, (lit.l 132-133“C). 0 ^  (200 MHz, 
CDCI3 ), 2.10 (15 H, s, OAc), 3.85 (1 H, m, 5-H), 4.1 (1 H, dd, J = 13 and 5.2 Hz, 6  
or 6 '-H), 4.3 (1 H, dd, J = 13 and 5.2 Hz, 6  or 6 '-H), 5.2 (3 H, 3 t, 2, 3, 4-H ) and 5.7 
(1 H, d, J = 10 Hz, 1-H). ÔC (50 MHz, CDCI3 ), 21.00, 21.14 and 21.25 (OAc), 
61.85, 66.13, 70.52, 73.10 and 73.17 (C2 - C 6 ), 92.09 (C l), 169.38, 169.67, 169.81, 
170.51 and 171.01 (OAc).
A ce to b ro m o g lu co se  [2] was prepared by stirring, in an ice bath, (3-D -glucose 
pentaacetate (17 g, 44 mmol) dissolved in DCM (50 ml) with 30% HBr in acetic acid (17 
ml) and acetic anhydride 12 ml for 2 hours. The resultant mix was evaporated after the 
addition of toluene several times and the acetic acid removed as an azeotrope. A pale 
brown oil was produced. The oil was diluted with DCM, washed with saturated 
N aH C 0 3  solution and evaporated to a clear oil. Ether was added and a white solid 
appeared on refrigeration. This was filtered yielding white crystals (11.4 g, 63%), m.p. 
88-90"C, (lit.2 88-89“C). Sg (200 MHz, CDCI3 ), 2.1 ( 1 2  H, s, OAc), 4.15 (1 H, m, 5- 
H), 4.3 (2 H, m. 6  and 6 '-H), 4.85 (1 H, dd, J = 9.4 and 4.2 Hz, 2-H), 5.15 (1 H, t, J 
= 10.2 Hz, 3 or 4-H), 5.55 (1 H, t, J = 10.5 Hz, 3 or 4-H) and 6.65 (1 H, d, J = 4.2 
Hz, 1-H). 5 c  (50 MHz, CDCI3 ), 21.04, 21.11 and 21.15 (OAc), 61.41, 67.62, 70.62,
71.06 and 72.60 (02  - 06), 87.04 (01), 169.88, 170.45 and 171.32 (OAc).
2 .3 .4 . 6  T etra-O -acety l-p-D -g lucopyranosy l isoH iiouron ium brom ide [3]
was prepared by the addition of acetobromoglucose (6.75 g, 16 mmol) to thiourea (1.25
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g, 16 mmol) in dry acetone (30 ml). The mixture was refluxed for 20 minutes until a 
white solid apppeared. The mixture was cooled to room temperature, filtered and 
washed with acetone. Recrystallisation from acetone gave a white solid product (4.5 g, 
57.7%), m.p.l93-194°C, (lit.3 193-196°C). 8 ^  (200 MHz, D 2 O), 2.0 (12 H, m, OAc),
4.15 (2 H, m, 6  and 6 '-H), 4.3 (1 H, dd, 5-H) and 5.05 - 5.35 (4 H, m, 1, 2, 3 and 4- 
H). ÔC (50 MHz, D 2 O), 22.3 and 23.1 (OAc), 64.8, 70.4, 71.3, 76.2, 78.7 and 83.9.
l-T h io -p -D -g lu co se  te tra a c e ta te  [4] was prepared by the addition of the above 
product [3], with stirring, to a solution of K 2 S2 O 5  (1.68 g, 7.56 mmol) in water (20 ml) 
at 85°C. To this was added DCM (25 ml) and the mixture was refluxed for 15 minutes 
with stirring. Upon cooling the DCM layer was separated and washed with water (3 x 
25 ml) then diied (MgSO^^) and evaporated to give an oil. A white solid formed from the 
oil. Recrystallisation from methanol gave white crystals (2.1 g, 62.4%), m.p. 108“C, 
(lit.4 110-112°C). ÔH (200 MHz, CDCI3 ), 2.05 (12 H, s, OAc), 2.3 (1 H, d, J = 10.6 
Hz, HS-), 3.75 (1 H, m, 5-H), 4.2 (2 H, 2 dd, J = 12.7 and 5.3 Hz, 6  and 6  -H), 4.55 
(1 H, t, J = 10.6 Hz, 1-H) and 5 - 5.2 (3 H, 3 t, 2, 3 and 4-H). 2555 (SH
stretch). 8 c  (50 MHz, CDCI3 ), 21.087 and 21.255 (OAc), 62.427, 68.469, 73.913, 
73.915, 76.716 and 79.156. (Found: C, 46.14; H, 5.66%. C 1 4 H 2 0 O 9 S requires C, 
46.15; H, 5.49%)
S -N itroso -l-th iO "p-D -gIucose te tra a c e ta te  [5] was prepared by dissolving the 
thiol [4] in the minimum amount of methanol followed by the addition of an equivalent 
amount of water. Excess NaN 0 2  and HCl were added. A pink solid was filtered off 
and dried, 342 nm. tj / 2  of 30 - 50 mins in aqueous buffer /  methanol at 20°C. 
^max/cm-1 1 5 5 0  (NO stretch), no signal at 2555. 8 y  (200 MHz, CDCI3 ), 2.05 (12 H, s, 
OAc), 3.75 (1 H, m, 5-H), 4.20 (2 H, m, 6  and 6  -H), 4.65 (1 H, d, J = 10.1 Hz, 1-H) 
and 5.10 - 5.30 (3 H, m, 2-, 3-, 4-H). 8 ^  (50 MHz, CDCI3 ), 21.08, 21.17 and 21.31 
(OAc), 62.04 , 68.32, 70.17, 74.32, 76.62 (C2 - C 6 ) and 87.69 (C l).
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p-D -galactose pen taaceta te  [6 ] was prepared by the same method as glucose, using 
D(+)-galactose. White crystals were produced (12.3 g, 56.8%). m.p. 137°C, (lit.^ 140- 
142°C). ÔH (200 MHz, CDCI3 ), 2.1 (15 H, m, OAc), 4.1 (3 H, m, 5, 6  and 6 '-H),
5.05 (1 H, dd, J = 12.5 and 3.75 Hz, 2-H), 5.35 (1 H, t, 4-H), 5.45 (1 H, dd, 3-H) 
and 5.7 (1 H, d, J = 10 Hz, 1-H). 6 c  (50 MHz, CDCI3 ), 20.98, 21.09 and 21.25 
(OAc), 61.52, 67.27, 68.26, 71.24 and 72.09 (C2 - C6 ), 92.55 (C l), 169.47, 169.87, 
170.45, 170.63 and 170.85 (OAc).
A cetobrom ogalactose [7] was prepared by the same method as acetobromoglucose 
except the reaction was carried out at room temperature. White crystals were produced 
(7.2 g, 57%). m.p.75°C, (lit.5 84-85°C). ôy (200 MHz, CDCI3 ), 2.1 (12 H, m, OAc),
4.15 (2 H, m, 6  and 6 ’-H), 4.45 (IH , t, J = 7 Hz, 5-H), 5.05 (1 H, dd, J = 11 and 4.4 
Hz, 2-H), 5.45 (2 H, dd, 3 and 4-H) and 6.7 (IH , d, J = 4.4 Hz, 1-H). Ôq (50 MHz, 
CDCI3 ), 21.05, 21.10, 21.22 (OAc), 61.31, 67.44, 68.22, 68.44 and 71.52 (C2 - C 6 ) 
and 88.60 (C l).
2 ,3 ,4 ,6 -T e tra -O -a c e ty l-p -D -g a la c to p y ra n o sy l iso th io u ro n iu m  b ro m id e  [8 ]
was prepared by dissolving acetobromogalactose (4.5 g, 11 mmol) in dry acetone (4.5 
ml) and refluxing with thiourea (0.85 g, 11.1 mmol) until a white solid appeared (20 
mins). The solid was filtered off and washed with acetone then recrystallised from 
acetone to give white crystals (4.25 g, 79.7%). m.p. 166°C, (lit.^ 169°C), Ôy (200 
MHz, D 2 O), 2.0 (12 H, m, OAc), 4.15 (2 H, d, 6  and 6 ’-H), 4.3 (1 H, t, 5-H) and 5.2 
- 5.5 (4 H, m, 1, 2, 3 and 4-H). 6 ^  (50 MHz, D 2 O), 22.89, 22.97 and 23.05 (OAc), 
64.95, 69.49, 70.74, 74.38 and 78.30 (C2 - C6 ) and 84.26 (C l).
1-T hio-p-D -gaIactose te tra a c e ta te  [9] was prepared by the addition of the above 
salt [8 ] (3.5 g, 7.2 mmol) to a solution of K 2 S2 O 5  (1.25 g, 5.6 mmol) in water (4 ml) 
heated to 85°c with stirring. DCM (5.5 ml) was added and the mixture refluxed for 15 
minutes. The DCM layer was separated and washed with water (3 x 1 0  ml). The water
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layer was washed with DCM and the organic extracts combined and dried (MgSO^). 
The mix was filtered and evaporated leaving a thick oil. Upon standing this slowly 
solidified yielding a white solid (1.65 g, 63.1%) which could not be recrystallised. 
Dmax/cm-l 2560. by (200 MHz, CDCI3 ), 2.05 (12 H, m, OAc), 2.4 (1 H, d, J = 10 Hz, 
-SH), 3.95 (1 H, m, 5-H), 4.15 (2 H, m, 6  and 6  -H), 4.55 (1 H, t, J = 10 Hz, 1-H),
5.0 (1 H, dd, J = 10 and 3.6 Hz, 3-H), 5.2 (1 H, m, 2-H) and 5.45 (1 H, d, J = 3.6 
Hz, 4-H). ÔC (50 MHz, CDCI3 ), 21.07, 21.20 and 21.34 (OAc), 61.98, 67.73, 71.31,
72.05 and 75.42 (C2 - C 6 ) and 79.66 (C l). (Found: C, 46.19; H, 5.11%. C 1 4 H 2 0 O 9 S 
requires C, 46.15; H, 5.49%)
5 -N itro so -l- th io -p -D -g a Ia c to se  te tra a c e ta te  [10] was prepared by dissolving 
the above thiol [9] in the minimum amount of methanol and adding water until just 
before precipitation occurs. Excess NaN 0 2  and HCl were added with stirring to give a 
deep red solution. This was extracted into DCM and the solvent removed by evaporation 
without heating. A pink powder was produced with ~344 nm. tj / 2  of 5 - 10
mins in aqueous buffer /  methanol at 20°C. The material was unstable as a solid making 
the iH  NMR spectrum indistinct. 0^ (50 MHz, CDCI3 ), 21.16 and 21.23 (OAc),
61.89, 67.79, 66.80, 72.59, 75.87 and 85.75.
Xylose te traace ta te  [11] was prepared as for glucose (using D-xylose) giving white 
crystals (11.8 g, 55.9%). m.p. 118-120°C, (lit.4 120°C). §h (200 MHz, CDCI3 ), 2.05 
(12 H, m, OAc), 3.5 (1 H, dd, J = 12 and 7.5 Hz, 5a-H), 4.25 (1 H, dd, J = 12.5 and 5 
Hz, 5b-H), 5.0 (2 H, m, 2-, 3-H), 5.2 (1 H, t, J = 8.75 Hz, 4-H) and 5.7 (1 H, d, J = 
10 Hz, 1-H).
A cetobrom oxylose [1 2 ] was prepared by the addition of 10 g of the above product 
[11] to 30% HBr in acetic acid solution (13 ml) and acetic anhydiide (1 ml) in dry DCM 
(32 ml). This was covered in foil and stirred for 2 hours. The resultant mix was 
evaporated using toluene to azeotrope away the acetic acid, yielding a pale brown oil.
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The oil was diluted with DCM and washed (saturated NaHCOg solution). The resultant 
solution was then dried (MgSO^) and evaporated to an oil. Ether was added and the 
solution left to crystallise in the fridge. Large white crystals were filtered off (4.8 g , 
45%). m.p. 98-99“C, (lit.4 98-100“C). 5h (200 MHz, CDCI3 ), 2.05 (9 H, OAc) 3.85 
(1 H, t, J = 11.5 Hz, 5a-H), 4.05 (1 H, dd, J = 11.5 and 7 Hz, 5b-H), 4.75 (1 H, dd, J 
= 10.4 and 4.3 Hz, 2-H), 5.05 (1 H, td, J -  10.4 and 6  Hz, 4-H), 5.55 (1 H, t, J = 9.7 
Hz, 3-H) and 6 . 6  (1 H, d, J = 4.3 Hz, 1-H)
2 ,3 ,5 -T ri-O -a c e ty l-p -D -x y Io p y ra n o sy l iso th io u ro n iu m  b ro m id e  [13] w as
prepared by the reflux of acetobromoxylose (3.29 g, 9.7 mmol) in dry acetone (3.5 ml) 
with thiourea (0.74 g, 9.7 mmol) for 15 mins. A white solid was precipitated. This was 
filtered off, washed with acetone and recrystallised from acetone yielding a white powder 
(2.69 g, 6 6 .8 %). m.p. 159°C, (lit.7 176-178°C). 5h (200 MHz, DgO), 2.1 (9 H, m, 
OAc), 3.75 (1 H, dd, J = 12.9 and 5.9 Hz, 5a-H), 4.4 (1 H, dd, J = 12.9 and 4.3 Hz, 
5b-H), 4.95 (1 H, m, 4-H), 5.15 (2 H, m, 2-,3-H) and 5.7 (1 H, d, J = 7.5 Hz, 1-H).
1 -T h io-p-D -xylose  tr ia c e ta te  [14] was prepared by the addition of the above 
product (2.82 g, 6 . 8  mmol) to a solution of K2 S2 O5  (1.41 g, 6.3 mmol) in H 2 O (5.5 ml) 
at 85°C. DCM (7 ml) was added and the mixture allowed to reflux with stirring for 15 
mins. The lower organic phase was separated and washed with water (3 x 25 ml), dried 
(MgSO^) and evaporated to an oil. The oil solidified upon refrigeration and was then 
recrystallised from methanol yielding white crystals (0.6 g, 30%) m.p. 120°C, (lit.^ 
123°C). ÔH (200 MHz, CDCI3 ), 2.1 (9 H, m, OAc), 2.3 (1 H, d, J = 10 Hz, -SH), 3.4 
(1 H, t, J = 11 Hz, 5b-H), 4.2 (1 H, dd, J = 12 and 5 Hz, 5a-H), 4.6 (1 H, t, J = 9.2 
Hz, 1-H), 4.95 (1 H, t, J = 9.2 Hz, 2/3-H), 5.0 (1 H, dd, J = 9.2 and 5.4 Hz, 4-H) and
5.2 (1 H, t, J = 9.2 Hz, 2/3-H). (Found: C, 44.94; H, 5.39%. C nH igO ^S  requires C, 
45.21; H, 5.48%).
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5 -N itro so -l- tlîio -p -D -x y Io se  te tra a c e ta te  [15] was prepared by dissolving the 
above product in the minimum amount of methanol followed by the addition o f the 
maximum amount of water possible without inducing precipitation. Excess NaNÛ2  was 
added followed by excess HCl with stirring. The red liquid produced was extracted into 
DCM and evaporated without heating. A pale pink solid was produced (0.32 g, 48.5 %) 
with ""350 nm. 1 1 / 2  of 3 - 5 mins in aqueous buffer /  methanol at 20°C. The
product was unstable in the solid fomi making NMR studies impossible.
M altose octaacetate [16] was prepared by the addition of maltose (20 g) and sodium 
acetate (20 g) to acetic anhydride (100 ml). The mixture was stirred on a boiling water 
bath for 3 hrs. The resultant solution was evaporated to an oil and dissolved in DCM. 
The solution was washed with a saturated solution of NaHCOg and dried (MgSO^^). 
After filtering, the liquid was boiled with decolourising charcoal and evaporated to an oil. 
The oil was dissolved in ether and a product crystallised out upon refrigeration, (19.26 
g, 51.1%). m .p.l51-153°C, (lit.4 155-156T). 6 ^  (200 MHz, CDCI3 ), 2.1 (24 H, m, 
OAc), 3.85 - 4.05, 4.25 and 4.45: (4 H, m) (2 H, m) and (1 H, dd, J = 13.6 and 2.4 
Hz), (4a, 5a, 6 a, 6 a', 5b, 6 b and 6 b'-H), 4.85 (1 H, dd, J = 10.3 and 4.6 Hz, 2b-H),
5.0 (1 H, t, J = 9.5 Hz), 5.05 (1 H, t, J = 10.9 Hz), 5.3 (2 H, 2 t, J = 9.5 Hz) (2a, 3a, 
3b and 4b-H), 5.4 (1 H, d, J = 4.1 Hz, Ib-H) and 5.75 (1 H, d, J = 8.2 Hz, la-H). ôc 
(50 MHz, CDCI3 ), 21.02, 21.10, 21.24 and 21.30 (OAc), 61.91, 62.98, 68.42, 69.03, 
69.74, 70.46, 71.38, 72.90, 73.43, 75.66, 91.71 and 96.16 (C la  - C 6 b '), 169.25,
169.89, 170.03, 170.32, 170.50, 170.88, 170.94 and 171.00 (quaternaries). (Found: 
C, 49.80; H, 5.38%. C2 8 H 3 8 O 1 9  requires C, 49.51; 5.60%)
A cetobrom om altose [17] was prepared by the addition of 30% HBr in AcOH ( 8  ml) 
and acetic anhydride (1.5 ml) to a solution of maltose octaacetate [16] ( 6  g) in dry DCM 
(25 ml). The mixture was covered and stirred at room temperature for 4 h. Toluene was 
added and the solvent evaporated to produce a pale brown oil. Repeated solvation in 
ether followed by evaporation gave a fluffy white powder (4.4 g, 71%). m.p. 69°C,
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(lit.4 84'C). 5h (200 MHz, CDCI3 ), 2.1 (21 H, m, OAc), 3.95 - 4.25 and 4.5 ( 6  H. m) 
and (1 H, dd, J = 14.5 and 3.7 Hz) (4a, 5a, 6 a, 6a’,5b ,6 b and 6 b'-H), 4.7 (1 H, dd, J 
= 10,5 and 4.4 Hz, 2b-H), 4.9 (1 H, dd, J = 10.5 and 4.4 Hz, 2a-H), 5.1 (1 H, t, J =
9.6 Hz, 3a or 4a-H), 5.4 (2 H, m, 3b and 4b-H), 5.45 (1 H, d, J = 4.4, Ib-H), 5.6 (1 
H, t, J = 9.6 Hz, 3a or 4a-H) and 6.5 (1 H, d, J = 4.4 Hz, la-H ). 8 c  (50 MHz, 
C D CI3 ), 21.06, 21.25 and 21.33 (OAc), 61.80, 62.31, 68.36, 69.10, 69.70, 70.47, 
71.48, 72.02, 72.80, 73.01, 86.54 and 96.24 (C la  - C 6 b'), 170.00, 170.34, 170.98 
and 171.16 (quaternaries). (Found: C, 45.36; H, 5.01%. C 2 gH 3 5 0 i 7 Br requires C, 
44.64; H, 5.01%).
1 - T h io - P - D - m a l t o s e  h ep ta a ce ta te  [19] w as p rep a red  as fo llow s: 
acetobromomaltose (2.4 g) was dissolved in dry acetone (3 ml) and refluxed with 
thiourea (0.3 g) for 15 mins. Upon slow evaporation of the acetone, a pale brown oil 
was produced, which solidified upon standing giving the thiouronium bromide salt 
[18]. This salt was added to a solution of K2 S2 O 3  (1.3 g, 5.8 mmol) in water (5 ml) at 
80°C. DCM (2 ml) was added and the solution refluxed with stirring for 20 mins. The 
organic phase was separated and washed with water ( 3 x 1 5  ml), dried (MgSO^) and 
evaporated to an oil. The oil solidified and was recrystallised from methanol to give a 
white solid (1.15 g, 51%) m.p.l56°C (lit.? 149 - 152°C). 8 h  (200 MHz, CDCI3 ), 2.1 
(21 H, m, OAc), 2.25 (1 H, t, J = 9.4 Hz, SH), 3.7 (1 H, m), 4.0 (3 H, m), 4.2 (2 H, 
m) and 4.45 (1 H, dd, J = 12.3 and 2.1 Hz) (4a, 5a, 6 a, 6 a', 5b, 6 b and 6 b'-H), 4.6 (1 
H, t, J = 9.4 Hz, la-H ), 4.8 (1 H, t, J = 9.3 Hz), 5.05 (1 H, t, J = 9.7 Hz), 5.25 (1 H, 
t, J = 8.9 Hz) and 5.35 (1 H, t, J = 10.5 Hz) (2a, 2b, 3b and 4b-H), 4.85 (1 H, dd, J =
10.5 and 4 Hz, 3a-H) and 5.4 (1 H, d, J = 3.8 Hz, Ib-H). Sg (50 MHz, CDCI3 ), 
21.08, 21.18 and 21.37 (OAc), 61.92, 63.45, 68.39, 69.04, 69.73, 70.44, 73.02,
74.78, 76.54, 78.69 (CHs), 96.10 (C lb) (Found: C, 47.32; H, 5.55%. C2 6 H 3 6 O 1 7 S 
requires C, 47.81; H, 5.52%).
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1-Tlîioacetyl m altose h ep taac te ta te  [20] was prepared as follows: [17] (4,5 g) 
was dissolved in DCM (30 ml). A mixture of KOH (0.62 g) and thioacetic acid (0.9 ml) 
in ethanol (10 ml) was added and the solution refluxed for 1 h. The mixture was allowed 
to cool, the precipitated salts filtered and the filtrate evaporated to an oil. The oil was 
dissolved in DCM, washed with water, dried (MgS0 4 ) and decolourised with charcoal. 
Evaporation gave a yellow oil which was recrystallised from ethanol to give a white 
powder, (3.3 g, 73.9 %). m.p. 147 - 149°C (lit. 8  151-153T). by (300 MHz, CDCI3 ),
2.1 (21 H, m, OAc), 2.2 (3 H, s, SAc), 3.80 (1 H, m, 5a-H or 5b-H), 3.95 (1 H, m, 
5a-H or 5b-H), 4.0 (1 H, t, J = 9.2 Hz, CH), 4.05 (1 H, dd, J = 12.6, 2.3 Hz), 4.2 (1 
H, dd, J = 12.4 and 4.1 Hz), 4.25 (1 H, dd, J = 12.4, 3.8 Hz) and 4.45 (1 H, dd, J = 
12.4, 2.5 Hz) (6 a, 6 a’, 6 b and 6 b'), 4.85 (1 H, dd, J = 10.7, 4.1 Hz, 2b-H), 5.0 (1 H, 
dd, J = 10.4, 9.1 Hz, CH), 5.05 (1 H, t, J = 9.7 Hz), 5.3 (3 H, m, CH), 5.4 (1 H, d, J 
= 4.1 Hz, Ib-H). be (75 MHz, CDCI3 ), 21.08, 21.17, 21.31 and 21.36 (OAc), 31.32 
(SAc), 61.91, 63.20, 68.41, 69.02, 69.78, 70.25, 70.49, 72.99, 76.80, 77.03, 80.27 
(C la ), 96.15 (C lb), 169.94, 170.09, 170.34, 170.47, 170.94, 171.00 and 171.07 
(OAc) and 192.29 (SAc).
1 -T h io -p -D -m alto se  h ep ta a c te ta te  [19] was prepared from the thioacetate as 
follows: S-A cetylm altose (2 g) was dissolved in dry THE (40 ml) under N 2 . 
Benzylamine (0.47 ml, 1.5 eq) was added and the solution stirred for 4 h when TLC 
showed that no starting material was present. The solvents were evaporated to a yellow 
oil. The oil hardened with cooling and was recrystallised for ethanol to give a white 
solid, (0.74 g, 39.4 %). ^H and nmr as for the previously described thiol 
preparation.
S -N itro s o - l- th io -P -D -m a lto s e  h e p ta c e ta te  [2 1 ] was prepared by passing a 
stream of N 2 O 3  through a solution of [20] (1 g) in DCM. The solvent was evaporated 
to give a pale pink powder, (0.88 g, 84.2 %). t % /2  = 50 - 60 mins in aqueous buffer, 
^max at -345  nm (SNO). b^  (200 MHz CDCI3 ), no peak at -2 .25. be  (50 MHz,
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C D C I3 ), 20.92, 21.08, 21.16 and 21.38 (OAc), 61.94, 63.23, 68.42, 69.12, 69.77, 
70.25, 70.52, 73.02, 76.91 and 77.34 (CH), 84.83 (C la ), 96.23 (C lb ), 169.95,
170.45 and 171.07.
Lactose octaacetate  [22] was prepared by the addition of lactose (20 g) to a mixture 
o f pyridine (60 ml) and acetic anhydride (120 ml). The mixture was heated on a boiling 
water bath with stirring for 45 minutes by which time all the solid had dissolved. The 
mixture was poured into ice water (11) and stirred. A white solid was filtered off and 
dried (36.3 g, 96%). m.p. 88-89°C, (lit.4 90-91"C). 6 % (200 MHz, CDCI3 ), 5.7 (0.6 
H, d, J = 8.3 Hz, Ib-H) and 6.3 (0.4 H, d, J = 3.5 Hz, la-H ). (Found: C, 49.82; H, 
5.68%. C2 8 H 3 8 O 1 9  requires C, 49.51; H, 5.60%).
A cetobrom olactose [23] was prepared by the addition of 20 g of [22] to 30% HBr 
in acetic acid solution (50 ml). This was stirred at room temperature for 2.5 hrs. The 
resulting mixture was poured into ice water (500 ml) with stirring. A white precipitate 
was collected by vacuum filtration. The solid was recrystallised from methanol yielding 
a white solid (7.12 g, 29%). m.p. 144-145“C, (lit.9 145°C). by  (200 MHz, CDCI3 ),
2.1 (21 H, m, OAc), 3.9 (2 H, m) and 4.15 (4 H, m), (5a , 6 a, 6 a’, 5b, 6 b, 6 b’-H), 4.5 
(2 H, m), 4.8 (1 H, dd, J = 10.2 and 4.3 Hz, 2a-H), 4.95 (1 H, dd, J = 10.2 and 3.3 
Hz, 3b-H), 5.15 (1 H, m), 5.35 (1 H, d, J = 3.8 Hz, 4b-H), 5.55 (1 H, t, J = 10.2 Hz, 
3a-H) and 6.55 (1 H, d, J = 10.2 Hz, la-H ). (Found: C, 42.93; H, 4.67%. 
C2 6 H 3 5 0 i 7 Br requires C, 44.60; H, 5.00%)
H ep ta-< 7-acety l lac tose  iso th io u ro n iu m  b ro m id e  [24] was prepared by the 
reflux of acetobromolactose (4 g) and thiourea (0.5 g) in dry acetone (5 ml) for 20 mins. 
The solvent was evaporated slowly to give a white solid (3.5 g, 79%).which could not 
be satisfactorally recrystallised.
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1-Thio-p-D-lactose heptaacetate [25] was prepared by the addtion of [24] (3.5 g) 
to a solution of K 2 S2 O 5  in water (5 ml) at 75°C. DCM (7 ml) was added and the mixture 
stirred for 20 mins. The organic phase was sepaiated and washed with water (3 x 20 
ml), dried (MgSO^^) and evaporated to a white solid which could not be recrystallised, 
(1.4 g, 45.6 %). ÔH (200 MHz, CDCI3 ), 2.3 (1 H, d, J = 10.3 Hz, -SH). (Found: C, 
47.69; H, 5.25%. C2 6 H2 0 O 1 7 S requires C, 47.81; H, 5.52%).
5 -N i tro so - l- th io -p -D -la c to se  heptaacetate [26] was prepared by dissolving 
[25] in the minimum amount of methanol followed by the addition of an equal amount 
of water. Excess NaN 0 2  was added followed by excess cone HCl. A dark red solution 
formed. The product was extracted into DCM and the solvent evaporated under vacuum 
without heating. A pink powder was produced, (1.13 g, 77.3 %) with ~^45 nm
and t i / 2  of 55 mins in aqueous buffer /  methanol. 0 ^  (200 MHz, CDCI3 ) as above 
except no peak at 2.3, indicating loss of -SH.
The attempted preparation of Mannose pentaacetate [27] was performed as follows: 
mannose (20 g) was stirred in pyridine and cooloed in an ice bath. Acetic anhydride 
( 1 0 0  ml) was added and the mixture stirred in ice until all of the mannose had dissolved. 
The solution was stirred at room temperature overnight. The solvents were evaporated, 
the oil produced was dissolved in DCM and washed with 3 M HCl and saturated 
NaHC 0 3  solution. The DCM layer was dried and evaporated to a pale brown oil.
(50 MHz CDCI3 ), 21.10, 21.19 and 21.29 (OAc), 62.56, 66.01, 68.80, 69.203 and
71.08 (C2 - C6 ) and 91.065 (Cl).
The attempted preparation of acetobromomannose [28] was performed as follows: 
mannose pentaacetate [27] (20 g) was dissolved in DCM (55 ml) and acetic anhydride 
(3 ml). The solution was chilled in ice with stirring. 30% HBr in acetic acid (20 ml) 
was slowly added, the reaction stirred at 0°C for 2  h and at room temperature for 2 h. 
The solvents were evaporated with addition of toluene to give a brown oil. be (50 MHz,
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CDCI3 ), 2 1 .0 2 , 21.10 and 21.20 (OAc), 61.89, 65.72, 68.39, 72.65 and 73.28 (C2  - 
C 6 ), 83.62 (C l), 170.01 and 170.96 (quaternaries).
The a ttem pted  p repara tion  o f 2 ,3 ,4 , 6 - t e t r a - O - a c e t y lm a n n o p y r a n o y s l  
isothiouronium brom ide [29] was perform ed as follows: acetobromom annose
[28] (4 g) was dissolved in acetone (25 ml) and refluxed with thiourea (1.5 g) for 15 
min. A white solid was obtained. This was filtered and the liquid evaporated to give a 
white gum. (50 MHz, DMSG), 23.06 (OAc), 64.75, 68.32, 72.22, 72.22 and 73.72 
(C 2 -C 6 ) and 84.81 (C l).
The attem pted preparation of l-th io-2,3 ,4 ,6-tetraacetylm annopyranose [30] 
was performed as follows: K2 S2 O 5  (2 g) was dissolved in water (25 ml) and stirred at 
85"C. The thiouronium salt [29] (3.5 g) was added slowly, followed by DCM (30 ml). 
The solution was refluxed for 15 min and allowed to cool. The DCM layer was 
separated, washed with water, dried (MgSO/^) and evaporated to an oil. by (200 MHz, 
CDCI3 ), 2.3 (1 H, d, J = 6 . 8  Hz, -HS). be (50 MHz, CDCI3 ), 21.16 and 21.32 (OAc), 
62.62, 66.54, 68.99, 70.10 and 72.33, (C2 - C6 ) and 77.41 (Cl).
T h e  a t te m p te d  p r e p a r a t io n  o f  1-5 - n i t r o s o t h i o - 2 , 3 , 4 , 6 - 
tetraacetylm annopyranose [31] was performed as follows: the above thiol [30] 
was dissolved in methanol /  water. NaN0 2  and HCl (2 eq) were added producing a red 
solution. The product was extracted into DCM and evaporated to give a stable red oil. 
^max -351 nm. b^ (50 MHz, CDCI3 ), 21.08, 21.14 and 21.28 (OAc), 63.08, 6 6 .6 8 ,
68.78, 69.37, 71.02, and 92.53.
Pentabenzoyl glucose [32] was prepared as follows: dry pyridine (25 ml) and dry 
DCM (21 ml) were chilled in a 3 necked flask. A chilled solution of benzoyl chloride (21 
ml) in DCM (21 ml) was added dropwise. Glucose (10 g) was added slowly with 
vigorous stirring. The mixture was allowed to stand in an ice bath overnight. The
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solution was diluted with DCM, washed with copious quantités of 2 M HCl, saturated 
NaHCOg, water and dried (MgSOz^). Upon evaporation an oil was produced which 
solidified to give a white powder which was recrystallised from acetone/water, (18.2 g, 
46.8%). m.p. 183“C, (lit.5 184-186"C). Ôy (200 MHz, CDCI3 ), 4.6 (3 H, m, 5, 6  and 
6 '-H), 5.7 (1 H, dd, J = 10.4 and 3.6 Hz, 2-H), 5.9 (1 H, t, J = 9.9 Hz, 4-H), 6.3 (1 
H, t, J = 9.9 Hz, 3-H), 6.85 (1 H, d, J = 3.6 Hz, 1-H) and 7.3 - 8.2 (25 H, m, 
aromatics). 6 c  (50 MHz, CDCI3 ), 62.439, 68.475, 71.113, 71.971 and 73.212 (C2 - 
C 6 ), 87.382 (C l), 128.9, 130.4, 133.8 and 134.2 (aromatics).
B enzobrom oglucose [33] was prepared as follows: [32] (5.65 g) was dissolved in 
DCM ( 6  ml). 30%HBr in AcOH (5.8 ml) was added and the mixture stirred for 3 h. 
The mixture was evaporated with toluene to give a brown oil. The oil was dissolved in 
DCM and washed with large quantities of saturated NaHC 0 3  and dried (MgSO^). A 
white powder was produced upon evaporation, (3.46 g, 65.2%). m.p. 58°c, (lit.^ 8 8 - 
89"C). ÔH (200 MHz, CDCI3 ), 4.5 (1 H, dd, J = 13.8 and 4.8 Hz) and 4.7 (2 H, m) (5, 
6 , and 6 '-H), 5.35 (1 H, dd, J=10.3 and 4.2 Hz, 2-H), 5.8 (1 H, t, J = 9.6 Hz, 3 or 4- 
H), 6.3 (1 H, t, J = 9.6 Hz, 3 or 4-H), 6.9 (1 H, d, J = 4.8 Hz, 1-H), 7.3 - 7.5 (12 H, 
m, aromatics) and 7.9 - 8.05 ( 8  H, m, aromatics). 6 c  (50 MHz, CDCI3 ), 62.439, 
68.475, 71.113, 71.971 and 73.212 (C2 - C6 ), 87.382 (C l), 129.0 - 130.5 and 133.8 -
134.2 (aromatics). (Found: C, 64.19, H, 4.37%. Cg4 H 2 7 BrOg requires C, 61.19, H, 
4.10% ).
1 - T h io a c e ty I g lu c o s e  t e t r a b e n z o a t e  [3 4 ]  was p repared  as fo llow s: 
benzobromoglucose (8.3 g) was dissolved in a mixture of DCM (30 ml) and ethanol (20 
ml). Potassium thioacetate (3.3 g) was added and the mixture refluxed for 3 h. The KBr 
was filtered off and the solvents evaporated. The yellow oil produced was dissolved in 
DCM and washed with water, dried (MgSO^) and evaporated to a yellow oil. The oil 
was heated in methanol and a white solid was precipitated, (4.6 g, 55.8%). m.p. 176 - 
178'C. ÔH (200 MHz, CDCI3 ), 2.35 (3 H, m, SAc), 4.3 (1 H, m, 5-H), 4.5 (1 H, dd.
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J = 12.5 and 5.2 Hz, 6  or 6 ‘-H), 4.6 (1 H, dd, J = 12.5 and 3.0 Hz, 6  or 6 '-H), 5.7 (3 
H, m) and 6.0 (1 H, m) (1, 2, 3, and 4-H), 7.4 (12 H, m) and 8.0 ( 8  H, m) (aromatics). 
ÔC (50 MHz, CDCI3 ), 31.350 (SAc), 63.388, 69.598, 70.333, 74.659, 77.317 and 
81.132 (C l - C 6 ), 128.8 - 130.4 and 133.6 - 134.0 (aromatics). (Found: C, 64.49, H, 
4.53%. C3 (5H 3 ()OioS requires C, 66.10, H, 4.59%).
The attempted preparation of 1 -th io -te trabenzoy Ig Iucose  [35] was carried out as 
follows: 5-acetylglucose tetrabenzoate (0.4 g) was dissolved in dry THF (20 ml). 
Benzylamine (0.1 ml, 1.5 eq) was added and the mixture stirred under N 2  overnight. 
The reaction was followed by TLC. The formation of thiol could be observed and the 
solution attained a strong thiol smell, but this could be observed breaking down to the 
disulphide. The mixture was evaporated to a semi-solid, dissolved in DCM and washed 
with 3 M HCl (200 ml). The DCM layer was dried, evaporated to a gum and heated in 
methanol. A white solid was precipitated, presumed to be the disulphide. m.p.l06°C. 
ÔH (200 MHz, CDCI3 ), 3.9 (1 H, m, 5-H), 4.55 (2 H, m, 6  and 6 '-H), 4.95 (1 H, d, J 
= 10.2, 1-H), 5.55 (1 H, t, J = 9.7 Hz), 5.75 (1 H, t, J = 9.7 Hz) and 6.0 (1 H, t, J =
9.4 Hz) (2, 3 and 4-H), 7.3 - 7.5 (12 H, m, OBz) and 7.8 - 8.1 ( 8  H, m, OBz). 0^ (50 
M Hz, CDCI3 ), 63.31, 69.84, 70.96, 74.23, 77.27 and 90.30 (C l - C 6 ), 128.91, 
130.34, 133.76 and 134.00 (benzoyl).
P en tabenzoy lga lac to se  [36] was prepared as follows: dry pyridine (25 ml) and 
DCM (21 ml) were chilled in a flask and a chilled solution of benzoyl chloride (21 ml) in 
DCM (21 ml) was added slowly with vigorous stirring. Galactose (10 g) was added 
carefully. The mixture was stirred for 30 mins in an ice bath and then left to stand 
overnight. The mixture was diluted with DCM and washed with large quantities of 2 M 
H 2 SO/} saturated NaHCO^ and water, dried (MgSO^) and evaporated to a sticky oil 
which hardened very slowly, (19.2 g, 49.4%). 6 ^  (200 MHz,CDClg), 4.5 - 4.9 (3H, 
m, 5, 6  and 6 '-H), 6.1 - 6.25 (3 H, m, 2, 3, 4-H) and 7.0 (1 H, d, J = 3.7 Hz, 1-H). 
6 c  (50 MHz, CDCI3 ), 62.369, 68.216, 68.988, 69.055 and 69.965 (C2 - C 6 ), 91.197
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(C l), 129.3, 130.3, 133.8 and 134.2 (aromatics). (Found: C, 66.14, H, 4.73%. 
C4 1 H 3 2 O 1 1  requires C, 70.29, H, 4.57%).
B en zo b ro m o g alac to se  [37] was prepared as follows: [36] (10g) was dissolved in 
DCM (50 ml). Acetic anhydride (1 ml) and 30% HBr in AcOH (20 ml) were added and 
the mixture stirred at room temperature for 5 h. The solvents were evaporated with 
toluene to give a pale brown oil. The oil was diluted with DCM and washed with 
saturated NaHC0 3 , dried (MgSO^) and evaporated to a sticky brown oil, (16 g, 71 %).
1 -T h io a c e ty lg a Ia c to p y ra n o sy I te tra b e n z o a te  [38] was prepared as follows: 
benzobrom ogalactose ( 8  g) was dissoved in DCM (20 ml) and ethanol (20 ml). 
Potassium thioacetate (2.8 g) was added and the mixture refluxed for 5 hrs. The KBr 
was filtered off and the solvent evaporated. The oil was dissolved in DCM, washed with 
water diied (MgSO^) and evaporated to a yellow oil. Successive recrystallisations from 
methanol gave a white powder, (3.7 g, 46.6%). m.p. 130 - 132”C. 6 ^  (200 MHz, 
C D C I3 ), 2.35 (3 H, s, SAc), 4.35 - 4.65 (3 H, m, 5, 6  and 6 '-H), 5.65 (1 H, d, J = 
10.3 Hz, 1-H), 5.75 (1 H, dd, J = 10.3 and 3.7 Hz, 3-H), 5.95 (1 H, t, J = 10.3 Hz, 2- 
H) and 6.10 (1 H, d, J = 3.7, 4-H). 6 ^  (50 MHz, CDCI3 ), 31.39 (SAc), 62.52, 67.98, 
73.19, 76.22, and 81.42. (Found: C, 65.06, H, 4.39%. C 3 6 H 3 0 O 1 0 S requires C, 66.1,
H, 4.59%).
I ,2 :5 ,6 - D i- 0 - is o p r o p y I id e n e g lu c o f u r a n o s e  [40] was prepared as follows: 
glucose (7.5 g) was stirred in acetone (50 ml). Anhydrous ZnCl2  ( 6  g) was added 
followed by 85% H 3 PO4  (0.375 ml). The mixture was stirred at room temperature for 2 
days. The unreacted glucose was filtered off. A solution of NaOH (4.25 g) in water 
(42.5 ml) was added and the Zn(0 H ) 2  filtered off and washed with acetone. The organic 
layers were combined and the solvents evaporated. The oil was diluted with water, 
extracted with DCM and washed with water. A white powder was produced upon 
evaporation of the solvent, (6.1 g, 56.5 %). m .p.lO TC, (lit.^O 105-109“C). 8 ^  (50
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M Hz, CDCI3 ), 25.63, 26.66, 27.27 and 27.32 (diisopropylidene), 68.10, 73.84, 
75.55, 81.56 and 85.73 (C2 - C6 ), 105.54 (C l), 110.14 and 112.30 (diisopropylidene).
3 -O -M ethy lg lucose [42] was prepared as follows: [40] (7.8 g) was dissolved in 
acetone (7.5 ml). Pulverised NaOH (3.2 g) was added and the mixture stirred at 45“C 
until the NaOH had dissolved. Dimethyl sulphate (4.26 ml) was added over 30 mins. 
The mixture was warmed to 50°C for 3 h and then kept at 60°C for 3 h. The orange 
liquid was diluted with water and extracted with DCM. Upon evaporation an oil was 
obtained [41]. The oil was refluxed in water at pH 2.6 (H2 SO4 ) overnight. The amber 
liquid was decolourised with norit charcoal. Ethanol was added and the solvents 
evaporated to give an oil.
3 -0 -M etIiy lg lu co se  te tra a c e ta te  [43] was prepared as follows : [42] (5 g) was 
dissolved in di^ y pyridine (60 ml). Acetic anhydride (35 ml) and a few crystals of DMAP 
were added and the mixture stirred for 3 h and then left to stand overnight at room 
temperature. DCM was added and the mixture washed with 2 M HCl, saturated 
NaHC 0 3  solution and dried (Na2 S0 4 ). The solvents were evaporated to leave a thick 
oil, (6.45 g, 69.3 %). 0 ^  (200 MHz, CDCI3 ), 2 . 1  ( 1 2  H, m, OAc), 3.45 (3 H, s, 
OMe), 3.7 ( IH, t, J = 10.7 Hz, 3-H), 4.0 - 4.2 (3 H, m, 5, 6  and 6 '-H), 5.0 - 5.1 (2 
H, m, 2 and 4-H), 5.65 (<1 H, d, J = 4.6 Hz, l-H (a)) and 6.3 (<1 H, d, J = 9.2 Hz, 1- 
H(p)).
The attempted preparation of l-b ro m o -3 -0 -m e th y l-2 ,4,6 -triace ty l glucose [44]
was carried out as follows: [43] (6.75 g) was dissolved in dry DCM (25 ml). Acetic 
anhydride (1 ml) and 30 % HBr in acetic acid (10 ml) were added. The flask was 
covered in foil and stirred at room temperature for 1.5 h. Toluene was added and the 
solvents were evaporated under reduced pressure. The oil produced was dissolved in 
DCM, washed with saturated NaHC 0 3  solution , dried (MgS0 4 ) and evaporated to an 
oil. Upon addition of ether a white solid precipitated. When filtering was attempted the
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white solid became a intractable sticky brown gum, either on exposure to moisture or to 
air. Attempts to purify the gum were unsuccessful.
3 - 0 - m e s y l - l ,2 : 5 ,6 - d i i s o p r o p y l id e n e g lu c o f u r a n o s e  [45] was prepared as 
follows: [40] (5 g) was dissolved in dry pyridine (35 ml) and cooled in an ice bath. 
Mesyl chloride (3 ml) was added dropwise. The solution was stirred in ice for 15 mins 
and a white solid precipitated. The mixture was left to stand overnight and then heated 
on a boiling water bath for 1 h. The brown solution formed was poured onto crushed ice 
(200 ml) and extracted with DCM (100 ml). The DCM was washed with 2 M HCl (200 
ml), dried (MgSO^) and decolourised with charcoal. Evaporation gave a thick oil. The 
oil was dissolved in ethanol, water was added until precipitation occurred and left under 
refrigeration to crystallise. A white solid was isolated, (4.0 g, 60 % yield), m.p.60 - 
61% (lit. 83 - 84°C). ÔC (50 MHz, CDCI3 ), 25.71, 26.67, 27.21 and 24.42 
(isopropylidene), 38.54 (S 0 2 Me), 68.49, 73.83, 81.39, 84.01, 85.30 (C2 - C6 ),
106.88 (Cl), 111.07 and 114.00 (isopropylidene). (Found: C, 46.35, H, 6 .6 8 %. 
C 1 3 H 2 2 O 8 S requires: C, 46,15, H, 6.51%).
3 - 0 - T o s y l - l ,2 : 5 ,6 - d i i s o p r o p y l i d e n e g lu c o f u r a n o s e  [46] was prepared as 
follows: [40] (5 g) was dissolved in pyridine (30 ml). Tosyl chloride (7.5 g, 2 eq) was 
added and the mixture stirred at room temperature for 1 h then allowed to stand 
overnight. Finally the solution was heated on a boiling water bath for 1 h. The mixture 
was poured into ice water, extracted into DCM washed with 2 M HCl, dried (MgSO/}) 
and evaporated to a thick oil. The oil was recrystallised from ethanol/water to give a 
white solid, ( 6  g, 75.4%). m.p. 103 - 106°C, (lit. 12 120 - 121°C). (50 MHz,
CDCI3 ), 22.18 (tosyl), 25.34, 26.67, 27.06 and 27.06 (diisopropylidene), 67.53, 
72.21, 80.27, 82.50 and 83.74 (C2 - C 6 ), 105.55 (C l) ,  109.53, 112.98 
(diisopropylidene), 128.93 and 130.16 (tosyl). (Found: C, 55.47, H, 6.43%. 
C 1 9 H 2 5 O 8 S requires: C, 55.07, H, 6.28%).
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3 -0 -T r if ly l- l ,2 :5 ,6 -d iis o p ro p y H d e n e g lu c o fu ra n o se  [47] was prepared as 
follows: triflic anhydride (3 ml) in DCM (60 ml) were stirred in an acetone/ice bath. 
Pyridine (3 ml) in DCM (30 ml) were added slowly. l,2:5,6-Diisopropylidene glucose 
[40] (3 g) in DCM (30 ml) was added dropwise. The solution was stirred for 30 min 
and then poured into ice water (200 ml) containing NaHCOg (0.4 g). The layers were 
separated, the DCM layer washed with cold 3% HCl, water and saturated NaHCOg 
solution. The solution was dried (MgSO^) and evaporated to a solid. Recrystallisation 
from ethanol /  water gave a white powder, (3.9 g, 86.2%). m.p. 69-70°C (lit.l^ 70“C). 
Ôy (200 MHz, CDClg), 1.3 - 1.55 (12 H, m, diispropylidene), 4.0 (1 H, m) and 4.2 (3
H, m) (4, 5, 6 , 6  -H), 4.75 (1 H, d, J = 3.7 Hz, 2-H), 5.25 (1 H, s, 3-H) and 6.0 (1 H, 
d, J == 3.7 Hz, 1-H). ÔC (50 M Hz, CDClg), 25.33, 26.71, 27.03 and 27.28 
(diisopropylidene), 68.07, 72.16, 80.34 and 83.71 (C2, 4, 5 and 6 ), 88.64 (C3), 
105.47 (C l), 110.34 and 113.58 (diisopropylidene). (Found: C, 40.03, H, 4.89%. 
CigHjpFgOsS requires: C, 39.8, H, 4.85%).
3 - 5 - A c e ty l - l ,2 :5 ,6 - d i i s o p r o p y l id e n e g lu c o f u r a n o s e  [48] was prepared as 
follows: [47] (1.4 g) and tetrabutylammonium thioacetate (4 g) were refluxed in toluene 
(40 ml) for 2 h. The solution was filtered and evaporated to give a thin brown liquid. 
The liquid was dissolved in DCM washed with water, dried (MgSO^) and evaporated to 
give a brown liquid from which a white solid precipitated. The solid was recrystallised 
from hexane, (0.4 g, 35.2 %). m.p. 89°C Q itM  88-89“C). ôy  (200 MHz, CDClg),
I.35 - 1.55 (12 H, s, diisopropylidene), 2.4 (3 H, s, SAc), 3.7 (1 H, dd, J = 10.5, 5 
Hz, 3-H), 4.05 - 4.2 (4 H, m, 4, 5, 6 , 6 '-H), 4.7 (1 H, t, J = 3.7 Hz, 2-H), 5.85 (1 H, 
d, J = 3.7 Hz, 1-H). ÔC (50 MHz, CDClg), 25.65, 26.82, 26.82 and 27.08 
(diisopropylidene), 30.95 (SAc), 46.41 (C3), 65.70, 75.98, 79.84 and 81.38 (C2, C4, 
C5 and C 6 ), 104.91 (C l), 110.25 and 112.85 (diisopropylidene).
3 -T h io -l ,2 :5 ,6 -d iiso p ro p y H d e n e g Iu c o fu ra n o se  [49] was prepared as follows: 
[48] (1 g) was disolved in dry THF (30 ml) under N 2 . Benylamine (0.35 ml, 1.5 eq)
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was added and the mixture stirred under for 3 days. The solvent was evaporated to 
give a brown liquid. The liquid was purified by flash column chromatography (hexane : 
EtOAC 3:1) to give a pale yellow oil, (0.42 g, 48.4 %). 8 ^  (200 MHz, CDClg), 1.35 - 
1.50 (12 H, 4 s, diisopropylidenes), 2.05 (1 H, d, J = 9.7 Hz, -SH), 3.00 (1 H, 2 dd, J 
= 10.4, 5.1 Hz, 3-H), 3.95 - 4.15 (3-H, m, 4-, 6 -and 6 '-H), 4.30 (1 H, m, 5-H), 4.60 
(1 H, t, J = 4.4 Hz, 2-H) and 5.80 (1 H, d, J = 3.9 Hz, 1-H). 8 c  (50 MHz, CDClg), 
25.58, 26.86, 26.94 and 27.07 (diisopropylidenes), 41.65 (C3), 66.10, 76.15, 82.39, 
83.46 and 104.48 (C l), 110.33 and 112.48 (quaternaries).
3 -5 -N itro s o tI iio - l ,2 :5 ,6 -d i is o p ro p y U d e iie g Iu c o fu ra n o se  [50] was prepared 
by bubbling N2 0 g through a sample of [49] in DCM. A red liquid was produced. 
Evaporation gave a stable red oil. ~341nm. 8 c  (50 MHz, CDClg), 25.47, 26.80 
and 27.08 (diisopropylidenes), 50.02 (C3), 66.58, 76.38, 79.83 and 81.92 (C2, and C4 
- C 6 ) and 105.04 (C l).
3 - Io d o - l ,2 :5 ,6 “d iiso p ro p y lid e n e g lu c o fu ra n o se  [51] was prepared as follows: 
[47] (1.2 g) and tetrabutylammonium iodide (2.25 g) were refluxed in toluene (50 ml) 
for 2 days. After cooling, the solvent was evaporated to give a brown semi-solid slurry. 
The slurry was extracted with hot hexane (3 x 50 ml) and filtered. The hexane was 
evaporated to give a brown oil. 8 ^  (200 M Hz, CD Clg), 1.3 (12 H, m, 
diisopropylidenes), 3.65 (1 H, dd, J = 10, 4.5 Hz) and 3.95 - 4.2 (4 H, m) (3, 4, 5, 6 , 
6 -H), 4.5 (1 H, t, J = 4.5 Hz, 2-H) and 5.7 (1 H, d, J = 4.1 Hz, 1-H). 8 c  (50 MHz, 
CDClg), 19.85 (C3), 25.69, 26.91, 27.06 and 27.10 (diisopropylidenes), 66.13, 75.88, 
81.86 and 82.13 (C2, C3, C5 and C 6 ), 103.57 (C l) , 110.31 and 111.98 
(diisopropylidenes).
l ,2 :4 ,5 -D iiso p ro p y lid e n e fru c to se  [52] was prepared as follows: fructose (7 g) 
was stirred in dry acetone (140 ml). H 2 SO4  (0.7 ml) was added and the mixture stirred 
at room temperature for 2 h during which all the sugar had dissolved. NaOH (2.2 g) in
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water (20 ml) was added and a yellow oil formed. The oil was extracted into DCM, 
washed with water, diied (MgSO^) and evaporated to a white powder, (5.4 g, 51.9%). 
m .p.l05°C  (lit.l5l04-109°C). 8 c  (50 MHz, CDClg), 26.47, 26.78, 26.88 and 28.47 
(diisopropylidene), 61.12, 70.82, 72.69, 73.82 and 77.81 (C2 - C 6 ), 105.01 (C l),
109.88 and 112.36 (diisopropylidene).
3 -0 -T o s y l- l ,2 :4 ,5 -d i is o p ro p y I id e n e f ru c to s e  [53] was prepared as follows: 
Diisopropylidene fructose (5 g) was dissolved in pyridine (30 ml) and chilled in an ice 
bath. Tosyl chloride (7.5 g) was added and the mixture stirred for 30 min. The mixture 
was left to stand overnight and finally heated on a boiling water bath for 1 h. The 
solution was poured onto crushed ice (150 ml), extracted with DCM, washed (2 M HCl 
and water), dried (MgSO^) and evaporated to a white solid (5.9 g, 74.6 %). m.p. 96°C 
(Iit.l6  97-98'C). 5c (50 MHz, CDCI3 ), 22.19 (tosyl), 26.12, 26.69, 27.14 and 28.38 
(isopropylidenes), 60.50, 72.08, 74.51, 75.49 and 78.57 (C2 - C 6 ), 103.65 (C l), 
110.09 and 113.07 (isopropylidene), 128.52 and 129.98 (tosyl).
The attempted preparation of 3 - tr i f ly l- l ,2 :4 ,5 -d iis o p ro p y lid e n e f ru c to se  [54]
was as follows: triflic anhydride (7.5 ml) was dissolved in dry DCM (100 ml) in a salt /  
ice bath. Pyridine (7.5 ml) in dry DCM (50 ml) was added dropwise. Diisopropylidene 
fructose (7.5 g) dissolved in dry DCM (35 ml) was added over a 10 min period with 
vigorous stirring. The mixture was stirred for a further 30 min and then poured into ice 
water (400 ml) containing NaHCOg (1 g). The layers were separated and the organic 
phase wahed with 3% HCl (2 x 100 ml), water (100 ml) and saturated NaHCOg (100 
ml). The solution was dried and evaporated to a white oil. The oil was dissolved in 
ethanol /  water and heated until the oil solidified. Filtration and recrystallisation from 
ethanol gave a white powder, (4.2 g). m.p. 78°C (dec). 8 ^  (50 MHz, CDClg), 25.95 
and 26.01 (isopropylidene), 65.36, 68.08, 69.80, 71.64, 85.53 (C3), 103.35 (C l), 
111.82 (isopropylidene). The results suggest that an isopropylidene group had been 
lost.
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l ,2 :3 ,4 -d iis o p ro p y lid e n e g a la c to p y ra n o s e  [55] was prepared as follow s: 
galactose (10 g) was dissolved in acetone (125 ml). ZnCl2  (12 g) and H 2 SO4  (0.4 ml) 
were added and the mixture stirred at room temperature for 18 h. A solution of Na2 COg 
( 2 0  g) in water (35 ml) was. The Zn(OH ) 2  produced was filtered and washed with 
acetone. The combined filtrates were evaporated to give a yellow oily solid. The 
product was dissolved in ether and dried by shaking with M gS 0 4  for 1 0  min and 
allowing to stand for 24 h. Filtration and evaporation gave a brown syrup (14.2 g, 98.1 
%). 5c (50 MHz, DMSO), 24.46, 25.12, 26.09 and 26.17 (isopropylidenes), 60.20,
68.46, 70.21, 70.21 and 70.37 (C2 - C 6 ), 95.87 (C l) , 107.88 and 108.28
(isopropylidenes).
6 -T o s y l- l ,2 :3 ,4 -d i is o p ro p y l id e n e g la c to s e  [56] was prepared as follows: 
l,2:3,4-diisopropylidenegalactose (16 g) was stirred in pyridine (40 ml) forming a 
suspension. The suspension was chilled and tosyl chloride (18 g) added slowly. The 
solution eventually became clear. The solution was stirred at room temperature for 6  h 
by which time pyridine hydrochloride had formed as a precipitate. The mixture was 
poured into water and extracted with DCM. The DCM was washed with 2 M HCl and 
water, dried (MgS0 4 ) and evaporated to an oil. Recrystallisation from methanol/water 
left an oil which slowly hardened to an amorphous white solid. The solid was 
recrystallised from ethanol to give white crystals, (21.5 g, 84.5 %). m.p. 91 - 92°C 
(lit. 17 91 - 92°C). ÔH (200 MHz, CDClg), 1.3 - 1.5 (12 H, m, isopropylidenes), 2.45 
(3 H, s, tosyl, -CHg), 4.05 - 4.2 (4 H, m, 2 or 3-H, 5, 6 , and 6 -H), 4.3 (1 H, dd, J =
4.5, 2.5 Hz, 4-H), 4.6 (1 H, dd, J = 8.2 and 2.5 Hz, 2 or 3-H), 5.45 (1 H, d, J = 4.5
Hz, 1-H), 7.35 (2 H, d, J = 8.2 Hz, tosyl) and 7.8 (2 H, d, J = 8.2 Hz, tosyl). 5c (50 
MHz, CDClg), 22.09 (tosyl -CHg), 24.80, 25.37, 26.27 and 26.43 (isopropylidenes), 
66.32 (CH), 6 8 . 6 8  (C 6 ), 70.82 (CH), 70.87 (CH), 70.97 (CH), 96.59 (C l), 109.41 
and 110.05 (isopropylidenes).
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6 -T h io a c e ty l- l,2 :3 ,4 "d iiso p ro p y lid e n e g a Ia c to se  [57] was prepared as follows: 
the above tosylate [56], (3.4 g) was dissolved in DMF (40 ml). Potassium thioacetate 
(4 g) was addded and the mixture stirred under N 2  at 115°C for 7 h. The slurry was 
cooled in ice, poured into chilled xylene and stirred for 30 min. A large amount of water 
soluble precipitate was filtered off. The solvents were evaporated and the process 
repeated. A dark brown oil was produced. This was dissolved in pyridine (9 ml) and 
acetic anhydride (6 ml), stirred for 16 h at room temperature and poured into ice water. 
A brown gum was precipitated. This was collected and the water extracted with toluene. 
The gum was dissolved in the toluene, dried (MgSO^) and evaporated to an orange oil. 
The oil was distilled (175°C /  0.05 mmHg) to give a yellow oil, (1.9 g, 72.8 %). ô j| 
(200 MHz, CDClg), 1.35 - 1.55 (12 H, m, isopropylidenes), 2.4 (3 H, s, SAc), 3.05 (1 
H, dd, J = 13.8, 9.2 Hz, 6 or 6'-H), 3.2 (1 H, dd, J = 13.8, 4.6 Hz, 6 or 6 ’-H), 3.85 
(1 H, m, 5-H), 4.25 (1 H, d, J = 2.8 Hz, 4-H), 4.3 (1 H, dd, J = 5.2, 2.8 Hz, 3-H),
4.6 (1 H, dd, J = 8.1, 2.8 Hz, 2-H), 5.5 (1 H, d, J = 4.6 Hz, 1-H). 5 c  (200 MHz, 
CDClg), 24.91, 25.47, 26.43 and 26.43 (isopropylidenes), 30.17 (C6), 31.03 (SAc), 
67.29, 70.98, 71.40 and 72.51 (C2 - C5), 97.00 (C l) , 109.27 and 109.94 
(isopropylidenes).
6 -T liio -l,2 :3 ,4 -d iiso p ro p y Iid en e  ga lac to se  [58] was prepared as follows: [57] 
(1.5 g) was dissolved in methanol (20 ml). Sodium metal (8.5 mg) was added and the 
solution stirred under N 2  for 3 days. CO2  was bubbled through the solution to neutralise 
the NaOMe and the solvent evaporated to give a yellow gum. The gum was extracted 
into ether and evaporated to a yellow oil with a strong thiol smell, (1.15 g, 88.1 %). ôjj 
(200 MHz, CDClg), 1.35 - 1.55 (12 H, m, isopropylidenes), 2.05 (1 H, t, -SH), 2.7 -
2.8 (2 H, m, 6 and 6'-H), 3.8 (1 H, td, J = 7, 1.8 Hz, 5-H), 4.35 (2 H, m, 3 and 4-H), 
4.65 (1 H, dd, J = 7.9, 2.4 Hz, 2-H), 5.55 (1 H, d, J = 5.1 Hz, 1-H). ôc (200 MHz, 
CDClg), 24.90 (C6), 24.90, 25.41, 26.44 and 26.53 (isopropylidenes), 70.33, 70.98, 
71.31 and 71.73 (C2 - C5), 97.64 (C l), 109.29 and 109.79 (isopropylidenes).
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The attempted preparation of 6 -n itro so th io -l,2 :3 ,4 -d iiso p ro p y lid en e  galactose 
[59] was performed as follows: the thiol [58] (1 g) was dissolved in methanol (8 ml) 
and water (2 ml). Excess NaNÛ2  and HCl were added to give a deep red solution. The 
solution was extracted with DCM and evaporated to give a red sticky solid, 332 
nm. This was shown to be mostly disulphide, (50 MHz, CDClg), 24.91, 25.49, 
26.43 and 26.52 (isopropylidenes), 38.70 (C6) 67.13, 71.02, 71.36 and 71.94 (C2 - 
C5), 97.10 (C l), 109.24 and 109.74 (isopropylidenes). The nitrosothiol has should 
have a signal for C6 at 33.76.
6 -T o sy I" l,2 ,3 ,4 - te tra a c e ty lg Iu c o se  [60] was prepared as follows: 1,2,3,4 
tetraacetyl glucose (5 g) was dissolved in pyridine (50 ml) and chilled in an ice bath. 
Tosyl chloride (10 g) was added slowly with vigorous stirring. The mixture was stirred 
overnight and poured into ice water (200 ml). The water was extracted with DCM (100 
ml) and washed with 2 M HCl (4 x 50 ml). The organic phase was dried (MgSO^) and 
evaporated to a white solid. The solid was recrystallised from ethanol, (6.16 g, 85.4 
%). m.p. 194°C.(lit.l8 194°C). ôy (200 MHz, CDClg), 2.0 (12 H, m, OAc), 2.5 (3 H, 
s, OTs), 3.85 (1 H, m, 5-H), 4.15 (2 H, m), 5.05 (1 H, dd, J = 9.1, 2.5 Hz) and 5.15 -
5.2 (2 H, m) (2, 3, 4, 6, 6 -H), 5.65 (1 H, d, J = 8.1 Hz, 1-H), 7.35 (2 H, d, J = 8.1 
Hz, OTs) and 7.8 (2 H, d, J = 8.1 Hz, OTs). ôc (50 MHz, CDClg), 20.98, 21.03 and
21.24 (OAc), 22.18 (OTs), 67.19, 68.33, 70.44, 72.57, 73.02 (C2 - C6), 91.96 (C l), 
128.64, 130.34, 133.20 and 145.68 (OTs), 169.26, 169.63, 169.76 and 170.59 (OAc).
6 - B r o m o m e t h y l g I u c o p y r a n o s i d e  [61]  was p repared  by d isso lv ing  
methylglucopyranoside (5 g, 26 mmol) and A-bromo succinimide (9.15 g, 52 mmol) in 
DMF (70 ml). This was stirred in an ice bath and 13.5 g PhgP was slowly added. The 
solution was stirred at 50°C for 1.5 hrs and the reaction then quenched with methanol. 
Butanol was added and the solvents evaporated to give a yellow oil. The oil was 
dissolved in DCM and washed with water (3 x 50 ml). PhgPO remained in the organic 
phase. The aqueous phases were combined and evaporated to give an orange oil. This
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became a milky orange solid upon standing, ô^ (200 MHz, CDClg), 4.85 (1 H, d, J =
4.5 Hz, 1-H).
M eth y l- 6 -b rom oglucopyraiioside  tr ia c e ta te  [62] was prepared from crude [61] 
by acétylation in acetic anhydride (40 ml) and dry pyridine (60 ml), with stirring at room 
temperature for 3 h. The solution was then poured into ice water (300 ml) with good 
stirring and a brown gum was produced. The aqueous solution was extracted with DCM 
and added to a solution of the brown gum in DCM. The solution was washed with 
copious quantities of 1 M HCl followed by saturated NaHCOg solution, dried (MgSO^) 
and evaporated to a brown oil. Recrystallisation gave from ethanol gave a white well 
crystallised product, (3.5 g, 35.4 % over 2 steps), m.p. 110°C (lit.^^ 116 - 117°C). 0^ 
(200 MHz, CDClg), 2.1 (9 H, m, OAc), 3.4 (1 H, dd, J = 11.3, 6 . 8  Hz, 6  or 6 '-H),
3.45 (3 H, s, OMe), 3.5 (1 H, dd, J = 11.3, 2.6 Hz, 6  or 6  -H), 4.0 (1 H, m, 5-H), 4.9 
(1 H, dd, J = 10.0, 3.9 Hz), 5.0 (2 H, m, 1 and 3 or 4-H), 5.5 (1 H, t, J = 9.7 Hz, 3 or
4-H). ÔC (50 MHz, CDClg), 21.21 (OAc), 31.71 (C6 ), 56.04 (OMe), 68.95, 70.36,
71.24 and 71.60 (C2 - C5), 97.09 (C l).
6 -5 "A c e ty l-2 ,3 ,4 - tr ia c e ty lm e th y Ig Iu c o p y ra n o s ld e  [63] was prepared by the 
following methods:
1. [62] (1.1 g) and tetrabutylammonium thioacetate (1.8 g) were refluxed in toluene (50 
ml) for 2.5 h. Upon cooling the mixture separated into two layers. The pale brown 
upper layer was decanted into ice cold xylene and stirred for 30 min. A dark brown 
precipitate was filtered off. The filtrate was evaporated to give a pale brown oil. 
Distillation under vacuum (175 °C /  0.05 mmHg, lit.^^ 165-170°C /  0.02mmHg) gave an 
orange oil. (0.53 g, 48.4 %). ôy (200 MHz, CDClg), 2.1 (9 H, m, OAc), 2.4 (3 H, s, 
SAc), 3.1 (1 H, dd, J = 14.3, 6 . 6  Hz, 6 - or 6 -H), 3.2 (1 H, dd, J = 14.3, 3.5 Hz, 6 - 
or 6 '-), 3.4 (1 H, s, OMe), 3.95 (1 H, m, 5-H), 4.85 - 4.95 (3 H, m, 1-, 2-, and 3- or
4-H), 5.45 (1 H, t, J = 9.3 Hz, 3- or 4-H). ôc (50 MHz, CDClg), 21.19 (OAc), 30.46
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(C6 ), 30.90 (SAc), 55.81 (OMe), 68.65, 70.43, 71.35 and 71.35 (C2 - C6 ), 97.01 
(C l), 170.36 (OAc) and 195.03 (SAc).
2. [62] (1 g) and potassium thioacetate (1.2 g, 4 eq) were dissolved in DMF (45 ml) and 
heated with stirring at 110°C under for 3 h. The slurry formed was cooled in ice then 
poured into ice cold xylene and stirred for 30 min. A brown precipitate was filtered. 
The solvent was evaporated and the process repeated. Evaporation gave a brown oil. 
The oil was dissolved in acetic anhydride ( 6  ml) and pyridine (9 ml) and stirred at room 
temperature for 24 h. The mixture was poured into water with no signs of a precipitate 
forming. The water was extracted with DCM which was dried and evaporated to give a 
thick orange oil. The oil was distilled to give the same product as above, (0.28 g, 28.4 
%).
3. [62] (1 g) and potassium thioacetate (1.1 g) were refluxed in acetone (30 ml) for 5 h. 
The mixture was allowed to cool, filtered and evaporated to a red sludge. The residue 
was dissolved in DCM, washed with water and evaporated to a thick red /  brown oil. 
The oil was purified by column chromatogtaphy (hexane : EtOAc 3:1) to give the desired 
product as above, (0.30 g, 30.6 %).
The attempted preparation of 6 -tliio -2 ,3 ,4 -tr ia a ce ty lm eth y lg Iu co p y ra n o s id e
[64] was carried out from the above thioacetates as follows: [63] (0.3 g) and 
benzylamine (0.1 ml, 1.5 eq) were dissolved in dry THE (40 ml) and stirred under N 2  
for 3 days. TLC revealed all of the starting material had been hydrolysed. Flash column 
chromatography using the same solvent system (hexane : EtOAc 3:1) gave no product 
suggesting that the thiol was breaking down to disulpide on the column.
The attem pted p reparation  o f m e th y l-2 ,3 ,4 -tr ia c e ty l-6 - iso th io u r o n iu m  
glucopyranosyl brom ide [65] was carried out by dissolving [62] in dry acetone
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(10 ml) and refluxing with thiourea (2 g) for 20 mins. Upon slow evaporation, a 
colourless oil was produced.
The attem pted preparation o f m e th y l-2 ,3 ,4 - tr ia c e ty l-6 “th io g Iu c o p y ra n o s id e  
[64] was carried out as follows: [65] (4 g) was added to a solution of K 2 S2 O 5  in water 
(5 ml) at 75“C. DCM ( 6  ml) was added and the mixture refluxed with stirring for 15 
mins. The DCM layer was separated and washed with water (3 x 1 5  ml), diied (MgSO^^) 
and evaporated to an amorphous white solid. The solid was recrystallised from methanol 
to give a white powder (0.75 g). m.p. 56 'C  (lit.20 40°C). 0^  (200 MHz, DMSO), 2.0 
(9 H, m, OAc), 2.1 (1 H, d), 3.35 (1 H, m), 3.4 (3 H, s, OMe), 3.55 (1 H, dd, J =
10.8 and 6.5 Hz) and 3.75 (1 H, dd, J = 10.9, and <lH z) ( 6  and 6 '-H), 3.9 (1 H, t, J = 
8.7 Hz), 4.75 (1 H, dd, J = 10 and 3.5 Hz, 2-H), 4.8 (1 H, m), 4.95 (1 H, t, J = 3.9 
Hz) and 5.3 (1 H, t, J = 9.8 Hz). It is assumed by the elevated melting point that a high 
percentage disulphide has been fomied. The above product was nitrosated as described 
previously. A red oil was isolated but could not be solidified before decomposition had 
occurred.
6 -A z id o -2 ,3 ,4 -triace ty Im eth y Ig lu co p y ran o sid e  [6 6 ] was prepared as follows: 
the bromosugar [62] (2.4 g) and sodium azide (1.3 g) were stirred in DMF (20 ml) in a 
boiling water bath for 4 h. The product was poured into ice water (50 ml) and a white 
precipitate collected, (1.72 g, 79.7 %). m.p.l02°C (lit.^^ 103°C) 2100. ôfj
(200 MHz, CDCI3 ), 2.05 - 2.15 (9 H, m, OAc), 3.3 (2 H, m, 6  and 6 '-H), 3.45 (3 H, 
s, OMe), 3.95 (1 H, m, 5-H), 4.9 (1 H, dd, J = 9.8, 4.0 Hz, 2-H), 4.95 (1 H, d, J =
4.0 Hz, 1-H), 4.95 (1 H, t, J = 9.8 Hz, 3 or 4-H), 5.45 (1 H, t, J = 9.8 Hz, 3 or 4-H), 
ÔC (50 MHz, CDCI3 ), 21.14 (OAc), 51.41 (C 6 ), 56.01 (OMe), 69.00, 70.13, 70.26 
and 71.17 (C2 - C5), 97.05 (C l), 170.14, 170.52 and 170.57 (OAc).
6 -A m in o -2 ,3 ,4 - te tr a a c e ty lm e th y lg lu c o p y ra n o s id e  [67] was prepared as 
follows: 6 -azidoglucose (1.7 g) was dissolved in methanol (100 ml). A catalytic amount
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of 10 % Pd on c  was added and the mixture hydrogenated for 24 h. The suspension 
was filtered through celite and the filtrate evaporated to give a clear oil which solidified 
with standing, (0.66 g, 42.1 %). ôc  (50 MHz, CDClg), 22.67 (OAc), 40.31 (C6 ), 
54.55 (OMe), 70.46, 72.04, 72.13 and 73.14 (C2 - C5), 99.81 (C l) and 170.30 (OAc).
2 ,5 “D im e s y l - l ,3 ,4 ,6 - d ia n h y d r o m a n n i to l  [69] was prepared as follows: 
isomannide ( 1 0  g, 0.068 mol) was dissolved in dry pyridine (60 ml) in an ice bath. 
Nitrogen was bubbled through the solution for 5 mins. Mesyl chloride (11 ml, 0.142 
mol) was added from a dropping funnel with vigorous stirring. Stirring was continued 
for 10 mins and the solution then left to stand: in the ice bath for 3 h, at room 
temperature for 1 h and finally on a steam bath for 1 h. Water was added to dissolve the 
pyridine hydrochloride precipitate and the solution poured into 250 ml cold water. A 
white precipitate was filtered, washed with water and dried under vacuum to give fine 
white crystals, (11.6 g, 56%). m.p. 96°C (lit.22 lO l'C ). ôy  (200 MHz, CDClg), 3.05 
( 6  H, m, -CHg), 3.95 (2 H, dd, J = 9.5 and 6.9 Hz, lb  and 6 b-H ), 4.15 (2 H, dd, J =
9.2 and 6 . 6  Hz, la  and 6 a-H), 4.75 (2 H, m, 3 and 4-H) and 5.1 (2 H, m, 2 and 5-H).
2 ,5 -D ito s y l- l ,3 ,4 ,6 -d ia n h y d ro m a n n ito l [70] as follows: isom annide (9.5 g, 
0.065 mol) was dissolved in pyridine (7.5 ml). Tosyl chloride (26 g, 0.136 mol) was 
slowly added with vigorous stirring. The solution was left to stand at room temperature 
for 4 hrs and then heated on a steam bath for 1 hour. The solution was allowed to cool 
and poured onto crushed ice (400 ml). The product was extracted into DCM, washed 
with 2 M HCl and water, dried (MgSO^) and evaporated to a yellow oil. The oil 
solidified upon standing and was recrystallised from methanol yielding a white solid 
(26.1 g, 88.4 %). m.p.91 - 93°C (lit.:^3 gq _ ÇQ-Q. ôy (200 MHz, CDClg), 2.50 ( 6  H, 
s, CHg), 3.70 (2 H, dd, J = 9.5 and 7.7 Hz, Ib and 6 b-H), 3.9 (2 H, dd, J = 9.5 and
6 . 6  Hz, la  and 6 a-H), 4.5 (2 H, m, 3 and 4-H) and 4.85 (2 H, m, 2- and 5-H). ô^ 
(200 MHz, CDClg), 22.21 (CHg), 70.57, 78.37 and 80.43 (ring carbons), 128.46, 
130.44, 133.42, 145.85 (aromatics).
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2 .5 - D i t r i f ly l - l ,3 ,4 ,6 - d ia n h y d r o m a n n i to I  [71] was prepared as follow s: 
isomannide (1.15 g) was dissolved in di*y DCM (7.5 ml) and dry pyridine (2.5 ml). 
Argon was passed over the solution for 5 mins whilst chilling in an ice bath. A solution 
of triflic anhydride (5 g, 2.8 ml) in DCM (5 ml) was added from a dropping funnel over 
a period of 15 mins with vigorous stirring. The solution was allowed to warm and was 
stirred at room temperature overnight then poured into 3 M HCl (50 ml). The product 
was extraced into DCM and dried (Na2 S0 4 ). Evaporation yielded a yellow oil which 
solidified and was recrystallised from ethanol to give fine white needles, (2.4 g, 74.3 
%). m.p. 54°C, (lit.24 60°C). ôy (200 MHz, CDClg), 4.15 (4 H, m, la , lb , 6 a and 6 b- 
H), 4.8 (2 H, m, 3 and 4-H) and 5.2 (2 H, m, 2 and 5-H). 8 ^  (50 MHz, CDClg), 
71.35, 80.81 and 83.89.
2 .5 -D ith io a c e ty l- l ,3 ,4 ,6 -d ia iih y d ro m a n n ito l [72] was prepared by refluxing 
isomannide ditiiflate [71] (1 g) and potassium thioacetate (1 g) in a mixture of dry DCM 
(10 ml) and dry ethanol (10 ml) for 2 h. The resultant mixture was filtered boiled with 
decolourising chai’coal and evaporated to a brown oil, (0.45 g, 71.1 %). ôjg (200 MHz, 
CDClg), 2.4 ( 6  H, m, SAc), 3.8 (2 H, dd, J = 9.9 and 3 Hz, lb  and 6 b-H), 4.0 (2 H, 
dd, J = 5.3 and 3 Hz, 2 and 5-H), 4.25 (2 H, dd, J = 9.9 and 5.35 Hz, la  and 6 a-H) 
and 4.55 (2 H, m, 3 and 4-H). 8 c  (50 MHz, CDClg), 31.11, 48.67, 73.37 and 87.93. 
(Found: C, 43.0, H, 5.23%. C 1 0 H 1 4 O4 S2  requires: C, 45.8, H, 5.34%).
2 .5 -D ith io a c e ty I - l ,3 ,4 ,6 - d la n h y d r o n ia n n i to l  [72] was also prepared as 
follows: ditosyl isomannide [70] (5 g) and potassium thioacetate (5 g) were stirred in 
DMF (80 ml) and heated at 110°C in an oil bath for 5 h under N2 . The resulting brown 
mix was evaporated leaving a dark brown sludge. This was extracted with DCM, 
washed with water and left to stand over decolourising charcoal and MgS0 4 . Upon 
evaporation a pungent brown oil was produced. The oil was distilled under vacuum
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(175°C, 0.05 mmHg) to give an orange oil (1.6 g, 55.0 %) which did not solidify upon 
storage (lit.25 m.p. 35 - 37°C). Spectral details were as above.
2 .5 -D ith io -l,3 ,4 ,6 -d ian h y d ro m an n ito l [73] was prepared as follows: [72] (3 g)
was refluxed with 2.5 % HCl in methanol (50 ml) for 4 h. The solvent was evaporated 
to give an orange oil. This was dried under vacuum, over NaOH and chilled to give a 
brown sludge. The sludge was distilled under vacuum (70°C, 0.05 mmHg) to give a 
pale orange oil, (1.9 g, 93.2 %). (lit.25 m.p. 15 - 16°C). (200 MHz, CDClg), 1.75
(2 H, d, J = 8.0 Hz, -SH), 3.4 (2 H, m, 2 and 5-H), 3.8 (2 H, dd, J = 9.5 and 2.2 Hz, 
lb  and 6 b-H), 4.15 (2 H, dd, J = 9.5 and 5.0 Hz, la  and 6 a-H), 4.7 (2 H, s, 3 and 4- 
H). ÔC (50 MHz, CDClg), 43.82 (C2 and C5), 76.28 and 90.56 (C l, C3, C4 and C 6 ). 
Drnax/cm-l 2565 (SH).
2 .5 -D i-5 -n itro so th io - l ,3 ,4 ,6 -d ia n h y d ro m a n n ito l [74] was prepared from the 
thiol as follows: [73] (1 g) was dissolved in methanol ( 8  ml) and water (2 ml). Excess 
NaN 0 2  and HCl were added to give a deep red liquid. The product was extracted with 
DCM and evaporated to give a thick red oil, ^max 344 nm. 6q (50 MHz, CDClg),
52.31, 73.04 and 88.15.
2 .5 -D im esy l-l,3 ,4 ,6 -d ian h y d ro g lu c ito l [76] was prepared as for isomannide to 
give a white powder. The powder was recrystallised from ethanol to give fine white 
needles (17.3 g, 83.6%). m.p. 120°C (lit.26 120 - 121°C). 0^ (200 MHz, CDClg), 3.1 
( 6  H, m, -CHg), 3.9 (1 H, dd, J = 10.1 and 6.1 Hz, 6 b-H), 4.0 (1 H, dd, J = 11.5 and 
6.1 Hz, 6 a-H), 4.1 (1 H, dd, J = 14 and 3.4 Hz, la-H), 4.25 (1 H, d, J = 13.1 Hz, Ib- 
H), 4.7 (1 H, d, J = 4.7 Hz, 3-H), 4.9 (1 H, t, J= 4.7 Hz, 4-H) and 5.15 (2 H, m, 2 
and 5-H). (Found: C, 31.99; H, 4.69%. CgHi4 0 gS2  requires C, 31.79; H, 4.64%)
2 .5 -D ito sy !-l,3 ,4 ,6 -d ian h y c lro g lu c ito I [77] was prepared as for isomannide to 
give fine white crystals, (20.75 g, 70.2%). m.p. 95 'C , (lit.:^^ lOO-lOHC). Sy (200
180
MHz, CDClg) 2.45 (6 H, s, CHg), 3.7 (1 H, dd, J = 10.1 and 6.15 Hz, 6b-H), 3.8 (1 
H, dd, J = 10.1 and 6.2 Hz, 6a-H), 3.85 (1 H, dd, J = 11,5 and 3.5 Hz, la-H), 3.95 (1 
H, d, J = 11.6 Hz, Ib-H), 4.45 (1 H, d, J -  4.6 Hz, 3-H), 4.6 (1 H, t, J = 5.1 Hz, 4- 
H), 4.85 (2 H, m, 2 and 5-H) 7.35 (4 H, m, aromatics) and 7.75 (4 H, m, aromatics). 
Ôc (50 MHz, CDClg), 22.18 (OTs), 70.27, 73.71, 78.82, 80.85, 83.76 and 86.07 (ring 
carbons), 128.32, 128.41, 130.46, 130.63, 133.44, 133.49, 145.84 and 145.99 (OTs). 
(Found: C, 53.21; H, 4.83%. C2 0 H 2 2 O 8 S 2  requires C, 52.86; H, 4.85%).
2 ,5 - D i t r i f ly I - l ,3 ,4 ,6 - d ia n l iy d r o g lu c i to I  [78] was prepared  as follow s: 
isomannide (1.15 g) was dissloved in dry DCM (7.5 ml) and dry pyridine (2.5 ml). 
Argon was passed over the solution for 5 mins whilst chilling in an ice bath. A solution 
of triflic anhydride (5 g, 2.8 ml) in DCM (5 ml) was added from a dropping funnel over 
a period of 15 mins with vigorous stirring. The solution was then warmed and stirred at 
room temperature overnight, then poured into 3 M HCl (50 ml). The product was 
extracted into DCM and dried (Na2 S 0 4 ). Upon evaporation a white powder was 
produced, (2.4 g, 74.6 %). m.p. 56°C. ô^  (200 MHz, CDClg), 3.95 (1 H, dd, J =
11.9 and 4.4 Hz, 6b-H), 4.15 (2 H, m, la  and 6a-H), 4.35 (1 H, d, J = 12.2 Hz, Ib- 
H), 4.7 (1 H, d, J = 5.5 Hz, 3-H), 5.05 (1 H, t, J = 5.5 Hz, 4-H) and 5.35 (2 H, m, 2 
and 5-H). Ôc (50 MHz, CDClg), 71.86, 73.67, 81.50, 85.41, 86.41 and 88.78.
The attem pted preparation of 2 ,5“d ith io ace ty i- l,3 ,4 ,6 -d ia n h y d ro g lu c ito I  [79]
was as follows: isosorbide ditriflate (1 g) was refluxed with potassium thioactetate (1 g) 
in a mixture of dry DCM (10 ml) and dry ethanol (15 ml) for 2 hrs. The mixture was 
filtered, evaporated, dissolved in DCM , washed with w ater and boiled with 
decolourising charcoal. Upon evaporation a yellow oil was produced. ^^C spectra 
revealed the oil to be composed either of more than one product, or a product other than 
that expected, ô c  (50 MHz, CDClg), 30.96, 31.12, 39.06, 46.45, 48.47, 49.33, 
72.24, 73.04, 73.29, 74.10, 82.74, 83.37, 86.07, 87.71 and 88.60.
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S -N itroso th iog lycero l [82] was prepared as follows: thioglycerol [81] (2 g) was 
dissolved in DCM (10 ml) and N2 O 3  (from HCl dripped onto NaN 0 2 ) was bubbled 
throught the solution until not more thiol remained (no purple adduct formed with 
alkaline nitroprusside). The deep red solution was evaporated without heating to form a 
red oil, (2.5 g, 98.4 %). 332 nm. 0^  (50 MHz, D 2 O), 29.43 (C l), 67.08 and
72.90 (C2 and C3).
D ith iog lycero l a c e ta te  [83] was prepared as follows, thioglycerol ( 2  g) was 
dissolved in methanol. A few drops of triethylamine were added and the solution 
warmed gently with stirring over a 5 day period. Oxygen was bubbled through the 
solution intemiittently. The methanol was evaporated to leave a thin oil. The oil was 
dissolved in acetic anhydride (25 ml) with NaOAc (4 g) and stirrred in a boiling water 
bath for 2 h. The product was poured into ice water and an oil formed at the bottom of 
the beaker. The water was decanted, the oil dissolved in DCM, washed with copious 
quantities of saturated NaHCOg, water and dried (MgSO^). Evaporation with toluene 
gave a thin oil, (4.1 g, 57.7 %). 0^  (200 MHz, CDClg), 2.1 ( 6  H, s, OAc), 2.95 (2 H, 
d, J = 7.2 Hz, 1 and I'-H), 4.15 (2 H, dd, J = 10.8 and 5.2 Hz, 3 or 3'-H), 4.35 (2 H, 
dd, J = 12.4 and 4.1 Hz, 3 or 3'-H) and 5.25 (2 H, m, 2-H). ôc  (50 MHz, CDClg), 
21.231 and 21.447 (OAc), 39.640 (C l), 64.178 (C2) and 70.270 (C3).
2 ,3 -O -A c e ty I- l-m e rc a p to p ro p a n e d io l [85] was not prepared from  the above 
product as follows: the disulphide [83] (1 g) was dissolved in DCM (20 ml) and 
degassed with N 2 . Dithiothreitol (0.4 g) was added and the mixture stirred at room 
temperature under N 2  for 5 days. The solution was washed with water, dried (MgSO^) 
and evaporated to an oil. ^^C NMR revealed the oil to still be the disulphide.
Thioglycerol triace ta te  [84] was prepared as follows: thioglycerol (4 g) and sodium 
actetate ( 8  g) were dissolved in acetic anhydride and stirred in a boiling water bath for 2  
hrs. The product was poured onto crushed ice. An oil was observed at the bottom of the
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beaker. The water was decanted and the oil dissolved in DCM. The DCM was washed 
with copious quantities of saturated NaHCOg, water and dried (MgSO^). The solution 
was evaporated with ethanol to give an oil (4 g, 46.2%) 0 ^  (200 MHz, CDClg, 2.1 ( 6  
H, s, OAc), 2.35 (3 H, s, SAc), 3.05 (1 H, dd, J = 14.75 and 6 . 6  Hz, 1 or I'-H), 3.25 
(1 H, dd, J = 13.9 and 5.7 Hz, 1 or I'-H), 4.1 (1 H, dd, J = 11.5 and 5.7 Hz, 3 or 3'- 
H), 4.25 (1 H, dd, J = 12.0 and 4.1 Hz, 3 or 3'-H) and 5.15 (1 H, m, 2-H). ô c  (50 
MHz, CDClg), 21.22 and 21.39 (OAc), 29.78 (C l), 30.96 (SAc), 64.08 (C2) and 
70.41 (C3).
2 .3-< 7-A cety l-l-m ercaptopropanedioI [85] was prepared as follows, thioglycerol 
triacetate (3.4 g) was dissolved in dry degassed tetrahydrafuran (30 ml). Benzylamine 
(2.4 ml, 1.5 eq) was added and the solution stirred at room temperature under N 2  for 24 
hrs. The reaction was followed by TLC (hexane: EtOAc 2:1) (rf values: disulphide
0.36, S-Acetate 0.53, thiol 0.80). The solvent was evaporated and the oil produced 
dissolved in DCM. The solution was washed with 3 M HCl, saturated NaHCOg and 
water, dried (MgSO^) and evaporated to an oil. The oil was purified by column 
chromatography (EtOAc: hexane 1:1). (2.1 g, 82.1 %). ôy (300 MHz, CDClg), 1.50 (1 
H, t, J = 9 Hz, -SH), 2.1 ( 6  H, m, OAc), 2.7 (2 H, t, J = 6.5 Hz, 1 and I'-H), 4.25 (1 
H, dd, J = 12 and 5.7 Hz, 3 or 3’-H), 4.35 (1 H, dd, J = 11.7 and 3.6 Hz, 3 or 3'-H) 
and 5.05 (1 H, m, 2-H). ôc  (75 MHz, CDClg), 21.301 and 21.674 (OAc), 25.317 
(C l), 63.918 (C2) and 73.041 (C3).
2 .3 -0 -A ce ty I-l-5 -n itro so th io g ly ce ro l [8 6 ] was prepared by the nitrosation o f the 
above product with N2 0 g in DCM to give a deep red liquid. The solvent was evaporated 
to give a red oil with at -335  nm. tj / 2  of 50 - 60 mins in aqueous buffer /  methanol 
at 20°C. ÔC (50 MHz, CDClg), 21.29 and 21.51 (OAc), 33.29 (C l), 64.01 and 69.88 
(C2 and C3)
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2 , 3 - 0 -A c e ty l i î ie r c a p to p r o p a n e d io l  [85] was also prepared as follows: 
thioglycerol acetate [84] (1 g) was dissolved in dry DMF and degassed. Hydrazine 
acetate (6 . 8  ml, 1.25 M in DMF) was added and the solution stirred at room temperature 
under N 2  for 5 hrs. (TLC EtOAc: hexane 2:1). The solvent was evaporated and an oil 
produced. The oil was dissolved in EtOAc (100 ml), washed (1 M HCl, saturated 
NaHCOg, H 2 O and saturated NaCl), dried (MgSO^) and evaporated to an oil. The pure 
product was obtained by column chromatography (EtOAc: hexane, 1:1). ^^C and ^H 
spectra as above.
M e rc a p to su c c in ic  ac id  m e th y l e s te r  [8 8 ] was p repared  as fo llow s: 
m ercaptosuccinic acid [87] (7.5 g) and H 2 SO 4  (1.5 ml) were refluxed gently in 
methanol (40 ml) with a few dried molecular sieves for 7 hrs. The methanol was 
evaporated and the oil allowed to cool then poured into water (150 ml) in a separating 
funnel. The product was extracted into ether and washed with saturated NaHCOg 
solution. The ether was dried by shaking with MgS0 4  for 5 mins and left for 3 hrs to 
stand. The solvent was evaporated to give a thin oil, (5.7 g, 64.5 %). Ôjj (200 MHz, 
CDClg), 2.2 (1 H, d, J = 10 Hz, -SH), 2.7 (1 H, dd, J =  17 and 6  Hz, 3 or 3'-H), 3.0 
(1 H, dd, J =  17 and 9 Hz, 3 or 3'-H), 3.65 (3 H, s, OMe), and 3.75 (4 H, m, OMe and 
2-H). ÔC (50 MHz, CDClg), 36.403 and 40.069 (C2 and C3), 52.536 and 53.351 
(OMe).
5 -N itro so m ercap to su cc in ic  acid m ethyl es te r [89] was prepared as follows: 
[8 8 ] ( 1  g) was nitrosated using N2 0 g to give an extremely pungent deep red oil, ( 1 . 1  g,
94.6 %). at 337nm and t j / 2  o f > 24 hrs. (50 MHz, CDClg), 35.80 (C2),
48.06 (C l), 52.71 and 53.42 (OMe).
M ercaptosuccinic acid ethyl ester [90] was prepared as follows: mercaptosuccinic 
acid (7.5 g) and H 2 SO 4  (1.5 ml) were gently refluxed in ethanol (50 ml) with a few 
molecular sieves for 5 hrs. The ethanol was evaporated to give a thin oil. The oil was
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poured into water, extracted into ether, washed with saturated NaHCOg solution and 
dried (MgSO^). The solvent was evaporated to give a thin oil, (7.5 g, 72.8 %). ô^  (200 
MHz, CDClg), 1.25 ( 6  H, m, -CHoCHgl. 2.15 (1 H, d, J = 9.4 Hz, -SH), 2.70 (1 H, 
dd, J =  17 and 6  Hz, 2 or 2'-H), 2.95 (1 H, dd, J = 16.8 and 9 Hz, 2 or 2'-H), 3.70 (1 
H, m, 3-H) and 4.15 (4 H, m, -CH 2 CHg). 5c (50 MHz, CDClg), 14.45 and 14.57 (- 
CHoCHgT 36.66 and 40.32 (C2 and C3), 61.45 and 62.20 CCHgCHg).
5 -N itro som ercap to succin ic  acid ethyl este r [91] was prepared as follows: [90] 
(1 g) was nitrosated with N2 0 g to give a pungent deep red oil, (1.1 g, 96.6 %). with 
^max 338nm and ti / 2  > 24 hrs.
A nisylglucosam ine [93] was prepared as follows: glucosamine hydrochloride [92] 
(20 g) was dissolved in 1 M NaOH (94 ml). Anisaldehyde was added (11.4 ml) and the 
mixture shaken until a white precipitate was seen. The flask was cooled in a freezer for 
10 mins and filtered. The white solid was washed with ice water and chilled ether. The 
solid was dried in a vacuum oven to give a white product (26.2 g, 95.1%). m.p. 163°C 
(lit.27 166°C). ÔH (200 MHz, DMSO) 2.85 (1 H, t, J = 8.5 Hz, 2-H), 3.2 (1 H, m, 5- 
H), 3.85 (3 H, s, OMe), 4.65 (1 H, t, J = 5.6 Hz), 4.75 (1 H, t, J = 7.2 Hz), 4.9 (1 H, 
d, J = 4.8 Hz) and 5.0 (1 H, d, J = 4.8 Hz) (3,4,6 and 6 ’-H), 6 . 6  (1 H, d, J = 6 . 6  Hz, 
1-H), 7.0 (2 H, d, J = 8 . 6  Hz, aromatics), 7.7 (2 H, d, J = 8 . 6  Hz, aromatics), 8.15 (1 
H, s, CH=N). 5c  (50 MHz, DMSO) 55.54 (OMe), 61.52 (C2), 70.61, 74.80, 77.07 
and 78.40 (C3 - C6 ), 95.85 (C l), 114.18 and 129.94 (aromatics), 161.71 (CHN).
A nisy lg lucosam ine  te tra -O -a c e ta te  [94] was prepared as follows: [93] (15 g)
was cooled with stirring in a mixture o f pyridine (81 ml) and acetic anhydride (45 ml). 
The mixture was left to stand at room temperature overnight and then poured into ice 
water with stirring. A white precipitate appeared and was filtered off, dried and 
recrystallised from ethanol, (20.6 g, 88.0 %). m.p. 187°C (lit.27 188°C). 5jj (200 
MHz, CDClg) 1.85 - 2.05 (12 H, m, OAc), 3.4 (1 H, t, J = 8 . 6  Hz, 2-H), 3.8 (3 H, s.
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OMe), 3.95 (1 H, m, 5-H), 4.05 (1 H, dd, J = 12.6, 2.0 Hz, 6  or 6 ’-H), 4.35 (1 H, dd, 
J = 12.4, 4.6 Hz, 6  or 6 ’-H), 5.1 (1 H, t, J = 9.6 Hz, 3 or 4-H), 5.4 (1 H, t, J = 9.4 
Hz, 3 or 4-H), 5.95 (1 H, d, J = 8.2 Hz, 1-H), 6.9 (2 H, d, J == 8 . 6  Hz, aromatics),
7.65 (2 H, d, J -  8 . 6  Hz, aromatics) and 8.15 (1 H, s, CHN). ôc  (50 MHz, CDCI3 ) 
20.96, 21.1 and 21.24 (OAc), 55.87 (OMe), 62.27 (C2), 68.49, 73.23, 73.37 and
73,70 (C3 - C 6 ), 93.62 (C l), 114.54 and 130.74 (aromatics) and 164.77 (CHN).
G lucosam ine te tra -O -ace ta te  hydroch lo ride  [95] was prepared as follows: [94] 
(10 g) was was dissolved in the minimum amount of acetone with heating. A small 
quantity of water was added and the mixture cooled. Concentrated HCl was added 
dropwise until a precipitate was seen. Chilling was continued whilst stirring with ether, 
to remove the anisaldehyde. The solid was filtered and washed with chilled ether, (6.1 
g, 73.4 %). m.p. dec. (lit.27 dec), dy (300 MHz, D2 O), 2.0 (12 H, m, OAc), 3.6 (1 
H, t, J = 10 Hz, 2-H), 4.1 (3 H, m, 5, 6  and 6 '-H), 5.0 (1 H, t, J = 10 Hz, 3 or 4-H),
5.4 (1 H, t, J = 10 Hz, 3 or 4-H) and 5.9 (1 H, d, J = 10 Hz, 1-H). 5c (75 MHz, D 2 O)
22.93 and 23.05 (OAc), 55.14, 64.27, 70.83, 73.60, 74.98 (C2 - C 6 ) and 93.16 (C l).
G lu co sam in e  te tr a -0 - a c e ta te  [96] was prepared as follows: [95] (4.7 g) was 
dissolved in water. NaOAc (3.4 g, 2 eq) was added and a white suspension formed. 
The suspension was extracted with DCM (3 x 50 ml), dried (MgSO^) and evaporated. 
Recrystallisation from ether gave a white solid, (2.9 g, 6 8 . 6  %). m.p. 138 - 140“C (lit.^7 
143"C). ÔH (200 MHz, CDCI3 ), 2.05 - 2.20 (12 H, m, OAc), 3.0 (1 H, m, 2-H), 3.80 
(1 H, m, 5-H), 4.05 (1 H, dd, J = 12, 3 Hz, 6  or 6 '), 4.30 (1 H, dd, J = 12, 4.5 Hz, 6  
or 6 '), 5.0 (2 H, m, 3 and 4-H), 5.5 (1 H, d, J = 9 Hz, 1-H). Ôq (50 MHz, CDCI3 ) 
21.07, 21.21 and 21.40 (OAc), 55.50, 62.21, 6 8 .6 8 , 73.13 and 75.50 (C2 - C6 ) and
95.65 (C l).
A - (A -a c e ty lp e n ic iI Ia m in e ) -2 -a m in o -2 -d e o x y - l ,3 ,4 ,6 - te tra -0 -a c e ty I -p -D -  
g luco p y ran o se  (R IG  199) [97] was prepared as follows: [96] (1.3 g) and N -
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acetylpenicillamine (0.7 g) were stirred in DCM. The penicillamine remained as a 
suspension. The coupling agent l-cyclohexyl-3-(2-morpholino-ethyl) carbodiimide 
metho-p-toluene sulphonate ( 1 . 6  g, 1  eq.) was added and the mixture stirred at room 
temperature. The suspension briefly went into solution before a white precipitate 
appeared. Stirring was continued for 24 hrs. The solution was washed with 1 M HCl, 
saturated KHCO 3 ,water, dried (MgSO^) and evaporated. Recrystallisation from ether 
gave a white solid, (0.61 g, 32.4 %). ô c  (75 MHz, DMSO), 20.13, 20.28, 20.36,
20.45 (OAc), 22.20, 22.22 (NAc), 28.91 /  29.23 and 29.58 /  29.67 (HSCCGH3 ), 44.95 
/  45.17 (HSC(CH 3 ), 51.56 /  51.61 (C2), 61.53 /  61.53 (C6 ), 61.90 (NHCHR), 68.34 /
68.55, 71.38 / 71.60 arid 71.60 / 71.91 (C3, 4 and 5), 91.38 /  91.68) (C l) 168.47,
168.55, 169.14, 169.16, 169.31, 169.51 and 169.86 (quaternaries). 2560 
(SH). (Found: C, 48.46, H, 6.15, N, 5.38%. C2 1 H 3 2 N 2 O 1 1 S requires: C, 48.32, H, 
6.10, N, 5.25%).
A -(5 -n itr o so -A -a c e ty lp e n ic iU a m in e )-2 -a m in o -2 -d e o x y -l,3 ,4 ,6 -te tr a -0 -  
acetyl-p-D-glucopyranose (RIG 200) [98] was prepared by the nitrosation o f the 
above product with HCl / NaN0 2  and extraction into DCM. Evaporation and addition of 
ether gave a stable green solid, (0.96 g, 92.6 %). NMR reveal led the presence of two 
isomers, m.p. 125“C (dec.), at 340 nm. ôc (75 MHz, DMSO), 20.04, 20.20, 
20.30 and 20.37 (OAc), 22.02 / 22.07 (NHAc), 24.73 / 24.78 and 26.19 /  26.29 
(0 N S C (C H 3 )2 , 51.73 / 51.81 (C2), 58.48 /  58.73 (O N SC (C H 3 ), 59.44 /  59.65 
(NHÇHR), 61.52 /  61,91 (C6 ), 68.19 /  68.53, 71.40 /  71.63, and 71.63 /  71.92 (C3, 4 
and 5), 91.32 /  91.68 (C l), 168.39, 168.52, 168.80, 168.88, 169.11, 169.20, 169.33 
and 169.87 (OAc and NHAc quaternaries). FARMS (m/e) 519 (M-NO-)
A “Prop ionylpen icilIam iiie [99] was prepared as follows: penicillamine ( 6  g) and 
sodium propanoate (7.7 g, 2 eq) were stirred in a chilled solution of 90% aqueous THF 
(20 ml). Propionic anhydride (5.2 ml, 1 eq) was added and the suspension stirred under 
N 2  at room temperature for 5 h and then left to stand overnight. The THF was
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evaporated to give an oily residue. The oil was dissolved in water and cone HCl added 
until precipitation occurred. After chilling overnight, the solid was filtered, washed and 
dried under vacuum. The solid was finally purified by washing with hexane, (6 . 6  g,
79.7 %). ÔH (200 MHz, DMSO), 1.0 (3 H, t, J = 7.6 Hz, CH 2 Ç H 3 ), 1.45 ( 6  H, s, 
(CH 3 )2 ), 2.25 (2 H, q, J = 7.6 Hz, ÇH 2 CH 3 ), 2.95 (1 H, s, SH), 4.45 (1 H, d, J = 9.5 
Hz, CH), 8.05 (1 H, d, J = 9.5, NH). 5c (50 MHz, DMSO), 10.23 (CH2 Ç H 3 ), 28.37 
(C H 2 C H 3 ), 29.79 and 30.19 ( ^ 3 )2 0 ), 45.44 (H SC (C H 3 )2 ), 61.50 (R C H N H ), 
171.64 and 173.67 (NHPr and CO 2 H). (Found: C, 46.89, H, 7.27, N, 6.74%. 
C 8 H 1 5 N O 3 S requires: C, 46.83, H, 7.32, N, 6.83%)
5 -N itro so -A -p ro p io n y lp en ic ilIam iiie  [100] was prepared from the non-isolated 
product of [99]. The oily residue was dissolved in water and treated with NaN 0 2 /H C l 
and produced a green /  red dichroic solution with cooling. After 10 min a dai'k green 
solid was precipitated. The solid was filtered, washed with water and dried under 
vacuum, (6.1 g, 64.5 % over 2 stages), m.p. dec. at 125"C. ^max 338 nm. HPLC 
showed the compound to be greater than 99% pure. 5^ (200 MHz, DMSO), 0.95 (3 H, 
t, J = 7.6 Hz, CH 2 Ç H 3 ), 2.00 ( 6  H, 2s, C lCH ^ln l  2.20 (2 H, q, J = 7.6, Ç H 2 CH 3 ), 
5.20 (1 H, d, J = 9.5 Hz, CH), 8.45 (1 H, d, J = 9.5 Hz, NH). 5c  (50 MHz, DMSO),
10.09 (CH 2 C H 3 ), 25.51 and 26.51 (C(GH 3 )2 ), 28.29 (GH 2 CH 3 ), 58.69 (G(CH 3 )2 ), 
59.26 (CH), 171.14 (CONH), 173.59 (CO2 H).
iV“(A -p ro p io n y Ip e n ic i lIa m in e ) -2 -a m iiio -2 -d e o x y - l,3 ,4 ,6 - te tra -0 -a c e ty l-P -  
D -glucopyranose (RIG  299) [101] was prepared as follows: glucosamine acetate 
(2 g) and A-propionylpenicillamine (1.77 g, 1.5 eq) were stirred in dry DCM (40 ml). 
l-Cyclohexyl-3-(2-morpholino-ethyl) carbodiimide metho-p-toluene sulphonate (3.66 g,
1.5 eq) was added. The mixture was stirred under N2  overnight. The suspension was 
filtered and the filtrate washed (1 M HCl (25 ml), saturated KHCO 3  (50 ml) and water 
(25 ml), dried (MgSO^) and evaporated to an amorphous white gum. Trituration with 
ether gave a white solid, (1.1 g, 36.2 %). m .p .l75“C. 5c  (50 MHz, DMSO), 10.12
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(C H 2 C.H3 ), 20.50, 20.67, 20.76 (OAc), 28.22 (C H 2 C H 3 ), 29.24 and 29.96
(C (C H 3 )2 ), 45.34 /  45.53 (H SC(CH 3 )2 ), 51.68 (02), 61.71 (06), 62.00 (HNCHR), 
68.38 /  68.64, 71.59 /  72.12 and 71.75 /  71.75 (0 2 , 3 and 4), 91.57 /  91.89 (C l), 
170.32 and 173.31 (RÇONH and NHPr).
A -(5 -n itr o so -A -p r o p io n y lp e n ic in a m in e )-2 -a m in o -2 -d e o x y -l,3 ,4 ,6 -te tr a -
O -acetyl-p-D -glucopyra iiose (RIG 300) [102] was prepared as follows: [103] 
(1 g) was dissolved in methanol (10 ml). W ater (3 ml) was added and the solution 
chilled in an ice bath. Excess NaN 0 2  and HCl were added and the green solution 
extracted with DCM (15 ml). The solvents were evaporated to give a green gum. 
Trituration with ether gave a dark green solid, (0.8 g, 76.5 %). m.p. 134°C (dec.), 
^max 343 nm. ôc (50 MHz, DMSO), 10.10 (CH2 ÇH3 ), 20.65 and 20.73 (OAc), 24.98 
and 26.58 (C(GH3 )2 ), 28.13 (ÇH2 CH 3 ), 51.88 (C2), 58.88 /  59.11 (0 NSG(CH 3 )2 ), 
59.52 /  59.69 (HN(]HR), 61.70 (C6 ), 68.22 /  68.61, 71.58 /  71.78 and 71.78 /  72.25 
(C3, 4 and 5), 91.48 /  91.86 (C l), 169.42, 169.51, 169.78, 170.27 and 173.31 
(quaternaries).
A -V alerylpen icillam ine [103] was prepared as follows: penicillamine (3 g) and 
sodium valerate (3.84 g, 2 eq) were chilled in 80 % aqueous THE (20 ml). Valeric 
anhydride (3.95 ml, 1  eq) was added slowly and the solution stirred under N2  overnight. 
The THE was evaporated leaving an oily residue. The residue was dissolved in water 
and cone HCl added until a thick white oil was precipitated. The mixture was cooled in 
an ice bath for 2 h and the oil solidified. The solid was filtered, dried, washed with 
hexane and dried again to give a white powder, (4.3 g, 91.3 %). m.p. 117°C. D^iax 
/cm-1 2565 (SH). ôy (200 MHz, DMSO), 0.90 (3 H, t, J = 6 . 8  Hz, CH0 CH 3 ). 1.30 (2 
H, m, CH 2 ), 1.40 ( 6  H, s, C(CH 3 )2 ), 1.50 (2 H, m, CH2 ), 2.20 (2 H, m, CH 2 ), 4.40 
(1 H, d, J = 9 Hz, NHCHR). 8.0 (1 H, d, J = 9 Hz, NHCHR). Ôc (50 MHz, DMSO),
14.02 (CH2 C H 3 ), 22.04 and 27.77 (CH2 ), 29.81 and 30.20 (C(CH3 ) 2 ), 45.38 
(HSC(CH 3 )2 ), 61.47 (NHCHR), 171.17 (NHCOVa), 173.54 (CO2 H).
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5 -N itro sO “V -v a le ry lp en ic illa m in e  [104] was prepared as follows: [103] (1 g)
was dissolved in methanol (20 ml). W ater (10 ml) was added and the mixture was 
chilled in an ice bath. Sodium nitrite (2 eq) was added followed by the dropwise 
addition of HCl until precipitation occurred. The mixture was chilled for a further 30 
mins and the dark green solid filtered off. The solid was dried, washed whith hexane 
and dried again, (1.0 g, 92.4 %). m.p. 103°C (dec.). ^,nax 338 nm. ôy  (200 MHz, 
DMSO), 0.9 (3 H, t, J = 6 . 8  Hz, CH 2 Ç H 3 ), 1.35 (2 H, m, CH 2 ), 1.45 (2 H, m, CH 2 ),
2.0 ( 6  H, s, C(CHg)2 ), 2.2 (2 H, t, J = 6 . 8  Hz, COCH 2 ), 5.2 (1 H, d, J = 9 Hz, 
NHCHR). 8.5 (1 H, d, J = 9 Hz, NHCHR). 6 c  (50 MHz, DMSO), 13.94 (CH2 Ç H 3 ),
21 .94  (C H 2 ), 25.45 and 26.58 (C (C H 3 )2 ), 27.66 and 34.80 (CH 2 ), 58.70 
(0 NSC(CH 3 )2 ), 59.33 (NHCHR), 171.12 and 172.94 (quaternaries).
A -(V -v a le ry lp e n ic in a m in e ) -2 -a m in o -2 -d e o x y - l ,3 ,4 ,6 - te tra -0 -a c e ty I -p -D -  
g lucopyranose [105] was prepared as follows: [103] (2 g, 1.5 eq) and glucosamine 
acetate [96] (2.3 g, 1 eq) were dissolved in dry DCM (30 ml) and degassed (N2 ). 1- 
Cyclohexyl-3-(2-morpholinoethyl)cai'bodiimide metho-p-toluenesulphonate (4 g, 1.5 eq) 
was added and the mixture stirred under N 2  overnight. The by-product urea was filtered 
and the filtrate washed with 1 M HCl (25 ml), saturated NaHC0 3  solution (50 ml) and 
water (50 ml). The organic layer was dried (MgSO^) and evaporated to a yellow oil. 
The oil was triturated with dry ether and left in the refrigerator. Small quantities of white 
powder were produced, (0.42 g, 11.4 %). m.p. 180°C. 6 c  (50 MHz, DMSO), 14.00 
(valeryl CH 3 ), 20.49, 20.66, 20.75 (OAc), 22.07 (CH2 ), 27.69 (CH 2 ), 29.20 /  29.40 
and 29.95 /  30.08 (HSC(CH 3 )2 ), 34.81 (CH 2 ), 45.44 /  45.64 (H SCC H 3 )2 ), 51.68 
(C2), 61.53 (C6 ), 61.53 /  61.76 (COCHNHR), 68.43 /  68.70, 71.66 /  71.76 and 71.76 
/  72.16 (C3 - C5), 91.62 /  91.89 (C l), 168.45, 168.78, 169.02, 169.15 and 169.79 
(quaternaries).
190
A -(S -n i tro s o th io -A -v a le ry lp e n ic in a m in e ) -2 -a m in o -2 -d e o x y - l,3 ,4 ,6 - te tra -
O -acety l-p-D -glucopyranose [106] was prepared as follows: the thiol [105] ( 1 0 0  
mg) was dissolved in methanol (5 ml) and water (1 ml). Excess NaN 0 2  and HCl were 
added, giving a green foam. This was extracted with D C M  and evaporated to a green 
semi-solid. Trituration with ether gave the product as a mid-green powder (42 mg, 40.0 
%). m.p. 135 - 137“C. 343 nm. 6 ^  (50 M H z , D M S O ) ,  13.94 (valeryl-CHg),
20.41, 20.56, 20.67 and 20.75 (OAc), 21.94 (CH2), 24.91 /  24.94 and 26.62 /  26.68 
( O N S C ( C H 3 ) 2 ), 27.64 (CH 2 ), 34.62 (CH 2 ), 51.89 (C2), 58.98 /  59.21 
( 0 N S C ( C H 3 ) 2 ) ,  59.39 /  59.54 (C O C H N H R ) ,  61.72 (C6 ), 68.28 /  68.67, 71.67 /  71.78 
and 71.78 /  72.26 (C3 - C5), 91.55 /  91.90 (C l), 168.78, 169.09, 169.16, 169.55, 
170.28 and 172.64 (quaternaries).
A -H eptaiioy lpenicillam ine [107] was prepared as follows: penicillamine ( 6  g) and 
sodium heptanoate (12.3 g, 2 eq) were stimed in a chilled solution of 90% aqueous THE. 
H eptanoic anhydride (10.5 ml, 1 eq) was added and the mixture stirred at room 
temperature overnight. The THE was evaporated and the oily residue dissolved in water. 
Cone HCl was added until precipitation occuned. The precipitate was filtered, washed 
with water and dried under vacuum. The white powder was stirred with hexane to 
remove remaining heptanoic acid, (9.3 g, 88.7 %). m.p. 118-119°C. 1 )^^^ /cm 'l 2560 
(SH). ôjj (200 MHz, DMSO), 0.9 (3 H, m, heptanoyl CH3 ), 1.25 - 1.5 (15 H, m) and
2.2 (3 H, m) (heptanoyl CH2 S and penicillamine CH 3 S), 2.95 (1 H, s, SH), 4.45 (1 H, 
d, J = 9 Hz, CH), 8.1 (1 H, d, J = 9 Hz). 5c  (50 MHz, DMSO), 14.21, 22.31, 25.59 
and 28.54 (NHp), 29.81 and 30.21 (HSCH 3 )2 ), 31.28 and 35.15 (NHp), 45.38 
(H S£(CH )2 ), 61.49 (HNÇHR), 171.63 and 172.73 (NHp and CO2 H). .
5 -N itro so -A -h ep tan o y lp en ic in am in e  [108] was prepared as for [107] to give an 
oily residue. The oil .was dissolved in water and nitrosated with NaN 0 2 /H C l. 
Extraction into DCM and evaporation gave a red oil. The oil was chilled for several days 
and a green solid formed. The solid was stirred with hexane and filtered to give a green
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powder. NMR revealed the presence of impurities thought to be the thiol. The product 
was dissolved in DCM and N 2 O 3  passed throught he solution. Evaporation and 
trituration with hexane gave a dark green solid, (6.5 g, 56.1 %) . m.p. 55°C (dec.). 
A.max 341 nm. 6 ^  (50 MHz, DMSO), 0.90 (3 H, m, CH 3 ), 1.30-1.55 (12 H, m, 3 x 
CH 2  and (CH 3 )2 ), 1.95 (2 H, m, CH 2 ), 2.15 (2 H, m, CH2 ), 5.20 (1 H, d, J = 10 Hz, 
CH), 8.45 (1 H, d, J = 10 Hz, NH). 6 ^  (200 MHz, DMSO), 14.12, 22.26, 25.55 and 
26.60 (C(CH^)2 ), 25.25, 28.44, 31.21, 35.08, 58.60 (C(CH 3 )2 ), 59.21 (CH), 170.09 
and 172.84 (NHHp and CO2 H).
A -(V -h e p ta n o y !p e n ic iH a m in e ) -2 -a m iiio -2 -d e o x y - l,3 ,4 ,6 - te tra -0 -a c e ty l-p -  
D -glucopyranose (RIG  699) [109] was prepared as follows: glucosamine acetate 
(2 g) and V-heptanoylpenicillamine (2.25 g, 1.5 eq) were stirred in dry DCM (30 ml). 
l-Cyclohexyl-3-(2-morpholino-ethyl)carbodiimide metho-p-toluene sulphonate (3.66 g,
1.5 eq) was added and the mixture stirred under N2  for 24 h. The suspension was 
filtered and the filtrate washed (1 M HCl (25 ml), saturated NaHC 0 3  (50 ml and water 
(50 ml), dried (MgSOz^) and evaporated to a white gum. Repeated trituration with dry 
ether gave a white powder (1.3 g, 38.5 %). m.p. 183 - 185°C. 6 ^  (50 MHz, DMSO), 
14.20, (CH 2 £ H 3 ), 20.50, 20.66, 20.76 and 20.86 (OAc), 22.27 (CH 2 ), 25.44 /  25.49 
(C H 2 ), 28.60 (CH 2 ), 29.18 /  29.41 (C (£ H 3 )2 ), 29.96 /  30.03 (C (£ H 3 ) 2 ), 31.29 
(CH 2 ), 35.10 (CH 2 ), 45.43 /  45.64 (H S£(C H 3 )2 ), 51.68 (C2 ), 61.72 (C 6 ), 61.56 /  
61.82 (RÇHNH), 68.40 /  68.67, 71.65 /  71.76, and 71.76 /  72.15 (C3, 4 and 5), 91.61 
/  91.91 (C l) , 168.89, 168.98, 169.56, 169.82, 170.29, 172.52 and 172.62 
(quaternaries). (Found, C, 53.26, H, 7.15, N, 4.79 %. C2 6 H 4 2 N 2 O 1 1 S requires: C, 
52.88, H, 7.12, N, 4.75 %).
A - (5 “N itro s o -A -h e p ta n o y lp e n ic i l la m in e ) -2 -a m in o -2 -d e o x y - l ,3 ,4 ,6 - te tra -
O -ace ty l-p -D -g lucopy ranose  (R IG  700) [110] was prepared as follows: [109] 
(1 g) was dissolved in methanol ( 8  ml). Water (2 ml) was added followed by excess 
NaN 0 2  and excess cone HCl with vigorous stirring. The greeen solution was extracted
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with DCM (15 ml) and evaporated to give a green semi solid. Trituration with dry ether 
gave a green powder. NMR revealed the presence of large quantities of thiol. The green 
solid was dissolved in DCM and N 2 O 3  bubbled through the solution for a few seconds. 
Evaporation and trituration with dry ether gave a dark green solid. (0.64 g, 60.7 %). 
m.p. 135°C (dec). 345 nm. NMR showed that all of the thiol had been nitrosated. 
6 c  (50 MHz, DMSO), 14.17 (CH 2 Ç H 3 ), 20.41, 20.57, 20.68 and 20.76 (OAc), 22.24 
(CH2 ), 24.86 (C(CH3 )2 ), 25.45 (CH2 ), 26.66 (C(£H 3 )2 ), 28.46 (CH2 ), 31.22 (CH2 ),
34.90 (CH 2 ), 51.88 (C2), 58.98 /  59.22 (O N S£(C H 3 )2 ), 59.36 /  59.54 (N H £H R ), 
61.71 (C6 ), 68.26 /  68.65, 71.66 /  71.79 and 71.79 /  72.27 (C3, 4 and 5), 91.53 /
91.91 (C l), 168.79, 169.08, 169.18, 169.55, 170.29, 172.54 and 172.64  
(quaternaries).
l-A z id o g lu c o p y r a i io se  te tr a a c te ta te  [111] was p repared  as follow s: 
acetobromoglucose [2] (3.3 g) and sodium azide (1.65 g) were stirred in dry DMF (23 
ml) over a boiling water bath under N2  for 2 h. The product was poured into ice water 
(50 ml) and a brown solid precipitated. The solid was washed with copious amounts of 
water, dried under vacuum and recrystallised from methanol to give pale yellow crystals 
(1.75 g, 58.4 %). m.p. 129-130'C (lit.28 129°C). Dmax/cm'l 2100 (N 3 ). by (200 
MHz, CDCI3 ), 2.05 (12 H, m, OAc), 3.80 (1 H, m, 5-H), 4.15 (1 H, dd, J = 13.5 and
2.3 Hz), 4.25 (1 H, dd, J = 13.5 and 4.7 Hz), 4.65 (1 H, d, J = 8 . 8  Hz, 1-H), 4.95 (1 
H, t, J = 9.4 Hz, 2/3/4-H), 5.10 (1 H, t, J = 9.4 Hz, 2/3/4-H), 5.20 (1 H, t, J = 9.4 
Hz), be (50 MHz, CDCI3 ), 20.98, 21.12 (OAc), 62.12, 68.36, 71.10, 73.05 and
74.70 (C2 - C6 ) and 88.34 (C l).
1-Am inogIucopyranose tetraacetate [1 1 2 ] was prepared by the hydrogenation of 
the above azide [111] (2 g) in methanol (150 ml) in the presence of 10% Pd on carbon 
(300 mg). The solution was stirred for 24 h under H 2 . The solution was filtered 
through celite and evaporated to a clear oil which hardened to an amorphous solid, (1.4 
g, 75.2 %). m.p. 121 - 125 (lit.29 127“C). by (200 MHz, CDCI3 ), 2.0 - 2.1 (12 H, m.
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OAc), 3.65 (1 H, m, 5-H), 4.1 - 4.25 (3 H, m, 1-, 6 - and 6  -H), 4.8 (1 H, t, J = 9.4 
Hz, 2/3/4-H), 5.0 (1 H, t, J = 9.4 Hz, 2/3/4-H) and 5.2 (1 H, t, J = 9.4 Hz, 2/3/4-H). 
ôc  (50 MHz, CDCI3 ), 21.12 and 21.30 (OAc), 62.74, 69.18, 72.47, 73.15 and 73.60 
(C2 - 06), 85.39 (C l), 170.08, 170.74 and 171.24 (OAc).
The preparation o f A -p e n ic illa m in y l- l-a m in o g lu c o se  [113] was attempted as 
follows: 1-aminoglucose [112] (2.5 g) and V-acetylpenicillamine (1.4 g) were stirred in 
dry DCM (40 ml) under N 2 . 1-Cyclohexyl - 3(2-morpholinoethyl)carbodiimide-p- 
toluene sulphonate (3.1 g) was added and the mixture stirred under N 2  for 24 h. A 
suspension formed which briefly became a clear solution before the urea by-product was 
precipitated. The precipitate was filtered off, the filtrate washed (1 M HCl, saturated 
N aH C 0 3 , water), dried (MgSO^) and evaporated to an oil. The oil could not be 
solidified. NMR reveal led the presence of a number of impurities, from which the 
desired product could not be separated. The oil was nitrosated to give a deep green 
liquid which again could not be adequately purified.
1 - A z id o g a I a c to s e  t e t r a a c t e t a t e  [1 1 4 ] was p rep ared  as fo llow s: 
acetobromogalactose [7] ( 6  g) and sodium azide (4 g) were stirred in DMF (40 ml) over 
a boiling water bath for 3 h. The dark browm mixture formed was poured into ice water 
(200 ml). A brown solid was filtered, washed with copious amounts of water, dried and 
recrystallised from methanol to give large cubic crystals, 3.8 g, 69.8 %). mp 8 8 “C j
(lit.28 91'C). Dmax ^100 (N3 ). by (200 MHz, CDCI3 ), 2.0-2.2 (12 H, m, OAc), |
4.0 (1 H, m, 5-H), 4.2 (2 H, m, 6 , 6 '-H), 4.6 (1 H, d, J = 8.5 Hz, 1-H), 5.0 (1 H, dd, j
J = 10.1 and 3.4 Hz, 3-H), 5.15 (1 H, t, J = 9.0 Hz, 2-H), 5.4 (1 H, dd, J = 3.4 and |
1.1 Hz, 4-H). b e  (50 MHz, CDCI3 ), 20.99 and 21.14 (OAc), 61.70, 67.31, 68.49,
71.16 and 73.28 (C2-C6), 88.72 (C l), 169.84, 170.45, 170.59, 170.84 (OAc). j
I
1-A m inogaIactose te tra a c e ta te  [115] was prepared as follows: the above azide 
[114] (2 g) was dissolved in methanol (150 ml) and hydrogenated for 24 h over 10 %
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Pd on C. The catalyst was filtered through ceelite and the filtrate evaporated to give an 
amorphous solid. Recrystallisation from ethanol gave a white powder, (1.6 g, 86.0 %). 
m.p. 135 - 137"C (lit.30 139“C). 6 ^  (50 MHz, CDCI3 ), 21.11, 21.18 and 21.42 (OAc), 
62.28, 68.03, 70.14, 71.72 and 71.83 (C2 - C 6 ), 85.71 (C l), 171.01 (OAc).
1-A zidom altose h ep taace ta te  [116] was prepared as follows: acetobromomaltose 
[17] (14 g) and sodium azide (5 g) were stirred in DMF (50 ml) over a boiling water 
bath for 3 h. The solution was poured into ice water (150 ml). A brown gum formed. 
The liquid was decanted and the gum repeatedly recrystallised from methanol to give a 
pale brown solid, (6.3 g, 47.6 %). 2105 (N3 ). m.p. 92°C (lit.31 96°C). 8q
(50 MHz, CDCI3 ), 21.05, 21.16, 21.26 and 21.32 (OAc), 61.86, 62.94, 68.31, 69.04, 
69.65, 70.40, 71.88, 72.69, 74.62, 75.50, 87.87 (C la), 96.11 (C lb).
1-A m inom altose h e p ta a c e ta te  [117] was prepared as follows: [116] (5 g) was 
dissolved in methanol (150 ml). 10% Pd on C catalyst (300 mg) was added and the 
mixture hydrogenation for 24 h. A white precipitate appeared during this time. DCM 
was added (75 ml) and the mixture heated until the precipitate had dissolved. The 
mixture was filtered through hot celite. The DCM was evaporated and the product 
allowed to crystallise in the refrigerator, (2.1 g, 43.7 %). m.p. 189 - 19TC  (lit.31 
1 9 r c ) .  be  (50 MHz, CDCI3 ), 21.05, 21.16, 21.26 and 21.42 (OAc), 61.86, 62.94,
68.31, 69.04, 69.65, 70.40, 71.88, 72.69, 74.62 and 75.50 (CH), 87.87 (C la), 96.11 
(C lb), 169.89, 169.98, 170.42, 170.58, 170.90 and 171.00 (OAc).
195
R e fe re n c e s
1. M.L.Wolfrom and A.Thompson, Methods in Carbohydrate Chemistry V olII, 211.
2. F.W eygand, H.Ziemann and H.Bestmann, Chem. Ber., (1958), 91, 2534.
3. M.Cerny, J.Vrkoc and J.Stanek, Chem. Listy, (1958), 52, 311.
4. P.M.Collins, Carbohydrates, Chapman and Hall, London, 1987.
5. B.Furniss, A.Hannaford, P.Smith and A.Tatchell, Vogel Textbook o f Practical 
Organic Chemistry 5th E dition, p648
6 . M.Cerny and J.Pacak, Monatsh. Chem., (1963), 94, 290.
7. J.Stanek, M .Sindlerova and M.Cerny, Collect. Czech. Chem. Commun., (1965), 
30, 297.
8 . M.Mori, M.Haga and S.Tejima, Chem. Pharm. Bull., (1974), 22, 1331.
9. F.J.Reithel and R.G.Young, J. Am. Chem. Soc., (1952), 74, 4210
10. C.Glen, G.Myers and G.Grant, J. Chem. Soc., (1951), 2568,
11. H.Strohl, D.Dargel and R.Haeussler, J. Prakt. Chem., (1964), 23, 309.
12. K.Freudenberg and O.Ivers, Chem. Ber., (1922), 55, 933.
13. L.Hall and D.Miller, Carbohydr. Res., (1975), 40, C1-C2.
196
14. U.Nayak and R.Whistler, J. Org. Chem., (1969), 34, 3819.
15. R.Brady, Carbohydr. Res., (1970), 15, 35
16. E.Hirst, W.Mitchell, E.Percival and E.Percival, J. Chem. Soc., (1953), 3170.
17. A.Raymond and E.Schroeder, J. Am. Chem. Soc., (1948), 70, 2788.
18. J.Cox and L.Owen, J. Chem. Soc.,(C), (1967), 1121.
18. E.Hai’degger and R.Montavon, Helv. Chim. Acta, (1946), 29, 1199.
19. S.Hanessian, M.Ponpipom and P.Lavalle, Carbohydr. Res, (1972), 24, 45.
20. G.Mate hell and G.Richards, J. Chem. Soc., (1961), 3308.
21. F.Cramer, H.Otterbach and H.Springmann, Chem. Ber., (1959), 92, 384
22. J. Thiem and H. Luders, Makromol. Chem., (1986), 187, 2775.
23. R.Hockett, H .Fletcher, E.Sheffield, R.Goepp and S.Soltzberg, J. Am. Chem.
(1946), 68, 930
24. R. Field, PhD Thesis, University o f  East Anglia , (1989).
25. P.Bladon and L.Owen, .J. Chem.Soc., (1950), 585
26. R.Montgomery and L.Wiggins, J. Chem.Soc., (1948), 237.
197
27. M.Bergmann and L.Zeiwas, Chem. Ber., (1931), 64, 975
28. W .Pfleiderer and E.Buhler, Chem. Ber., (1966), 99, 3022.
29. B.Helferich and A.Mitrowsky, Chem. Ber., (1952), 85, 6
30. A.Bertho and J.Maier, Liebigs Ann. Chem., (1932), 498, 60
31. A.Bertho, Liebigs Ann. Chem., (1949), 562, 229.
198
